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Abstract
Bacterial vaginosis (BV) describes a dysbiotic state of the vaginal mucosa, during which
the dominance by beneficial lactobacilli species is lost, the vaginal pH increases, and the flora
comprising the vaginal microbiome becomes more diverse. Bacterial taxa associated with this
dysbiotic state interact to form a dense polymicrobial biofilm on the surface of the vaginal
epithelium. This shift in the vaginal microflora is clinically important, even when symptoms are
not noted, as women with BV are at increased risk for acquisition of other sexually transmitted
infections, including HIV, and are more than two times as likely to experience preterm birth.
Moreover, BV has been associated with numerous other adverse outcomes, including pelvic
inflammatory disease, recurring urinary tract infections, chorioamnionitis, postpartum
endometritis, infertility, and adverse neonatal outcomes, even among full term infants. The
prevalence of BV, in the United States alone, is approximately 30% for women of reproductive
age, and is significantly increased in Hispanic and African American women. Standard
metronidazole treatment carries a recurrence rate of 52% within 12 months of treatment and recent
reports indicate that BV recurrence can, at least in part, be attributed to the inability to reestablish
the beneficial lactobacilli population after antibiotic treatment. Thus, it is clear that more targeted
approaches to BV treatment are needed.

While the last few decades of research have given us a better understanding of the
organisms that comprise the vaginal microbiome, there are still a lot of gaps in our understanding
of what they are doing and how they are interacting with the host and each other, both in the context
of health and disease. This is due to inadequacies of animal models and difficulty in culturing and
genetically manipulating vaginally relevant microorganisms. The overarching aim of this
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dissertation research was to characterize the factors that contribute to the establishment and
maintenance of vaginal dysbiosis, focusing on the role(s) of one organism, Gardnerella vaginalis.
Various tools were developed to further characterize putative virulence determinants produced by
Gardnerella to better understand how the bacterium interacts with the human host, with emphasis
on the cholesterol-dependent toxin, vaginolysin (VLY), and an opacity phenotype presumptively
driven by differential pilus production. Through the development of a human vaginal epithelial
model of Gardnerella infection, in which Gardnerella spp. grow to in vivo densities, we uncovered
a previously undescribed influence of tissue polarity on VLY activity. This influence was mediated
by differential expression of the proposed VLY co-receptor, CD59. Further investigation of VLY
in different Gardnerella strains revealed conserved amino acid differences within regions of the
toxin known to interact with host cells, allowing for the characterization of distinct VLY types.
Two predominant VLY types exhibited differential interaction with vaginal epithelial cells,
putatively related to CD59 availability. Bioinformatic analyses showed that certain VLY types are
restricted to select Gardnerella species and the dominant VLY type in vaginal samples has
implications for overall Gardnerella abundance and symptom frequency during BV. We then
characterized a colony opacity phenotype potentially susceptible to phase variation. Both opaque
and translucent variants were detected in all tested Gardnerella isolates, representing six different
species. Opaque variants exhibited increased bacterial aggregation in suspension as well as
increased surface biofilm formation, to suggest that opacity may promote resistance to host
defenses. Finally, we report the development of the first method for performing site-specific
mutagenesis in Gardnerella spp. After optimization, this oligonucleotide-based protocol yielded
transformants at an efficiency similar to that observed in other bacterial species. Using these
optimized methods, we were able to transform 3 strains of Gardnerella representing 3 different
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species. While this represents a significant advance in the field, continued optimization is
necessary to further improve transformation efficiency in order to increase the practicality of using
this tool to generate non-selectable transformants. In sum, continuing to build upon the knowledge
gleaned from this work will allow us to develop more targeted therapies for BV and ultimately
reduce its global health burden.
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CHAPTER 1
Introduction
The healthy vaginal microbiome
The human microbiome project has shown us that humans are intimately associated with
and dependent upon microbes for survival. Different body sites are characterized by different host
pathogen interactions that, when disrupted, can promote disease1–4. Within the niche of the vaginal
mucosa, a complex interplay between commensal lactobacilli species and the stratified epithelium,
immune cells, and secretions comprising this environment must be maintained to promote the
overall health of each woman as well as her progeny5–7. These lactobacilli, through numerous
functions, ultimately serve to create an environment that is exclusionary to invading organisms
that threaten this eubiosis8.

Specifically, lactobacilli directly compete with other organisms by adhering to the surface
of the epithelium to prevent their binding9,10. Lactobacilli acidify vaginal secretions through the
production of D- and L- lactic acid, which not only directly inhibit the growth of pathogenic
organisms, but also promote and inhibit the production of anti- and pro-inflammatory cytokines,
respectively11–14. In addition, by facilitating DNA repair through the inhibition of histone
deacetylase activity, lactic acid also enhances the survival of vaginal epithelial cells to maintain
barrier integrity15. Other inhibitory products secreted by vaginal lactobacilli include hydrogen
peroxide and bacteriocins, which may also suppress the growth of urogenital pathogens16–20.
Because of these important functions, and the abundance of these organisms in the vaginal
microflora of clinically healthy women, a healthy human vaginal microbiome is typically
described as one dominated by select lactobacilli species6,21,22. It is important to note, however,
1

that “health” is a relative term than can vary depending on ethnicity or age, among other factors23–
25

.
It is also worth mentioning that this lactobacilli dominance in the vagina is unique to

humans. While lactobacilli typically comprise over 70% of the bacteria in the healthy human
vagina, the microbiomes of other mammals are made up of less than 1% of lactobacilli26. This may
be due to physiological differences among species. The human vaginal mucosa in reproductive
aged women is described as a thick, multilayer squamous epithelium overlaying the lamina propria
and coated in secretions produced via mucin-secreting cervical glands and the Bartholin’s glands
in the vaginal wall, among other sources27–29. Keratinocyte cells originating from the basolateral
side, mature, differentiate, and flatten over time, through a process called cornification. During
this process, cells that were once actively replicating, become anucleated and devoid of organelles,
and build large cytoplasmic stores of glycogen. Cornified vaginal epithelial cells in some animals
are also keratinized; in humans they are not30. As these terminally differentiated apical epithelial
cells slough off, the deeper layers become progressively closer to the lumenal face. These sloughed
off cells are thought to contribute to the available pool of glycogen in vaginal secretions31. Alpha
amylase, also abundant in human vaginal mucus, contributes to glycogen break down so that it can
be further catabolized by lactobacilli to ultimately produce the lactic acid that maintains the low
vaginal pH32,33. Compared to other mammals, the levels of glycogen in the tissues and vaginal
fluid in humans are significantly higher 26. Likewise, humans also have a more acidic vaginal pH
relative to other mammals. In a comparison of 26 mammalian species, humans exhibited the lowest
vaginal pH at 4.5, whereas the median vaginal pH across the non-human mammals was 6.826.
While there are several interesting hypotheses to explain this human uniqueness and its

2

evolutionary consequences34, there is one immediate implication: non-human animal models
developed to study host-pathogen interplay within the vaginal microbiome are inherently limited.

Bacterial vaginosis
Many well-characterized urogenital and sexually transmitted infections (i.e. chlamydia,
gonorrhea, and yeast infections) are mediated by a singular pathogen. Bacterial vaginosis, on the
other hand, is better described as a polymicrobial infection35–38. During BV, the lactobacilli
dominance is lost, the vaginal pH increases, and the flora comprising the vaginal microbiome
becomes more diverse16,17,39–41. Bacterial taxa associated with this dysbiotic state interact to form
a dense polymicrobial biofilm on the surface of the vaginal epithelium38,42,43. When sloughed off,
these biofilm-coated clue cells can be used to diagnose BV44. Women with BV may present as
symptomatic or asymptomatic, with symptoms including a malodorous vaginal discharge and
vaginal discomfort44.

While these symptoms of BV are generally mild and frequently not reported, this shift in
the vaginal microflora is clinically important, even when symptoms are not noted45. This is likely
due to the finding that both the cervicovaginal mucus and the cervicovaginal epithelium of BV
positive women are compromised in their protective barrier functions46,47. In addition, women
dominated by a diverse, anaerobic flora exhibit an increase in Th17-associated cervicovaginal
cytokines as well as increased numbers of genital HIV target cell numbers48. Accordingly, women
with BV are at increased risk for acquisition of other sexually transmitted infections, including
HIV, wherein a BV positive status increases susceptibility to HIV by an estimated 60%49–51.
Women who experience BV during pregnancy are more than two times as likely to experience

3

preterm birth, potentially due to ascending infection from the vagina/cervix into the uterus or
premature cervical remodeling induced by dysbiotic cervicovaginal flora 52–55. Moreover, BV has
been associated with numerous other adverse outcomes, including pelvic inflammatory disease,
recurring urinary tract infections, chorioamnionitis, postpartum endometritis, infertility, and
adverse neonatal outcomes, even among full term infants 56–62. The prevalence of BV, in the United
States alone, is approximately 30% for women of reproductive age, and is significantly increased
in Hispanic and African American women63,64. Standard metronidazole treatment carries a
recurrence rate of 52% within 12 months of treatment63–67 and recent reports indicate that BV
recurrence can, at least in part, be attributed to the inability to reestablish the beneficial lactobacilli
population after antibiotic treatment68,69. Thus, it is clear that more targeted approaches to BV
treatment are needed.

Great progress has been made in the last 20 years with respect to understanding the risk
factors and adverse sequelae associated with the disorder as well as improving and validating
diagnostic methods70–75. However, there are still many gaps in the mechanistic understanding of
the progression of BV, with particular regard to the in vivo roles of specific taxa, virulence factors,
and host-pathogen interactions that promote this shift from lactobacilli dominance and that
contribute to its immunopathology. These gaps have limited the development of novel treatments
and have ultimately perpetuated BV’s significant public health burden. The overarching aim of
this dissertation research is to characterize the factors that contribute to the establishment and
maintenance of vaginal dysbiosis, focusing on the role(s) of one organism, Gardnerella vaginalis.

4

Evidence that Gardnerella plays a role bacterial vaginosis
BV is ultimately a polymicrobial disorder. The abundance of several bacterial species
concomitantly increases with the characteristic decrease in lactobacilli. However, the most
common bacterial species to predominate during BV is Gardnerella vaginalis39,70,76–80 . While G.
vaginalis is frequently detected in women without BV, its abundance is high in 95-99% of BV
positive subjects; it is the most abundant organism comprising the in vivo biofilm; and its mean
relative abundance increases just days prior to the onset of incident BV81. Multiple studies suggest
that distinct commensal and BV-associated strains may exist, potentially explaining why G.
vaginalis presence within the vaginal epithelium is less BV-specific compared to other BVassociated organisms82–85. Moreover, BV positive and negative women harboring G. vaginalis can
be distinguished by differences in their in vivo concentrations of the bacterium. G. vaginalis is
documented at 102-104 CFU/mL for healthy women but reach 105-108 CFU/mL during BV86–88.

In addition, the vast repertoire of putative virulence factors produced by G. vaginalis is
suggestive of its high virulence potential:

Iron acquisition
Multiple Gardnerella strains were shown to utilize iron salts and host iron compounds as
the sole source of iron for growth89. Human lactoferrin (120 kDa) and hemoglobin (124 kDa)
binding proteins were identified and associated with the Gardnerella cell surface90,91. The amount
of lactoferrin binding protein was increased under iron deplete conditions and may be specific for
human lactoferrin, as binding of bovine lactoferrin was not detected. The human specificity of
lactoferrin binding could potentially explain Gardnerella host restriction. Furthermore, a study of
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siderophore production showed that all 8 tested strains exhibited siderophore activity. These
mechanisms for iron acquisition may help the bacterium overcome nutritional immunity in vivo,
but this has yet to be studied.

Sialidase
A sialidase enzyme with a pH optimum of 5.5 was first isolated from G. vaginalis in 198492.
Later studies showed that sialidase activity was significantly increased in the vaginal secretions of
BV-positive women relative to BV-negative women93,94. A correlation between high sialidase
activity in vaginal secretions and increased degradation of anti-Gardnerella hemolysin IgA and
IgM as well as an inverse correlation with IL-8 levels were reported, suggesting that sialidases
present during BV diminish the immune response to the Gardnerella hemolysin95–97. It was also
found that pregnant BV-positive women with high sialidase activity were at an increased risk for
preterm birth and low birth weight98,99. Interestingly, not all Gardnerella strains make a functional
sialidase100–102. However, sialidase positive G. vaginalis strains were able to both catabolize and
consume sialoglycans from IgA and mucin in vitro103. This sialoglycan foraging was also observed
ex vivo in human vaginal secretions and in vivo in a murine infection model. These results
suggested that Gardnerella sialidase may contribute to mucus barrier degradation in addition to
immune suppression. More recent reports clarify the genetic basis of sialidase activity in
Gardnerella strains104. Three sialidase genes, nanH1, nanH2, and nanH3, were differentially
distributed among Gardnerella isolates, but nanH1 and nanH2 seemed to be the primary sources
of sialidase activity.
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Biofilm
Fifteen years ago, Swidsinski et. al reported the presence of a dense biofilm coving 50%
or more of the epithelial surface of vaginal biopsies from BV-positive subjects43. Using
oligonucleotide probes and fluorescence in situ hybridization (FISH), they showed that
Gardnerella spp. made up a majority of the biofilm mass. This biofilm was implicated in the sexual
transmission of Gardnerella between partners as all tested BV positive patients (20/20) and their
partners (10/10) exhibited the cohesive Gardnerella aggregates on desquamated, urine voided
epithelial cells and prepuce epithelial cells in seminal fluid42,105. The recalcitrance of the
Gardnerella biofilm to treatment was highlighted in a study investigating the efficacy of
intravaginal octenidine antiseptic treatment38. The 6-month cure rate was only 29.2% and 37.5%
of patients exhibited complete resistance at the one-year follow-up time point. In vitro studies of
the Gardnerella biofilm show that the biofilm phenotype enhances resistance to hydrogen peroxide
and lactic acid by 4-fold and 8-fold, respectively, relative to planktonic cells106. Gardnerella
strains produce thicker biofilms compared to other BV-anaerobes and N-acetylglucosamine
appears to be an important component of the biofilm matrix106,107.

Bacterial antagonism
A study of 11 G. vaginalis BV-isolates showed that all tested isolates reduced growth of at
least one out of twenty-two other vaginally relevant bacterial species108. This antagonistic activity
was partially characterized and attributed to a bacteriocin-like compound. In a different study, in
vitro assays show that G. vaginalis was able to displace adherent lactobacilli from vaginal
epithelial cells10. The mechanism behind this activity was not further characterized. In both studies,
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the pH at which these activities were detected, ~7.0, was more characteristic of a Gardnerelladominated vaginal environment. Thus, whether or not these antagonistic activities are possible
under lower pH conditions of a healthy vaginal microbiome is unknown.

Pili
In the 1980s, three publications showed evidence of pilus production in Gardnerella spp109–
111

. These studies reported that the diameter of Gardnerella pili varied from 3 to 7.5 nm, with

occasional aggregation into bundles. Pili were shown to interact with human erythrocytes to
promote agglutination but the degree of piliation among strains was highly variable. Heavy
piliation was observed more frequently on freshly isolated strains but declined upon repeated
laboratory passage, which suggests that pili are important for survival in the human host. There
was no mention of the genes suspected to be involved in Gardnerella pilus production. More recent
studies show that G. vaginalis exhibits increased attachment to host cells relative to other BVassociated bacteria; this could potentially be mediated by pili107.

Cholesterol-dependent pore-forming cytotoxin
In 1990, Rottini et. al noted zones of hemolysis on blood agar plates streaked with G.
vaginalis112. With this, they hypothesized that the bacterium secreted a hemolytic cytotoxin and
went on to purify a 61-63 kDa protein with cytolytic activity from Gardnerella culture
supernatants. Secretion of the toxin paralleled bacterial growth during logarithmic and early
stationary phases and plateaued during bacterial death phase. The hemolysin exhibited a species
selectivity for human erythrocytes. Erythrocytes from other species either required a greater
amount of toxin to achieve the same amount of lysis (rat erythrocytes) or were resistant to up to
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100-fold the amount of toxin used on human erythrocytes (horse, rabbit, sheep, guinea pig
erythrocytes). Purified toxin also mediated injury to endothelial cells and leukocytes. Hemolytic
activity was inhibited by temperatures below 20ºC, the addition of trypsin, and pre-incubation with
phospholipids.

The following year, a different group also purified and characterized a Gardnerella
hemolysin with a similar molecular mass113. They observed that toxin activity exhibited a
temperature optimum between 20-40 ºC and a pH optimum of 6.0. A loss in activity was observed
following protease, trypsin, glucosidase, and cholesterol treatment. They found that human
lymphocytes were 100-fold less susceptible to the hemolysin relative to human erythrocytes, and
similar to the Rottini et al. study, that the toxin exhibited a species specificity for human cells.
Results from binding and osmotic protection assays suggest that the hemolysin, rather than
functioning as an enzyme, instead mediates lysis through pore formation. These pores on human
erythrocytes were estimated to be approximately 1.4 to 2.1 nm in diameter.

In 1993, yet a third group purified and characterized the toxin114. Results from their studies
suggested that the protein required aggregation on the target membrane to form a functional lesion
and estimated the pore radius to be 2.4 nm. They similarly observed activity inhibition by the
addition of cholesterol, and more so when cholesterol was added alongside phospholipids, to
suggest that the negative surface potential increased affinity of the toxin for the membrane. This
group also reported for the first time the detection of Gardnerella hemolysin-specific IgA in the
vaginal fluids of BV-positive women. In a separate paper published the same year, this group
found that low ionic strength and divalent cations inhibited activity at a step subsequent to binding.
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They observed toxin-mediated damage on cholesterol-containing lipid vesicles and, in contrast to
other reports, a pH optimum at 5.0. Over the next 9 years, this group went on to generate several
publications highlighting the relevance of the toxin to BV and adverse pregnancy outcomes94,99,115.
These studies showed that 60% of women with overt BV and 18.5% of women with intermediate
flora exhibited a specific IgA response to the hemolysin. This specific response correlated with
increased IL-1ß levels and leukocyte counts in vaginal fluids. No woman with BV and a strong
anti-hemolysin IgA response had an adverse pregnancy outcome (preterm delivery or low
birthweight infant).

The availability of G. vaginalis genetic information later enabled further, and more detailed
characterization of the toxin. In 2008, Gelber et. al identified a 1.5 kb open reading frame in the
G. vaginalis genome with homology to known cholesterol dependent cytolysins116. Because of this
sequence similarity, they proposed the name “vaginolysin (VLY)” to maintain consistency with
CDC nomenclature. They subsequently cloned and recombinantly purified the toxin and then
demonstrated that it lysed erythrocytes in a species-specific manner. Pre-incubation of the toxin
with cholesterol prevented erythrocyte lysis. Importantly, they provide evidence that the human
complement receptor, CD59, contributed to the species specificity of lytic activity. When VLY
was added to cervical epithelial cells, the p38 MAPK pathway was activated and IL-8 production
was induced. A single amino acid substitution within the undecapeptide region (P480W)
significantly reduced cytolytic activity. Subsequent studies by this group show that VLY is also
cytotoxic towards human cervical epithelial (HeLa) and vaginal epithelial (VK2) cells117. Lower
concentrations of the toxin induced membrane blebbing, rather than pore-driven lysis. It was
hypothesized that epithelial cells respond to pore forming toxins in this way as a defense
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mechanism to expel the toxin from the cell118. The response of erythrocytes to VLY, on the other
hand, was shown to be rather distinct119. Co-incubation of VLY with erythrocytes induced lipid
raft enlargement by increasing the amount of CD59, cholesterol, and other raft-associated factors
in membrane fractions. Programmed cell death factors were also recruited to lipid rafts. This led
VLY-treated erythrocytes down a programmed necrosis pathway, which enhanced G. vaginalis
growth in vitro.

In 2013, Budvytyte et. al successful reconstituted VLY into tethered bilayer membranes120.
Using this tool, they were able to show that VLY damage of lipid membranes could occur in the
absence of CD59, but was absolutely dependent upon adequate membrane cholesterol levels (> 10
mol %). Despite CD59 being non-essential for pore formation, they suggest that in vivo it may
potentiate cytotoxicity by promoting monomer binding to the cell surface. Subsequent reports
provided evidence that VLY-mediated lysis can occur on cells via two separate pathways, one
involving only cholesterol, the other both cholesterol and CD59, due to the ability of the
undecapeptide region to adopt two distinct conformations121,122. Analysis of VLY pore formation
on artificial membranes suggest a membrane cholesterol content requirement between 40-55 mol%
and a neutral pH optimum, with weak to no activity at acidic pH123. Interestingly, VLY exerts 500fold less attracting force on CD59 relative to other CD59 dependent pore forming toxins 124.

Despite all that has been gleaned by studies of VLY, the function of the toxin in vivo is still
unknown. It could potentially help overcome nutritional immunity. Alternatively, it could protect
G. vaginalis from innate immune cells, as it has been shown to induce cell death in neutrophils112.
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In any case, evidence of evolution under strong constraint (purifying selection) suggests that VLY
is important to the fitness of Gardnerella spp125.

In sum, while the unfulfillment of classical Koch’s postulates initially cast doubt on the
contribution of G. vaginalis to BV, its fulfillment of the more modernized molecular guidelines
for establishing microbial disease causation proposed by Fredricks and Relman in 1996 clearly
suggests that G. vaginalis plays an important, causative role126,127. In fact, many groups have
hypothesized that a combination of G. vaginalis’s presence in healthy women, its inability to
induce a strong host immune response, its virulence potential, and its ability to form a robust,
resistant biofilm make this opportunistic pathogen an ideal candidate keystone species for the
establishment of BV128.

Obstacles in defining the role of Gardnerella spp. in bacterial vaginosis
Many studies have sought to investigate how G. vaginalis and its virulence factors interact
with the host to promote the development of BV. Unfortunately, many obstacles have impeded
detailed characterization of Gardnerella spp. virulence determinants and their interaction with the
host, making it difficult to definitively establish a role for G. vaginalis in BV. First, analyses of
multiple strains reveal substantial genetic and phenotypic heterogeneity within the genus84,85,101,129.
In an analysis of 17 different strains, the core genome made up only 51.6% of each strain’s genome.
Furthermore, for each measure studied, G. vaginalis isolates had the highest degree of difference
when compared to 23 other pathogenic bacterial species. Numerous studies of Gardnerella spp.
strains also highlight the vast phenotypic differences within the genus. Comparisons between
isolates in the production of certain biochemicals, resistance to antimicrobials and human serum,
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and virulence factor production, among many other things, illustrate the diversity employed by
this organism130–133. Because of this heterogeneity, studies prior to 2019 consistently supported the
regrouping of the Gardnerella genus into multiple species102,129,134. This regrouping was officially
proposed in a 2019 publication in the International Journal of Systematic and Evolutionary
Microbiology135. Through whole genome sequencing of all 81 sequenced full genomes of
Gardnerella spp., as well as phenotypic distinction using MALDI-TOF MS, Vaneechoutte et al.
proposed to delineate the Gardnerella genus into 13 distinct species. The contribution of each of
these newly defined species to BV, whether some or all are associated, as well as whether some
are more or less pathogenic, is currently unknown. Although, a recent publication found that some
species are more likely to co-occur while others are associated with various BV symptoms136.

Next, animal models of BV poorly recapitulate in vivo phenomena137–140. This may be due,
in part, to the uniqueness of the human vaginal mucosa, as previously mentioned. But this may
also be due to the human selectivity of key BV species, including G. vaginalis. Apart from 2 reports
of isolation of G. vaginalis-like organisms from mares, it has only been found in humans141,142.
Initial hypotheses proposed that the human restriction of G. vaginalis was attributable to the CD59
co-receptor for the vaginolysin toxin116. However, humanization of mice with human CD59 failed
to promote growth in mouse models of G. vaginalis infection (personal communication, Dr. Adam
Ratner, New York University). Thus, it is unclear what human-specific factors may be contributing
to the human specificity of Gardnerella spp.

Finally, the genetic intractability of Gardnerella has severely limited the characterization
of potentially important virulence determinants. There are no reports of directed mutagenesis in
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Gardnerella. Up to this point, studies of putative virulence factors have depended on the use of
purified or recombinantly-produced Gardnerella proteins or comparisons of non-isogenic
variants89–91,104,112,116. The only published documentation of genetic manipulation of G. vaginalis
involves selection of a spontaneous streptomycin resistant mutant on Gardnerella semi-selective
media supplemented with streptomycin138,139. While random mutagenesis using mutagenic
chemicals or UV-light is certainly possible, it often produces off-target effects and the process to
generate truly isogenic mutants is laborious and time-consuming. As Gardnerella produces a
variety of putative virulence factors that have the potential to mediate the development of BV, the
ability to perform efficient, directed mutagenesis in Gardnerella would be a huge advance for the
field and would be invaluable for future studies aiming to better understand the interplay between
G. vaginalis, the host, and other urogenital microbes.

Research objectives

In conclusion, while we have a better understanding of the organisms that comprise the
vaginal microbiome, there are still a lot of gaps in our understanding of what they are doing and
how they are interacting with the host and each other, both the context of health and disease. This
is due to inadequacies of animal models and difficulty in culturing and genetically manipulating
vaginally relevant microorganisms. In the studies presented herein, various tools were developed
to further characterize putative virulence determinants produced by Gardnerella to better
understand how the bacterium interacts with the human host, focusing on the cholesteroldependent toxin, vaginolysin, and the phase variable opacity phenotype presumptively attributed
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to differential pilus production. Continuing to build upon this understanding will allow us to
develop more targeted therapies for BV and ultimately reduce its global health burden.
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CHAPTER 2
Materials and Methods
Strains and culture conditions
Gardnerella strains (Table 3) were cultured anaerobically (90% N2, 5% H2, 5% CO2) at 37°C on
sBHI (brain heart infusion broth [Oxoid] containing 1.0% [wt/vol] gelatin, 1.0% yeast extract,
0.1% starch, and 0.1% dextrose) agar plates supplemented with 10% human blood or fetal bovine
serum (FBS), or in sBHI broth with or without 5-10% human serum (Fisher Scientific) or FBS at
37°C. Starch agar plates (0.75% [wt/vol] tryptone, 0.75% special peptone, 1.1% starch, 0.4%
potassium phosphate dibasic, 0.1% potassium phosphate monobasic, 0.5% NaCl, 0.0012%
bromocresol purple) were used to quantify Gardnerella growth on EpiVaginal tissues. sBHI plates
with FBS were used to distinguish Gardnerella colony morphology variants. E. coli was grown
in Luria-Bertani (LB) broth or on 1.5% agar LB plates supplemented with antibiotics as
appropriate (Table 4) at 37°C under atmospheric conditions.

The human vaginal epithelial cell line VK2/E6E7 was cultured at 37°C with 5% CO2 in
keratinocyte serum-free medium (Gibco) with 0.1 ng/mL human recombinant epidermal growth
factor (EGF), 0.05 mg/mL bovine pituitary extract, 0.4 mM CaCl2, 50 U/mL penicillin, and 50
µg/mL streptomycin. Partial thickness EpiVaginal tissues derived from primary human
vaginal/ectocervical cells were purchased from MatTek. Upon arrival, the tissues were moved
from semisolid transport medium into 2 mL of prewarmed serum-free VEC-100 medium (without
antibiotics, pH 7.2). The tissues were maintained at the air-liquid interface at 37°C with 5.0% CO2.
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The HL-60 cell line was cultured in IMDM (Quality BiologicalTM) supplemented with 20% FBS,
50 U/mL penicillin, and 50 µg/mL streptomycin.

Agarose gels
Gels for visualizing or purifying DNA were prepared with 1.5% (wt/vol.) low electroendosmosis
agarose (Ambion) in 1X Tris-acetate-EDTA (TAE) buffer (Invitrogen). Ethidium bromide (Pierce)
was added at 1 µg/mL to enable DNA visualization. After solidification, gels were submerged in
1X TAE buffer, loaded with samples mixed with gel loading dye (BioLabs), and electrophoresed
at 125 volts.

Polyacrylamide gel electrophoresis (PAGE)
Protein-containing samples were mixed with NuPAGE LDS Sample Buffer (ThermoFisher
Scientific) and NuPAGE Sample Reducing Agent (ThermoFisher Scientific) at 1X concentrations
and then heated at 70°C for 10 min before being added to NuPAGE 4-12% Bis-Tris protein gels
(ThermoFisher Scientific). The gels were then submerged in MES SDS Running Buffer prepared
at 1X concentration in ddH2O and electrophoresed with 125 volts applied. SDS gels were stained
with ImperialTM Protein Stain (ThermoFisher Scientific) overnight and rinsed and de-stained with
ddH2O.

gDNA extraction
DNA was extracted from Gardnerella strains using the DNeasy Blood and Tissue kit (Qiagen),
following the protocol for Gram-positive bacteria with the following modifications. Bacterial
pellets were resuspended in 200 µl enzymatic lysis buffer (20 µl 10X TE buffer, 2.4 µl TritonX100,
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177.6 µl ddH2O, 4mg lysozyme) and incubated at 37°C for 60 minutes. After adding proteinase K
and Buffer AL, the solution was incubated at 56°C until clear (lysed; ~15 min). Elution of genomic
DNA was achieved by adding 50 µl ultrapure ddH2O to the DNeasy membrane and collecting by
centrifugation twice for a final elution volume of 100 µl.

Plasmid extraction
Plasmids (Table 7) were extracted from E. coli using the QIAprep Sping Miniprep Kit (Qiagen),
according to manufacturer’s instructions (October 2011). Ultrapure ddH2O was used for elution.

PCR/Digest product purification
Following DNA amplification using the PCR parameters outlined in Table 5 or digestion (below),
DNA products were purified using the QIAquick Gel Extraction Kit (Qiagen) as outlined on the
kit insert (September 2010). Ultrapure ddH2O was used for elution.

Digestion
Double enzymatic digestion of plasmids (Table 7) and inserts (vly and λ bet) by BamHI and XhoI
(NEB) was performed in buffer 3.1 (NEB) for 3 hours at 37°C. Digested DNA was purified as
outlined above prior to ligation.

Ligation
Purified, digested plasmid (20-100ng) was mixed with a 3-fold molar excess of purified, digested
insert and adjusted to a final volume of 5 µl with ddH2O. A volume of 5 µl Instant Sticky-end
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Ligase Master Mix (NEB) was added and mixed by pipetting up and down 10 times. Reactions
were either used immediately or stored at -20°C.

Competent cell preparation
Competent E. coli strains (Table 3) were purchased from New England BioLabs. For competent
Gardnerella cells, a single colony of a given strain was used to inoculate 3 mL of sBHI. After 48
hours of growth under anaerobic conditions, 1 mL of this culture was used to inoculate 25 mL of
fresh sBHI. Following overnight growth, this culture was used to inoculate fresh sBHI and this
subculture was grown anaerobically until the cells reached early log phase (OD600 = 0.35). For G.
vaginalis 14018, this took approximately 6 hours. For G. leopoldii AMD, cells were first allowed
to reach an OD600 of 0.2, diluted 200-fold into fresh media, and then grown anaerobically for 16
hours. After reaching early log phase, cultures were placed on ice for 10 minutes and then
centrifuged at 4,000 rpm for 10 minutes at 4°C to collect cells. Translucent variant cells were
washed three times with ice cold 10% glycerol in ddH2O and resuspended in a volume of 10%
glycerol that is 100-fold less than the original culture volume. To prevent bacteria from sticking
to tube walls and losing the pellet, opaque variant cells were washed once with 50 mL ice cold
ddH2O, moved to 1.5mL Eppendorf tubes, and then washed 7 times in 1mL ice cold 10% glycerol,
increasing the centrifugation speed to 10,000 rpm. Aliquots of 100-200 µl were frozen at -80°C
until needed.

Transformation of chemically competent cells
NEB Stable competent cells were thawed on ice for 10 minutes and then 2ul of plasmid:insert was
added. The tube was flicked 5 times to mix and then incubated on ice for 30 minutes. Following
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incubation, cells were heat shocked for 30 seconds at 42°C and then placed on ice for 5 minutes.
NEB 10-beta/Stable Outgrowth Medium (950 µl) was added and the cells incubated at 37°C with
shaking for 60 minutes. Cells (50 µl) were added to pre-warmed plates with the appropriate
antibiotic (Table 4) and incubated overnight at °C. For the transformation of BL21(DE3), cells
were thawed on ice for 10 minutes and then 1 µl plasmid DNA was added. Cells were flicked to
mix, placed on ice for 30 minutes, then heat shocked at 42°C for 10 seconds. After 5 minutes on
ice, 950 µl of SOC medium was added and the cells were incubated at 37°C for 60 minutes with
shaking. Aliquots of 25, 50, or 100 µl were added to prewarmed plates and incubated at 37°C
overnight.

Vaginolysin expression and purification
The vly gene was amplified from Gardnerella strains using primers and PCR conditions outlined
in Table 5. Purified PCR products were digested with BamHI and XhoI and then ligated to
pET32XT. The vly-containing plasmid was transformed into E. coli strain NEB Stable. Single
colonies growing on LB agar containing ampicillin were used to inoculate LB broth. After
overnight growth at 37°C with shaking, plasmids were extracted and purified as described above
and presence of the vly gene was confirmed with Sanger sequencing (Eurofins). The plasmid was
then transformed into E. coli strain BL21(DE3) CodonPlus pRIPL (Agilent technologies) as
described above. Single colonies were used to inoculate 3 mL LB broth and after overnight growth
at 37°C with shaking, 1 mL of culture was used to inoculate 25 mL fresh LB broth. After overnight
growth at 37°C with shaking, the 25 mL culture was added to 500 mL fresh LB broth and incubated
at 37°C with shaking to exponential phase (OD600= 0.5). The expression of vly was induced by the
addition of 1 mM IPTG for 2 hours and then the bacteria were collected by centrifugation. Bacteria
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were then lysed in a French pressure cell in 25 mL B-PER™ (ThermoFisher Scientific) containing
protease inhibitors (EDTA-free cOmplete™, Sigma) and the lysate was cleared by centrifugation
and filtration. The protein was purified by cobalt affinity chromatography (His-Pur™, ThermoFisher Scientific) according to manufacturer instructions, eluted in 0.25 M imidazole, and dialyzed
against 1X phosphate buffered saline (PBS) overnight and then for two hours at 4°C. In some
instances, the affinity tag was removed by thrombin digestion (1 unit/mL, Sigma-Aldrich). VLY
in 1X PBS was then concentrated using a 3,000-molecular-weight(3K)-cutoff centrifugal filter
(Millipore). Purified, concentrated protein was then sterile filtered (Pall), and aliquots were frozen
at -80°C until needed. The empty vector control was similarly prepared. Protein purity was
assessed by denaturing PAGE gel as described above.

Protein quantification
For quantification of VLY used for EpiVaginal studies, and preparations of phage λ beta, a
NanoDropTM spectrophotometer was used. For more accurate quantification of VLY used in
comparative studies of AMD and 14018 VLY, a bicinchoninic acid (BCA) assay (PierceTM) was
used. This assay was performed according to the manufacturer’s instructions. In brief, absorbance
values at 562nm of sequential BSA concentrations were used to generate a standard curve.
Absorbance values of samples of diluted VLY were compared against the standard curve to
generate a total protein concentration for the sample. Then, because calculated values were total
protein and not just VLY concentrations, dilutions of each protein preparation were analyzed by
denaturing PAGE. Dilutions that exhibited the same intensity of VLY protein on the gel were
considered to have “similar” VLY concentrations and these dilutions were used for comparisons
in subsequent assays.
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Endotoxin quantification
Endotoxin contamination of protein preparations was assessed using a ToxinSensorTM Gel Clot
Endotoxin Assay Kit (GenScript). This Limulus Amebocyte Lysate-based test is a semiquantitative test for Gram-negative bacterial endotoxin. Endotoxin levels in negative samples are
lower than 0.25 EU. The endotoxin concentration value in a sample can be determined by
multiplying the dilution factor by 0.25. The assay was performed according to manufacturer’s
instructions. We determined that <25 EU/mL were added to each tissue during EpiVaginal
experiments and <2.5 EU/mL were added during cell monolayer experiments.

EpiVaginal cytotoxicity
One hundred µl of VLY (10 µg/mL) or G. leopoldii AMD (OD600 0.05 or ~105 CFU/mL) in PBS
without magnesium or calcium chloride, was added to the apical or basolateral side of EpiVaginal
tissue. Positive cytotoxicity controls (100 µl of 1.0% Triton X-100 or 100% methanol) were added
apically to tissues for 2 hours. To the side opposite of inoculation, 100 µl of PBS was added. After
16 hours of anaerobic incubation with VLY, the fluid from the apical side was combined with the
basolateral media and the tissue was removed. To the tissues incubated 16 hours with G. vaginalis,
300µl of fresh media was added apically to collect apically released LDH. Basolateral media was
decanted separately. The fluid was clarified by centrifugation (10,000 X g for 10 minutes), and
100 µl was used for quantification of extracellular LDH using a Cytotoxicity Detection Kit
(Roche). Spent media from the tissues and LDH substrate were incubated for 15 minutes at room
temperature. A490 values were measured after addition of stop solution to determine relative LDH
activity released from treated and untreated tissues. The % LDH release relative to controls was
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calculated using the following formula: ((LDHsample-LDHno
treatment

treatment)/LDHlysis reagent control-LDHno

)x100. The tissues were rinsed twice with 400 µl PBS and added to either 300 µl of 3-(4,5-

dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Calbiochem) (1mg/mL in
DMEM) or submerged in 1 mL 1:1 PBS: 0.4% trypan blue (Sigma). For MTT assays, tissues were
incubated with MTT for 3 hours at 37˚C and 5.0% CO2. Tissues were exposed to the trypan blue
solution for 3 minutes at room temperature. Stained tissues were then rinsed and fixed in 10%
formalin (~1.5mL) at 4˚C for 72 hours.

EpiVaginal co-culture growth assay
G. vaginalis was added to tissues apically or basolaterally as described above. After 16 hours of
anaerobic incubation at 37˚C and 5.0% CO2, CFUs were quantified by plating 10 µl of each 10fold dilution of tissue or basolateral media onto starch agar plates via the drip plate method. Each
dilution was sonicated for 10 seconds prior to plating to disperse bacterial aggregates. To quantify
bacteria located on and within the tissue, inserts were first moved to 1mL PBS and then sonicated
to homogenize the tissues using a Series 60 Sonic Dismembrator Model F60 set at the lowest
possible setting (Fisher Scientific). Plates were incubated anaerobically at 37˚C for 72 hours and
colonies counted from dilutions with 20-200 colonies. Bacteria in the basolateral media of tissues
inoculated only apically were removed from subsequent analyses, as this indicated that the tissue
integrity was compromised.

EpiVaginal kill assay
A log-phase culture of G. vaginalis was first diluted to an OD600 of 0.05 in sBHI and then 50µl
was added to wells of a 96-well plate. Next, 50µl of spent EpiVaginal tissue media from the apical
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or basolateral side or 50µl of sBHI (no treatment) was added to the wells. After 24 hours of
anaerobic growth at 37˚C, bacterial cultures were diluted, sonicated, and plated to quantify
CFU/mL.

EpiVaginal cytokine analysis
G. vaginalis or VLY was added to tissues apically or basolaterally as described in the
“Cytotoxicity” section above. For VLY-treated tissues, after 16 hours of anaerobic incubation, the
apical fluid was pooled with the basolateral media and the tissue was removed. For the G.
vaginalis-treated tissues, 300µl of fresh media was added apically to collect apically secreted
cytokines. Basolateral media was decanted separately. To compare cytokine secretion in response
to VLY or empty vector control, 1 µg/mL protein prep was added to 24-well plates of VK2 cell
monolayers and incubated anaerobically for 4 hours. Aliquots of clarified spent media were stored
at -80˚C until analysis. Supernatants were analyzed for relative cytokine concentrations using both
a Bio-Plex Pro Human 27-Plex Assay and a Quantikine HS ELISA Human IL-1β Immunoassay.
Assays were performed according to manufacturers’ instructions and plates analyzed by the BIORAD Bio-Plex MAGPIX Multiplex Reader. The Quantikine assay was used for IL-1β
quantification instead of the Bio-Plex assay because of its increased sensitivity, which was
important for detecting significant differences in our preliminary experiments. Cytokine
concentrations were quantified by comparing sample values to a standard curve. The standard
curve of each cytokine was fit with a 5-parameter logistic model. Some sample values from IL1ra were beyond the limits of this model. Consequently, standard curve values were fitted with a
power model (y = 24.639x4.3196, R2=0.953) and sample values calculated using its equation. Four

24

cytokines, IL-10, IL-5, IL-13, and Basic FGF were excluded from subsequent analyses because
their levels in spent media from the tissues were below the limit of detection.

EpiVaginal RT-PCR
Approximately 109 G. vaginalis AMD in PBS was added to the apical or basolateral face of
EpiVaginal tissue, EpiVaginal tissue culture media alone, or to sBHI. After 4 hr, the bacteria were
collected and resuspended in 500μl RNALater for 5 min. The bacteria were collected by
centrifugation and resuspended in 500 μl buffer RLT (Qiagen). The suspension was transferred to
Lysing Matrix B tubes (MP Biomedicals) and 500 μl of a 5:1 mixture of acid phenol: cholorform
(ThermoFisher) was added. The cells were lysed using a FastPrep FP120 Instrument
(ThermoFisher) with settings of power 6 and duration of 40 seconds. Samples were centrifuged 5
minutes 20,817 rpm at 4°C, the upper layer was transferred to a new microfuge tube containing
500 μL EtOH (500 μl), the samples were mixed by inversion, and the RNA purification was
performed using the RNeasy kit (Qiagen) according to manufacturer's instructions, and the RNA
was eluted in 90 μl of RNase-free water. DNA was removed using the Turbo DNA-free kit
(Ambion). Synthesis of cDNA from 1 μg RNA was carried out using the iScript kit (BioRad).
Resulting cDNA was diluted 1:10, and 2 μl of the diluted cDNA was used as a template for realtime
RT-PCR in reactions that included 0.4 μM of each forward and reverse primer as well as iTaq
Universal SYBR Green Supermix (BioRad). Primer sets are listed in Table 5. Control reactions
lacked reverse transcriptase enzyme to ensure that DNA contamination was minimal. Reactions
were performed on an IQ5 Multicolor Realtime PCR Detection System (Bio-Rad). Relative vly
transcript levels were determined by normalization to 16S rRNA gene expression using the
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equation 2^-(CTGOI- CT16S). Averages were obtained from technical replicates and standard
deviation was determined.

EpiVaginal histology
Trypan blue and MTT stained tissues were rinsed with PBS, fixed in 10% formalin at 4°C for 72
hours, and embedded in either paraffin or O.C.T Compound (Tissue-Tek®). Prior to tissue
processing, tissues were cut in half to prevent folding during the embedding process. Paraffinembedded tissues were processed using the standard core protocol using an automatic processor
under vacuum: 70% EtOH 30min; 2x 95% EtOH 45min each; 3x 100% EtOH 45min each; 2x
clearing agent (CitriSolv) 45min each; 4x paraffin (Paraplast plus) 30min each at 60 ˚C. To
visualize staining, 5 µM sections were cut, deparaffinized, and immediately cover-slipped with
mounting media. O.C.T-embedded tissues were first bathed in 15% and then 30% sucrose in PBS
for cryoprotection. To visualize staining, 5 µM cryosections were cut onto SUPERFROST® PLUS
Gold Slides, rinsed in PBS, and cover-slipped with 90% glycerol. Hematoxylin and eosin (H&E)
staining was performed by the VCU Massey Cancer Center Cancer Mouse Model Core Laboratory
(CMMCL). Digital images of tissue sections were captured on an EVOS® XL Core imaging
system. Percent trypan blue-staining was calculated by counting the number of stained cells in the
most apical or most basolateral layer of the tissue and dividing by the total number of cells in that
layer. Four tissue sections were counted for each treatment.

EpiVaginal immunohistochemistry
Immunohistochemistry (IHC) to detect CD59 (1:100, Novus Biologicals) was performed in the
CMMCL with the Leica Bond RX autostainer using heat-induced epitope retrieval buffer 2 (Leica,
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EDTA pH 8.0). Stained slides were then imaged on the Vectra Polaris (PerkinElmer). The color
deconvolution method was used to semi-quantitatively assess CD59 staining on apical vs
basolateral sections of tissues143. 3,3′-Diaminobenzidine (DAB) and hematoxylin were digitally
separated using the Fiji version of ImageJ software (version 2.0.0-rc-69/1.52i, National Institutes
of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/) and an ImageJ plugin for color
deconvolution144,145. Following deconvolution, the minimum image threshold was set to 20 and he
maximum to 200, using a black and white color scale. The number of pixels within apical or
basolateral sections of deconvoluted, DAB-stained images was assessed using ImageJ software,
and this value was divided by the cell number to give a value of Density/cell. Four total sections
were quantified.

Clade, species, and VLY type assignment to available Gardnerella genomes
In order to extract the VLY sequences from all the Gardnerella genomes available on NCBI, we
created a profile Hidden Markov Model using HMMER3 for the pfam PF01289 (Thiol_cytolysin
protein). All proteins and CDS from complete and draft from 110 Gardnerella genomes available
from NCBI were downloaded. Proteins were searched using HMMsearch to find hits to the PF0289
HMM profile created above and the corresponding CDS was extracted from each of the genomes.
The Gardnerella strains from which VLY sequences were extracted (84 strains) were
automatically aligned using MUSCLE and the final alignment was manually inspected. The
maximum-likelihood tree was inferred by PhyML using Phylogeny.fr tool using the gammadistributed heterogeneity rate categories with 1,000 bootstraps146,147.

Clade and species

designations were assigned manually using schema outlined in Ahmed et. al 2012 and
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Vaneechoutte et. al 2019, respectively129,135. VLY type was assigned based on the scheme
described below (Fig. 13).

VLY alignment
Extracted undecapeptide and CD59 region sequences were aligned using Clustal Omega; Guide
Tree; Cladogram and colored to highlight conserved and divergent sequences (Fig. 11)148.

Distinction of VLY types
Based on the similarities and differences observed in the sequence alignment, VLY types were
first classified based on sequence differences in the CD59 region149,150. Type 1 VLY contained
aspartate and serine in positions 4 and 6 of the CD59 region while type 2 VLY contained
asparagine and threonine and type 3 VLY contained asparagine and serine. The toxin types were
then sub-grouped based on sequence differences in the undecapeptide region. Since types 2 and 3
were uniform in this region, there were no subgroups for these types. Type 1, on the other hand,
had either double valine (1A), valine and alanine (1B), or glutamine and valine(1C) at positions 1 and 6 of the undecapeptide region (Fig. 12).

Comparison of VLY monolayer cytotoxicity
Preparations of either VLYAMD or VLY14018 containing similar concentrations of the toxin, as
determined by visualization of ~72 kDa band (57 kDa VLY plus 6xHis tag) on a NuPAGE 4 to
12% Bis-Tris gel under denaturing conditions, were compared. Protein preparations were diluted
to 1 or 5 µg/mL in VK2/E6E7 culture medium without antibiotics and then 100ul of diluted toxin
or control medium was added to at least 3 individual wells of 96-well plates of VK2 monolayers.
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After 30 minutes of co-incubation at 37°C, the media was removed and 100ul of a 1:1 solution of
0.4% trypan blue and PBS was added to each well and incubated at 37°C for 1 minute. The trypan
blue was removed, the wells rinsed with PBS, and 100ul of fresh medium was added. Monolayers
were then imaged by light microscopy to assess the percent of cells staining with trypan blue. This
was done on both “less mature” cells (4 days post-seeding), with and without anti-CD59
pretreatment (1:1000, 30 minutes), and “more mature cells” (7 days post-seeding). Percent trypan
blue staining was calculated by diving the number of blue stained cells in an image by the total
number of cells and multiplying by 100.

VK2/E6E7 monolayer cytokine analysis
Five hundred microliters of preparations of either VLYAMD or VLY14018 in VK2 medium
containing similar concentrations (less than 5ug/mL) of the toxin (predetermined to not lyse more
than 50% of the cells in each well) were added to 24-well plates in triplicate and then incubated
aerobically in 5% CO2 at 37°C. After 19 hours of co-incubation, media was decanted from wells,
clarified, and frozen at -80°C until analysis. Supernatants were analyzed for relative cytokine
concentrations using a Bio-Plex Pro Human 27-Plex Assay as outlined in the “EpiVaginal cytokine
analysis” section above. As a default, the standard curve of each cytokine was fit with a 5parameter logistic model. When any sample value for a given cytokine was beyond the limits of
this model, standard curve values were fitted with a different, appropriate model and all sample
values for that cytokine were re-calculated using its equation. These equations are presented in a
table below. While 27 cytokines were quantified, only those with different values between controls
and treatments (Fig. 15), or different values for AMD and 14018 VLY-treated cells (Fig. 16), are
presented.
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Table 1. Standard curve equations for VK2/E6E7 cytokines
Cytokine
Equation
R²
IL-1β
IL-1ra
IL-2
IL-4
IL-5
G-CSF

y = 4E-05x2 + 0.0073x + 0.2404
2

y = 0.0002x + 0.2825x + 48.306
y = 0.9218x + 3.5371
y = 0.1055x + 0.2119
y = 6.2281x + 9.001
y = 1.2522x + 8.0105

0.999
0.9998
0.9959
0.9981
0.9978
0.9983

GM-CSF y = 6E-08x3 - 0.0001x2 + 0.1957x + 1.1629
1
Eotaxin
y = 0.0212x + 0.1187
0.9972
MIP-1a
TNF-a

y = -0.0001x2 + 0.0837x + 0.5733
y = 1.6428x + 8.1568
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1
0.9977

Cohort 1 VLY type metagenomic data analysis

Participant recruitment: We analyzed 64 samples from our Vaginal Human Microbiome Project
(VaHMP) cohort. In this study, we collected more than 40,000 vaginal, cervical, introital and
buccal swab samples cross-sectionally from a racially diverse cohort of 3,815 women visiting
VCU Medical Center women’s clinics.

Sampling and sample processing: Samples were collected with BD BBL CultureSwab EZ swabs.
Swabs were processed immediately using MoBio Powersoil kit as described by the manufacturer.
DNA samples were stored at −80 °C.

Whole shotgun metagenomic sequencing: DNA libraries were prepared using Illumina Truseq
DNA library prep kit and sequenced on an Illumina HiSeq 2000 (2 × 100 b PE). Samples were
sequenced individually in each lane and 5 × 108 paired-end reads per sample were obtained.

Whole shotgun metagenomic data pre-processing: Raw sequence data were demultiplexed into
sample-specific fastq files using bcl2fastq conversion software from Illumina. The pre-processing
of raw paired-end sequence data was performed using Trimmomatic, by removing Illumina
specific adapters from the reads and trimming the 5ʹ end for quality using a sliding-window
approach (average Q20 over a window of 4 b). Reads shorter than 70 bases after trimming were
discarded. This was followed by removal of contaminant reads of vector and human origin by
aligning against the UniVec database (https://www.ncbi.nlm. nih.gov/tools/vecscreen/univec/) and
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the hg19 build of the human genome using bwa. Two samples had fewer than 100,000 high-quality
reads and were removed from further downstream analysis.

Taxonomic classification: Taxonomic classification of the metagenomics sequence data was
performed on high-quality non-human reads by alignment to a custom database of bacterial
genomes using CLARK-S, a discriminative space k-mer-based approach. Bacterial genomes were
downloaded from the NCBI Reference Sequence Database, accessed in March 2017, supplemented
with our in-house genome assembly of Lachnospiraceae_BVAB1. Species abundances were
estimated by normalizing the assigned read counts to species genome size.

Gardnerella spp. cpn60 database: In order to create a comprehensive cpn60 database, we first
created a profile Hidden Markov Model using HMMER3 for the pfam PF00118 protein family
(TCP-1/cpn60 chaperonin family). This method uses a homology detection approach by
comparing sequence reads to HMM profile. All proteins and CDS from complete and draft from
105 Gardnerella genomes available from NCBI were downloaded. Proteins were searched using
HMMsearch to find hits to the PF00118 model created above and the corresponding CDS was
extracted from each of the genomes. This cpn60 database was used to taxonomically classify the
Gardnerella reads from the metagenomic data to the species/strain levels.

Grouping samples by VLY type: The number of vly reads of each type in a given sample were
used to determine the “dominant” VLY type of the sample. The VLY type exhibiting a clear
majority of the total vly reads for a sample (representing ≥ 50% of all vly reads) was designated as
the dominant type. If two VLY types were equally represented and together made up a majority of
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the total vly reads in a sample, this sample was said to be dominated by both types and placed into
both VLY type groups.

Cohort 2 data analysis

Participant recruitment: We analyzed 733 of 762 samples from our Vaginal Human Microbiome
Project (VaHMP) cohort. This sub cohort of the VaHMP study has 3 groups with the following
characteristics: Group 01, 185 participants with current diagnosis of bacterial vaginosis (BV) but
no history of recurrent BV; Group 02, 191 participants with history of BV but no current BV
diagnosis and Group 03, 357 participants with no history nor current diagnosis of BV.

Sampling and sample processing: Samples were processed, and DNA was extracted as described
above.

16S rRNA taxonomic surveys: DNA in each sample was amplified with barcoded primers
targeting the V1–V3 region of the 16S rRNA Samples were amplified and sequenced on the 454
Titanium Sequencer and analyzed as previously described23. Each high-quality amplicon sequence
was taxonomically classified to the species level using STIRRUPS by alignment to a custom
reference database of vaginally relevant species151. Samples were filtered based on the sequencing
depth—samples having fewer than 1,000 high-quality amplicons were removed from further
analysis.
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Resolution of Gardnerella spp. using cpn60: The cpn60 gene encodes the 60 kDa chaperonin,
(also called groEL or hsp60). Similar to 16S rRNA gene heterogeneity, this gene is particularly
useful since a phylogenetically informative fragment of the gene can be amplified with degenerate
polymerase chain reaction (PCR) primers. The target region used in this study corresponds to
nucleotides 274–828 of the Escherichia coli cpn60 sequence. Targeted deep sequencing of the
cpn60 gene was performed using the tailed amplicon sequencing approach (a.k.a. Two-Step PCR
Approach). The PCR approach was carried out in 2 steps: the first round of PCR uses primers
containing a cpn60 locus-specific sequence (Table 5) and a common 5’ tail, and the second round
of PCR is performed to introduce the indexes (barcodes) as well as the Illumina-specific
sequencing adapters152. The first round of PCR was performed using High-Fidelity Polymerase,
0.2 mM each dNTP, and 0.4 μM of each primer. The PCR thermocycler profile used is detailed in
Table 5. Samples were purified using Agencourt® AMPure XP beads using DNA:beads ratio of
1.2 to remove primer and unincorporated dNTPs. Next, the second round of PCR was performed
using 1 μl of a 1/10 diluted first-round PCR product as template and Applied Biosystems 9700
PCR System with 1 U Thermo Scientific Phusion Hot Start II High-Fidelity PCR Master Mix, and
0.2 μM of each primer. The PCR thermocycler profile used is detailed in Table 5. Samples were
submitted to a second PCR clean-up using Agencourt® AMPure XP beads using DNA:beads ratio
of 1.12 to remove primer and unincorporated dNTPs. Libraries were quantified using fluorometric
quantification and pooled equimolarly. Libraries were sequenced using Illumina MiSeq v3 600
cycle kit. Samples were filtered based on the sequencing depth—samples having fewer than 1,000
high-quality amplicons were removed from further analysis. Each high-quality amplicon sequence
was taxonomically classified to Gardnerella strain level by alignment to the custom cpn60
reference database detailed in the Cohort 1 section above. High-quality reads that aligned at ≥ 99%
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identity using the USEARCH v4.0 global alignment algorithm were assigned to the same strainlevel taxon.

Grouping samples by VLY type: Since a given Gardnerella strain can be distinguished via its
cpn60 sequence, and each strain produces a specific VLY type, VLY type abundance in each
sample was extrapolated from cpn60 read data to classify the dominant VLY type of each sample.
Similar to Cohort 1, If two VLY types were equally represented and together made up a majority
of the total vly reads in a sample, this sample was said to be dominated by both types and placed
into both VLY type groups.

VLY type distribution among study participants
For Cohort 1, the number of reads of a given VLY type across all samples was divided by the total
number of vly reads across all samples and multiplied by 100 to give a percent value. For Cohort
2, after cpn60 reads were assigned to a specific VLY type, these reads were similarly divided by
the total number of reads and multiplied by 100 to give a percent value.

Frequency of vaginal symptoms in women with different VLY types
After each sample was assigned a dominant VLY type, they were then grouped according to the
symptoms reported. Samples with more than one reported symptom were placed in both symptom
groups. Then, in each symptom group, each sample was counted as a “yes” or “no” for having
each VLY type as the dominant VLY type. This answers the question, “Of women experiencing a
certain symptom, what percent of those women had a given VLY type as the dominant type?” For
Cohort 1, a Homogeneity test (appropriate for comparing proportions of 3 or more groups with
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binary outcomes) was used to detect any significant differences in the proportions among the VLY
types being compared for each symptom. For Cohort 2, a Chi-Square test (appropriate for
comparing proportions of two groups with binary outcomes and with expected frequencies all
greater than or equal to 5) was used.

Relative bacterial abundance in women with different VLY types
16S rRNA sequencing reads were used to determine the relative abundance of different bacterial
species in each sample as described above. After sample grouping by VLY type, the median
relative abundance of each bacterial species was calculated. As relative abundance data were not
normally distributed, a non-parametric Wilcoxon test was used to test for statistically significant
differences in the median relative abundance values between VLY type groups.

Transmission electron microscopy
One mL of an overnight culture of opaque variant bacteria grown in sBHI was spun down at 11,000
x g for 2 minutes, and the supernatant decanted. The bacterial pellet was washed once in 1mL PBS
and resuspended in 100ul of PBS. Bacteria were then fixed by adding 100ul of 0.2%
glutaraldehyde in 0.1M cacodylate buffer and incubating at 4°C for 2 hours. A formvar-carbon
coated mesh grid was first glow discharged and then floated on the surface of a drop of this
bacterial suspension for 15 minutes. The grid was blotted, washed twice by being dipped onto a
drop of distilled water, then transferred to a drop of 0.5% uranyl acetate for 60 seconds. The grids
were blotted and allowed to dry overnight before visualization on a Jeol JEM-1400Plus electron
microscope at 100 kV.
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Identification of Tad locus homologues
The tight adhesion (Tad) locus encodes the genes for the biogenesis of type IV pili in a wide variety
of bacterial species. Amino acid sequences from the genes encoded in the predicted Tad locus of
G. leopoldii AMD were used to perform a BLAST protein search on NCBI. Gardnerella strains
encoding proteins with at least 50% amino acid identity across at least 80% of the coding region
were noted. The appropriate operon organization of the respective genes (i.e. sequential, in the
same region of the chromosome) was verified, apart from tadV, which commonly resides outside
the operon in Gram-positive organisms.

Sequencing Tad locus
DNA for sequencing was extracted as outlined in the “gDNA extraction” section above. DNA was
extracted from both bacteria grown as colonies and in liquid cultures. The amplification of various
regions within and upstream of the Tad locus in G. leopoldii AMD was performed using the
primers and PCR parameters detailed in Table 5. Sanger sequencing was performed by Eurofins
Genomics.

Tad locus RT-PCR
Bacteria (both grown as colonies and in liquid cultures) were collected and resuspended in 500μl
RNALater for 5 min. The bacteria were collected by centrifugation and resuspended in 500 μl
buffer RLT (Qiagen). The suspension was transferred to Lysing Matrix B tubes (MP Biomedicals)
and 500 μl of a 5:1 mixture of acid phenol: cholorform (ThermoFisher) was added. The cells were
lysed using a FastPrep FP120 Instrument (ThermoFisher) with settings of power 6 and duration of
40 seconds. Samples were centrifuged 5 minutes 20,817 rpm at 4°C, the upper layer was
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transferred to a new microfuge tube containing 500 μL EtOH (500 μl), the samples were mixed by
inversion, and the RNA purification was performed using the RNeasy kit (Qiagen) according to
manufacturer's instructions, and the RNA was eluted in 90 μl of RNase-free water. DNA was
removed using the Turbo DNA-free kit (Ambion). Synthesis of cDNA from 1 μg RNA was carried
out using the iScript kit (BioRad). Resulting cDNA was diluted 1:10, and 2 μl of the diluted cDNA
was used as a template for realtime RT-PCR in reactions that included 0.4 μM of each forward and
reverse primer as well as iTaq Universal SYBR Green Supermix (BioRad). Primer sets are listed
in Table 5. Control reactions lacked reverse transcriptase enzyme to ensure that DNA
contamination was minimal. Reactions were performed on an IQ5 Multicolor Realtime PCR
Detection System (Bio-Rad). Relative Tad locus transcript levels were determined by
normalization to 16S rRNA gene expression using the equation 2^-(CTGOI- CT16S). Averages were
obtained from technical replicates and standard deviation was determined.

Biofilm assay
Single colonies of either G. vaginalis 14018 or G. leopoldii AMD were used to inoculate sBHI
and incubated anaerobically for 72 hours. Subcultures of 1:30 were prepared in fresh media and
allowed to grow anaerobically overnight. These overnight cultures were then adjusted to an OD600
of 0.075 (AMD) or 0.01(14018) in fresh sBHI. Two hundred microliters were added to 9 wells in
a 96-well CellBIND plate (Corning) and incubated anaerobically at 37°C for 24 hours. Six wells
were used to quantify OD600 and biofilm. The other 3 wells were used to determine the % of each
variant making up the cells in the medium and the adherent cells making up the biofilm. For biofilm
quantification, the medium was removed from each well and wells were washed once with 200ul
PBS. Wells were allowed to air dry for 1 hour. They were then stained with 200ul 100% safranin
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for 60 seconds, rinsed once in PBS, and then air dried again for 1 hour. Stained biofilms were then
solubilized by adding 200ul 33% acetic acid and then the A562 was quantified. Each biofilm A562
value was normalized against the average growth (OD600 output- OD600 input) in 3 wells. For
quantifying variants in the medium of each well (planktonic bacteria), 2.5 ul was taken off the top
of the well, added to 1mL PBS, diluted 1:100, and then 25ul was plated onto sBHI plates with 10%
FBS. For quantifying variants in the biofilm, all media was removed from each well, the biofilm
was rinsed once in PBS, then 200ul fresh PBS was added. Each well was sonicated for 5 seconds
and similarly diluted before plating.

Scoring bacterial aggregation
Overnight cultures of bacteria of each variant were grown in sBHI. Bacteria were collected by
centrifugation, rinsed once in PBS, and then resuspended in PBS. Bacteria were then adjusted to
1 x 107 cells/mL in IMDM or sBHI. Various substrates were added (final concentrations detailed
below) to see whether aggregation was impacted. One hundred microliters of bacteria in media
with different substrates were added to wells of a 96-well plate and incubated at room temperature
for 90 minutes. Media in wells was dumped, and media remaining in each well was allowed to air
dry overnight. Bacteria in wells were then fixed with 50 ul of methanol for 3 minutes and then
wells were allowed to air dry. Wells were stained with 50ul of 10% Giemsa stain for 25 minutes,
rinsed once in PBS, and air dried. Bacterial aggregates were then imaged using an inverted light
microscope and scored using the scoring system outlined in Figure 38.
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Table 2. Concentrations of substrates used in Gardnerella aggregation experiments
Compound
Final concentration
Fibronectin
0.01 mg/mL
EDTA
0.5 mM
Hyaluronic acid
0.01 mg/mL
BSA
0.1 mg/mL
Collagen VI
0.01 mg/mL
Elastin
0.01 mg/mL
Mucin
0.01 mg/mL
Lactic acid
0.90%
Streptomycin
1mg/mL
Sodium citrate
12.5 mg/mL
H2 O2
0.30%
Trypsin, EDTA 0.0005%, 0.0002%
Proteinase K
0.2 mg/mL
DNase
0.1 mg/mL
TritonX100
0.01%
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Opacity variant growth during stressor exposure
Cultures (48-72 hours old) of bacteria of each variant were grown in sBHI and 10 ul used to
inoculate 200 ul of fresh media (3 wells each) in a 96 well plate. Bacteria were added to wells with
and without stressors (lactic acid, hydrogen peroxide, metronidazole, streptomycin) at a range of
concentrations. The plates were incubated anaerobically for 48 hours and optical density at 600nm
measured. Percent optical density relative to untreated wells is presented for hydrogen peroxide.
It was calculated by dividing the OD600 of treated wells by the OD600 of untreated wells and
multiplying by 100. Average MIC50 is presented for the remaining stressors. It was calculated by
generating a standard curve using the percent OD600 values calculated above and then plugging
50% into the equation to give the appropriate concentration.

HL-60 differentiation
For cell differentiation, cells were treated with all-trans retinoic acid (ATRA) (Acros Organics) at
a final concentration of 0.3 µg/mL for 4 days in IMDM supplemented with 20% heat inactivated
FBS, 50 U/mL penicillin, and 50 µg/mL streptomycin.

NBT assay
A nitroblue tetrazolium (NBT) (Sigma) assay was used to confirm cell differentiation153. The
production of superoxide anion in differentiated, stimulated cells acts to reduce yellow, water
soluble NBT and promote the formation of water insoluble blue formazan deposits which can be
quantified. A final concentration of 0.5 µg/mL NBT was added to HL-60 cells with or without the
addition of the stimulant, phorbol 12-myristate 13-acetate (PMA, 600 ng/mL) (Abcam). Cells were
incubated at 37°C for one hour, washed with warm PBS, washed with 100% methanol, and then
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air dried for one hour. The formazan was solubilized by the addition of 2M KOH followed by
DMSO and the absorbance at 620nm was determined.

Opacity variant survival of phagocytosis
HL-60 cells were collected by centrifugation and resuspended in IMDM containing 10% human
serum. The cell density was adjusted to 2 x 106 cells/mL. Overnight cultures of G. vaginalis 14018
or G. leopoldii AMD were grown in sBHI. Bacteria were collected, rinsed once in PBS, and then
resuspended in PBS. Bacteria were then adjusted to 2 x 107 cells/mL in IMDM with 10% human
serum. Bacteria were incubated in medium for 15 minutes with end over end rotation at 37°C to
promote opsonization prior to the addition of HL-60 cells. Then, equal volumes of either medium
alone or HL-60s in medium were added to bacteria and incubated for 75 minutes with end over
end rotation at 37°C. Dilutions of bacteria were plated to determine the number of bacteria at input
and after 90 minutes of total incubation. The percent survival is determined by dividing the number
of bacteria in samples with HL-60s by the average of the number of bacteria in samples without
HL-60s and multiplying by 100.

Oligonucleotide recombineering
A 100ul aliquot of electrocompetent cells was thawed on ice for 10 minutes. Then, 10ug of
oligonucleotide in 1 uL volume was added to the 100ul aliquot of cells and incubated on ice for
10 min. Eighty microliters of this was added to a pre-chilled 0.1cm cuvette and electroporated
using the “Agr” protocol on the BIORAD MicroPulser. Immediately following electroporation,
220 ul of sBHI (without any antibiotics) was added to the cuvette and then this was added to 4.7mL
sBHI (without any antibiotics). Cells were incubated anaerobically overnight and then diluted and
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plated onto sBHI plates with 10% FBS, with or without 100ug/mL streptomycin to determine the
% of transformants.

Phage λ beta cloning, expression, and purification
Phage λ bet was amplified from pKD46 using the primers detailed in Table 5, designed to include
BamHI and XhoI restriction sites. Purified PCR products were digested with BamHI and XhoI and
then ligated to pET32XT. The bet-containing plasmid was transformed into E. coli strain NEB
Stable. Single colonies growing on LB agar containing 100 μg ampicillin / mL were used to
inoculate LB broth. After overnight growth at 37°C with shaking, plasmids were extracted and
purified as described above and presence of the bet gene was confirmed with Sanger sequencing.
The plasmid was then transformed into E. coli strain BL21(DE3) CodonPlus pRIPL (Agilent
technologies) as described above. Single colonies were used to inoculate 3 mL LB broth and after
overnight growth at 37°C with shaking, 1 mL of culture was used to inoculate 25 mL fresh LB
broth. After overnight growth at 37°C with shaking, the 25 mL culture was added to 500 mL fresh
LB broth and incubated at 37°C with shaking to exponential phase (OD600= 0.5). The expression
of bet was induced by the addition of 1 mM IPTG for 2 hours and then the bacteria were collected
by centrifugation. Bacteria were then lysed in a French pressure cell in 25 mL BPER™ (ThermoFisher Scientific) containing protease inhibitors (EDTA-free cOmplete™, Sigma)
and the lysate was cleared by centrifugation and filtration. The protein was purified by cobalt
affinity chromatography (His-Pur™, Thermo-Fisher Scientific) according to manufacturer’s
instructions, and then eluted sequentially in 0.25 M and 0.5M imidazole. Five units of free bovine
thrombin (Sigma-Aldrich) were added to 5mL eluate and this was dialyzed against 1X PBS at 4°C
overnight and then for 2 hours. Thrombin-treated eluate was then added to the His-Pur™ (Thermo
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Scientific) column, the flow through collected, and buffered into binding buffer (0.05M Tris-HCl,
0.05M NaCl, pH 7.4). A 1mL Benzamidine Sepharose 4 Fast Flow (GE Healthcare) column was
prepared, washed with 5mL H2O, and equilibrated with 5mL binding buffer. Buffered eluate was
then added to the prepared column and the flow through collected. To make sure all protein was
eluted from column, an additional 1mL of binding buffer was added to the column and collected.
This was then buffered into ultrapure H2O and concentrated to 500ul using a 3,000-molecularweight(3K)-cutoff centrifugal filter. After filter sterilization, the concentrated protein was further
concentrated using an Amicon Ultra Ultracel 10K centrifugal filter, centrifuged at 4°C. Aliquots
of 10ul were prepared and kept at -20°C until needed. Different volumes of a 1:1 mix of λ beta
and mutagenic oligo, incubated on ice for 10 minutes, were added to 100ul of electrocompetent
cells. Cells were then electroporated and plated as outlined in the above “Oligonucleotide
recombineering” section. For trials with the addition of MgCl2, 10ul of oligo was added alongside
0.4ul of 50mM MgCl2 to one 10ul aliquot of purified λ beta. This was incubated for 10 minutes at
37°C and then 5 ul of this mixture was added to 100ul of electrocompetent cells.

Statistical analysis
This section describes the default statistical analyses performed in this body of work. If a particular
experiment or project required differential statistical analyses than what is described below, it is
noted in the relevant section within Materials and Methods chapter. All data were assessed for
normality using the Shapiro-Wilk test. Equality of variance was assessed using the BrownForsythe test. The means of normally distributed data with equal variance were compared by using
either one-way ANOVA (analysis of variance) with a post hoc Tukey honestly significant
difference (HSD) test (for comparisons of > 2 means) or Student’s t test (comparisons of 2 means).
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The means of normally distributed data with unequal variance were compared using Welch’s t test
with a post hoc Tukey HSD test (for comparisons of > 2 means). The means of non-normally
distributed data were compared using a nonparametric Wilcoxon text. All statistical analyses were
performed using JMP Pro 14.0 software (SAS Institute Inc., Cary, NC, USA). All cytokine data
from EpiVaginal tissues were log transformed prior to analysis. P values of less than 0.05 were
considered significant. Fold changes of 2 or higher were considered biologically relevant.
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Table 3. Bacterial strains used in this study.
Species
Strain
Use
Gardnerella vaginalis 1 ATCC 14018
VLY purification, biofilm assays, phagocytosis
assays, oligonucleotide recombineering,
confirmation of opacity variation, aggregation
assays, opacity variant switch frequency
Gardnerella leopoldii 5 AMD
VLY purification, EpiVaginal growth,
EpiVaginal cytokines, EpiVaginal cytotoxicity,
biofilm assays, phagocytosis assays, tad locus
sequencing, tad locus RT-PCR, oligonucleotide
recombineering, confirmation of opacity
variation, aggregation assays, opacity variant
switch frequency
Gardnerella piotii 3
GV3
Oligonucleotide recombineering, confirmation of
opacity variation
GV1
Confirmation of opacity variation
Gardnerella 2
JCP7275
Confirmation of opacity variation
Gardnerella 8
101
Confirmation of opacity variation
Gardnerella
UM224
Confirmation of opacity variation
Gardnerella
UM35
Confirmation of opacity variation
Escherichia coli
NEB Stable
Transformation of plasmid:insert ligations,
plasmid replication and purification, maintenance
of expression vectors
Escherichia coli
BL21(DE3)
Recombinant protein expression

46

Table 4. Antibiotics used in this study.
Name
Concentration
Streptomycin
50 µg/mL
Streptomycin

100 µg/mL

Penicillin

50 U/mL

Ampicillin

100 µg/mL
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Use
Maintenance of tissue
culture cell lines
Selection of oligo. recomb.
transformants
Maintenance of tissue
culture cell lines
Selection of Table 5.
Plasmid-containing bacteria

Table 5. Primers used in this study.
Name
Sequence (5’à
3’)
FWD
GGAAGGGATC
CGATTCTTCTG
CAAAGCCTTC
TGC

AMD VLY
cloning

Initial denature: 94°C, 30 sec.
Cycle #: 35
----------Denature: 94°C, 30 sec.
Anneal: 60°C, 30 sec.
Extend: 72°C, 2 min.
----------Final extend: 72°C, 5 min.

AMD VLY
cloning

Initial denature: 94°C, 30 sec.
Cycle #: 35
----------Denature: 94°C, 30 sec.
Anneal: 60°C, 30 sec.
Extend: 72°C, 2 min.
----------Final extend: 72°C, 5 min.
GGAAGCTCGA Initial denature: 94°C, 30 sec.
GTCAGTCGTTC Cycle #: 35
TTTACAGTTTC ----------AGCAAC
Denature: 94°C, 30 sec.
Anneal: 60°C, 30 sec.
Extend: 72°C, 2 min.
----------Final extend: 72°C, 5 min.
GGTTCGATTCT Initial denature: 94°C, 30 sec.
GGCTCAGG
Cycle #: 35
----------Denature: 94°C, 30 sec.
Anneal: 50°C, 30 sec.
Extend: 68°C, 30 sec.
----------Final extend: 68°C, 5 min.

14018 VLY
cloning

GGAAGCTCGA
GTCAGTCATTC
TTTACAGTTTC
AGCAAC

Vaginolysin14018

GGAAGGGATC
CGCTCCTTCCG
CTAAGGATTC
TG

GV16SFullGENEFWD

Use

Initial denature: 94°C, 30 sec.
Cycle #: 35
----------Denature: 94°C, 30 sec.
Anneal: 60°C, 30 sec.
Extend: 72°C, 2 min.
----------Final extend: 72°C, 5 min.

REV

Vaginolysin14018REV

PCR Conditions
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14018 VLY
cloning

Confirmation
that opacity
variants were
Gardnerella
and not
contamination

GV16SFullGENEREVnew

TADAMDFWD

TADAMDREV

TadAMDSeq1

GGTACGGCTA Initial denature: 94°C, 30 sec.
CCTTGTTACGA Cycle #: 35
C
----------Denature: 94°C, 30 sec.
Anneal: 50°C, 30 sec.
Extend: 68°C, 30 sec.
----------Final extend: 68°C, 5 min.
ATCTACGATA Initial denature: 98°C, 30 sec.
CAGTGCAAGT Cycle #: 40
GC
----------Denature: 98°C, 5 sec.
Anneal: 58°C, 5 sec.
Extend: 72°C, 105 sec.
----------Final extend: 72°C, 60 sec.
GATCAACTTA Initial denature: 98°C, 30 sec.
GCAAAACGGC Cycle #: 40
AC
----------Denature: 98°C, 5 sec.
Anneal: 58°C, 5 sec.
Extend: 72°C, 105 sec.
----------Final extend: 72°C, 60 sec.
GCAAAGTCGA NA
TCTGTTGCAG
AAGC

TadAMDSeq2

GAGTTGTAGT
GAAGTTTAAG
AATGC

NA

TadAMDSeq3

TAGGCGTGAC
GATATTAAAG
AGC

NA
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Confirmation
that opacity
variants were
Gardnerella
and not
contamination
Amplification
of ~7kb of Tad
locus and
upstream
sequence

Amplification
of ~7kb of Tad
locus and
upstream
sequence

Sequencing of
Tad locus
starting at
~1500 bp
upstream of
GVAMD_112
4
Sequencing of
Tad locus
starting at
~1000 bp
upstream of
GVAMD_112
4
Sequencing of
Tad locus
starting at
~500 bp
upstream of
GVAMD_112
4

TadAMDSeq4

ATGGCTGGTA
CGTTGTCTGC

NA

TadAMDSeq5

GATGTTAAAC
GTTATGTTTAT
CCTCC

NA

TadAMDSeq6

ATGGCATGGT
AAATATCCTG
AACC

NA

TadAMDSeq7

ACGCGCAACT
CGAGTTCCAC

NA

TadAMDSeq8

GCATTATTCTT
GGTGAATGTC
G

NA

TadAMDSeq9

CAAAGAAGCG
CAATATGAAT
AAGAC

NA

TadAMDSeq10

GATTATTGTTT NA
CACTTCGTAGT
GG

TadAMDSeq11

GAAAGGTACA
AGATGATGGT
TGG
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NA

Sequencing of
Tad locus
starting at
~100 bp
downstream of
GVAMD_112
4
Sequencing of
Tad locus
starting at
~100 bp
downstream of
tadZ
Sequencing of
Tad locus
starting at
~600 bp
downstream of
tadZ
Sequencing of
Tad locus
starting at
~100 bp
downstream of
tadA
Sequencing of
Tad locus
starting at
~600 bp
downstream of
tadA
Sequencing of
Tad locus
starting at
~100 bp
downstream of
tadB
Sequencing of
Tad locus
starting at
~200 bp
downstream of
tadC
Sequencing of
Tad locus
starting at ~10

14018rpsLFWD

14018rpsLREV

BETFWDBam

BETREVXho

Gv16sc-FWD

Gv16sc-REV

TTGCGTGGCG
TGTGCAC

Initial denature: 94°C, 30 sec.
Cycle #: 35
----------Denature: 94°C, 30 sec.
Anneal: 50°C, 30 sec.
Extend: 68°C, 30 sec.
----------Final extend: 68°C, 5 min.
TTACTTCGCCT Initial denature: 94°C, 30 sec.
TCTTTGCTCC
Cycle #: 35
----------Denature: 94°C, 30 sec.
Anneal: 50°C, 30 sec.
Extend: 68°C, 30 sec.
----------Final extend: 68°C, 5 min.
GCGAATCGGA Initial denature: 94°C, 30 sec.
TCCATGAGTA Cycle #: 35
CTGCACTCGC
----------AACGC
Denature: 94°C, 30 sec.
Anneal: 62°C, 30 sec.
Extend: 68°C, 30 sec.
----------Final extend: 68°C, 5 min.
GCGAATCCTC Initial denature: 94°C, 30 sec.
GAGTCATGCT Cycle #: 35
GCCACCTTCTG ----------CTC
Denature: 94°C, 30 sec.
Anneal: 62°C, 30 sec.
Extend: 68°C, 30 sec.
----------Final extend: 68°C, 5 min.
AGATCATCAT Initial denature: 95°C, 120 sec.
GCCCCTTACG
Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
TTACTAGCGA Initial denature: 95°C, 120 sec.
CTCCGCCTTC
Cycle #: 45
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bp upstream of
GVAMD_111
9
Amplification
of rpsL to
check for
oligo-induced
nucleotide
changes
Amplification
of rpsL to
check for
oligo-induced
nucleotide
changes
λ beta cloning

λ beta cloning

Gardnerella
16s RT-qPCR

Gardnerella
16s RT-qPCR

MH7

CTTGCGCAGC
CAGCAAGG

MH8

GTTAATGGTG
CGCGATTTGC

TadCFWD

AGGAAACACT
TGCCCAACAG

TadCREV

TTGGCAATGG
GTGAGTTTG

TadDFWD

TAGCAGTGCA
GCAAAACCAG
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----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
Initial denature: 95°C, 120 sec.
Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
Initial denature: 95°C, 120 sec.
Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
Initial denature: 95°C, 120 sec.
Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
Initial denature: 95°C, 120 sec.
Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
Initial denature: 95°C, 120 sec.
Cycle #: 45
-----------

Gardnerella
vly RT-qPCR

Gardnerella
vly RT-qPCR

Gardnerella
tadC RTqPCR

Gardnerella
tadC RTqPCR

Gardnerella
tadD RTqPCR

TadDREV

TadGFWD

TadGREV

AMDTadPromoterFWD2

TadAMDSeq5

Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
ACTTGTTGCAC Initial denature: 95°C, 120 sec.
GATGCTCTG
Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
AGCCCAACAG Initial denature: 95°C, 120 sec.
AAACACGAAC Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
CGCAGTCTGC Initial denature: 95°C, 120 sec.
TCAATACTGG Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
ATCGTCAGCT
Initial denature: 95°C, 120 sec.
ATACATGG
Cycle #: 45
----------Denature: 95°C, 15 sec.
Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
GATGTTAAAC Initial denature: 95°C, 120 sec.
GTTATGTTTAT Cycle #: 45
CCTCC
----------Denature: 95°C, 15 sec.
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Gardnerella
tadD RTqPCR

Gardnerella
tadG(flp) RTqPCR

Gardnerella
tadG(flp) RTqPCR

Gardnerella
tadZ) RTqPCR

Gardnerella
tadZ) RTqPCR

H279

H279-N

H280

Anneal: 53°C, 15 sec.
Extend: 60°C, 20 sec.
RT
----------Cycle #: 31
Melt curve: 65 °C, 30 sec.
TCGTCGGCAG Step 1:
CGTCAGATGT Initial denature: 95°C, 120 sec.
GTATAAGAGA Cycle #: 30
CAGGA[I][I][I][I ----------]GC[I]GG[I]GAY Denature: 95°C, 15 sec.
GG[I]AC[I]AC[I] Anneal: 55°C, 30 sec.
AC
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.
Step 2:
Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
TCGTCGGCAG Step 1:
CGTCAGATGT Initial denature: 95°C, 120 sec.
GTATAAGAGA Cycle #: 30
CAGNGA[I][I][I] ----------[I]GC[I]GG[I]GA Denature: 95°C, 15 sec.
YGG[I]AC[I]AC[ Anneal: 55°C, 30 sec.
I]AC
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.

GTCTCGTGGG
CTCGGAGATG
TGTATAAGAG
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Step 2:
Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
Step 1:
Initial denature: 95°C, 120 sec.
Cycle #: 30

Targeted deep
sequencing of
cpn60 in
VaHMP
samples

Targeted deep
sequencing of
cpn60 in
VaHMP
samples

Targeted deep
sequencing of
cpn60 in

ACAGYK[I]YK[
I]TC[I]CCRAA[I
]CC[I]GG[I]GCY
TT

H280-N

H1613

GTCTCGTGGG
CTCGGAGATG
TGTATAAGAG
ACAGNYK[I]Y
K[I]TC[I]CCRA
A[I]CC[I]GG[I]G
CYTT

GTCTCGTGGG
CTCGGAGATG
TGTATAAGAG
ACAGCGRCGR
TCRCCGAAGC
CSGG[I]GCCTT

----------Denature: 95°C, 15 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.
Step 2:
Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
Step 1:
Initial denature: 95°C, 120 sec.
Cycle #: 30
----------Denature: 95°C, 15 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.
Step 2:
Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
Step 1:
Initial denature: 95°C, 120 sec.
Cycle #: 30
----------Denature: 95°C, 15 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.
Step 2:
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VaHMP
samples

Targeted deep
sequencing of
cpn60 in
VaHMP
samples

Targeted deep
sequencing of
cpn60 in
VaHMP
samples

H1612

H1612-N

TCGTCGGCAG
CGTCAGATGT
GTATAAGAGA
CAGGA[I][I][I][I
]GC[I]GGYGAC
GGYACSACSA
C

Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
Step 1:
Initial denature: 95°C, 120 sec.
Cycle #: 30
----------Denature: 95°C, 15 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.

Step 2:
Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
TCGTCGGCAG Step 1:
CGTCAGATGT Initial denature: 95°C, 120 sec.
GTATAAGAGA Cycle #: 30
CAGNGA[I][I][I] ----------[I]GC[I]GGYGA Denature: 95°C, 15 sec.
CGGYACSACS
Anneal: 55°C, 30 sec.
AC
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.
Step 2:
Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
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Targeted deep
sequencing of
cpn60 in
VaHMP
samples

Targeted deep
sequencing of
cpn60 in
VaHMP
samples

H1613-N

GTCTCGTGGG
CTCGGAGATG
TGTATAAGAG
ACAGNCGRCG
RTCRCCGAAG
CCSGG[I]GCCT
T

Step 1:
Initial denature: 95°C, 120 sec.
Cycle #: 30
----------Denature: 95°C, 15 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 4 min.
Step 2:
Initial denature: 95°C, 120 sec.
Cycle #: 10
----------Denature: 95°C, 30 sec.
Anneal: 55°C, 30 sec.
Extend: 72°C, 30 sec.
----------Final extend: 72°C, 5 min.
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Targeted deep
sequencing of
cpn60 in
VaHMP
samples

Table 6. Oligonucleotides used in this study.
Name
Sequence (5’à 3’)
GVrpsLMUT
CGAAGCGCAGAGTTTGGCTTCCGAGGAGTGGTGGTGTACACACG
(lead)
GVrplSMUTLAG CGTGTGTACACCACCACTCCTCGGAAGCCAAACTCTGCGCTTCG
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Table 7. Plasmids used in this study.
Name
Antibiotic resistance
pET32XT
Ampicillin, 100 µg/mL
pKD46

Ampicillin, 100 µg/mL
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Use
Recombinant protein
expression (VLY from AMD
and 14018 and λ beta)
PCR amplification of λ beta

Table 8. Cell lines and tissues used in this study.
Name
Cell type
Source
VK2/E6E7
Human vaginal
ATCC
keratinocyte
EpiVaginal VEC-100
Polarized,
MatTek
stratified human
vaginal
keratinocyte
CHO-K1
Cricetulus griseus McVoy lab, VCU
(Chinese hamster)
ovary epitheliallike
HL-60 CCL-240
Human peripheral Carlyon lab, VCU
blood
promyeloblast
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Use
VLY cytotoxicity and
cytokine assays
VLY and Gardnerella
growth, cytotoxicity,
and cytokine assays
VLY cytotoxicity
assays
Phagocytosis assays

CHAPTER 3
Characterization of G. vaginalis and VLY interactions with a stratified,
polarized model of the human vaginal epithelium
Introduction

Although G. vaginalis is found in both BV-positive and BV-negative women, its
abundance is significantly greater in those with the disease86–88. Moreover, this abundance
increases just days prior to the onset of incident BV, suggesting that factors contributing to G.
vaginalis growth in vivo may be important in the cascade of events leading to the establishment of
BV81. The Vaginal Human Microbiome Project (VaHMP) was a NIH-funded, VCU-led project
with the aim of characterizing the structure and composition of the vaginal microbiome in response
to host and environmental factors5. To do this, participants were asked to contribute samples from
various body sites, including the vagina, which were subsequently analyzed to generate 16S rRNA
and metagenomic data for each subject. Patient data including sociodemographic factors, sexual
and physical activity, diet regime, medication history, and substance use were also recorded. These
data were previously examined to investigate whether there were any significant associations
between patient meta-data and Gardnerella abundance154. Interestingly, of all the variables
examined, the only factor exhibiting a significant association with bacterial abundance was statin
use. Analysis of 16S rRNA survey profiles from women who were or were not using statins at the
time of sampling, revealed that women using statins had significantly lower proportions of G.
vaginalis and higher proportions of Lactobacillus crispatus relative to women not taking statins.
As statins are most frequently prescribed as cholesterol-lowering drugs, and G. vaginalis produces
a cholesterol-dependent virulence determinant, vaginolysin (VLY), it was hypothesized that
inhibition of the toxin via reduced cholesterol levels in vaginal epithelial cell membranes could
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potentially explain these observed in vivo differences in bacterial abundance116,155. This study went
on to show statin treatment of vaginal epithelial cell monolayers could indeed reduce VLYmediated cytotoxicity. Consequently, this led us to hypothesize that VLY promoted G. vaginalis
growth within the vaginal epithelium, through pore-formation and subsequent release of epithelial
cell contents (i.e. glycogen).

Vaginolysin has been the most extensively studied virulence factor of G. vaginalis due to
its conserved nature within the genus and its associations with bacterial vaginosis156. More than
half of women with bacterial vaginosis mount a specific IgA response against the toxin, and this
response is associated with increased levels of vaginal IL-1β and reduced adverse birth
outcomes94,99,115. In addition, BV isolates of G. vaginalis exhibit increased expression of vly
compared to non-BV isolates157. And most recently observed, higher concentrations of VLY in
vivo were associated with women who have a vaginal microbiota deficient in lactobacilli, a clinical
indicator of BV158. The toxin is characterized as a cholesterol dependent pore-forming cytolysin
(CDC) because of its sequence similarity to other CDCs and its documented lysis of human
erythrocytes, epithelial cells, and polymorphonuclear leukocytes112,116. However, whether or not
VLY concentrations produced in vivo are sufficient to lyse host cells, is questionable. It has been
shown that concentrations of VLY in the ng/µl range induce membrane blebbing rather than lysis
in epithelial cell monolayers, and in vivo VLY concentrations are estimated to be in this same
range118,158. VLY binding and pore formation are dependent on cell membrane cholesterol121.
Interactions with the human complement regulatory protein CD59 are thought to potentiate
binding and contribute to the species selectivity of the toxin159. Various roles for VLY in G.
vaginalis pathogenesis are plausible, considering the already characterized interactions of VLY
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with eukaryotic cells as well as the described roles of other cholesterol dependent toxins in
bacterial pathogenesis; however, a specific function for the toxin has yet to be described.

Various models have been used to characterize G. vaginalis host-pathogen interactions.
Murine models of G. vaginalis infection demonstrate that vaginal colonization by G. vaginalis is
possible; however, bacterial populations in this model are unstable, never achieving significant
growth, with steady clearance over time137,139,160. Conversely, in a porcine explant model, G.
vaginalis was able to colonize, grow to clinically relevant densities, and form a dense biofilm.
Interestingly, the epithelial cells directly covered by the biofilm were non-viable11. Threedimensional human epithelium models have been used to study the immune response to G.
vaginalis, but cytotoxicity was not observed and growth on these models was not measured161,162.
VLY interaction with epithelial cells has only been studied in the context of monolayer culture
systems116,118,121. Because of the limitations of these models, we sought to investigate the
contribution of VLY to Gardnerella growth using a commercially available, human-derived model
of the vaginal epithelium. Specifically, we investigated bacterial growth, tissue cytotoxicity, and
tissue cytokine production in order to identify interactions that might contribute to BV
pathogenesis, using a model that more closely resembles in vivo conditions compared to monolayer
and non-human models163. Our findings unexpectedly show pronounced differences in these hostpathogen interactions in relation to tissue polarity and provide insight into already characterized
aspects of BV pathogenesis.
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Results

G. vaginalis exhibits increased growth on the apical face of vaginal tissue relative to the
basolateral face.

To determine whether or not this EpiVaginal model of the vaginal epithelium would be
adequate to test our hypothesis of the contribution of VLY to G. vaginalis growth, we first
quantified bacterial growth in coculture with EpiVaginal tissues. To do this, ∼105 CFU/tissue were
added either apically or basolaterally, and CFU were determined after 16 h of anaerobic incubation.
Apically inoculated tissues were checked for tissue breaks by quantifying CFU in the basolateral
medium to ensure that bacteria did not gain access to the basolateral face. Apical EpiVaginal tissue
inoculation with G. vaginalis consistently yielded 3- to 4-log growth, with the maximum
concentration reaching 1.1 × 109 CFU/mL (Fig. 1A). The observed growth was not attributable to
nutritional components of the cell culture medium, as bacterial viability actually decreased in
medium alone. Interestingly, basolateral inoculation of EpiVaginal tissue on average yielded <2log growth, which was significantly lower than growth on the apical side. To further investigate
the differences in apical versus basolateral growth of G. vaginalis, we performed a kill assay using
spent medium from either side of the tissue to determine whether differentially secreted
components in the medium (i.e., antimicrobial peptides or glycogen) might impact bacterial growth
or survival. There was no observed reduction in survival from bacterial cultures treated with apical
or basolateral spent tissue medium relative to untreated cultures, but there was an ∼1-log-higher
concentration of bacteria in wells with apical medium added (Fig. 1B). These results suggest that
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the EpiVaginal model is a sufficient system in which to investigate bacterial growth in response to
VLY activity and that the apical vs basolateral sides of the tissue promote quantifiable differences
in bacterial growth.
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Figure 1. G. vaginalis growth is enhanced on the apical side of the vaginal epithelium. (A) A total of ∼105 CFU G.
vaginalis/mL was added to EpiVaginal tissues (apically or basolaterally) or to medium alone. After 16 h of
coincubation, both media and homogenized tissues were plated to determine CFU. Log growth was calculated by
subtracting input from output CFU. (B) Kill assay. Log-phase cultures of G. vaginalis were added to wells and were
either left untreated or treated with spent medium from the apical or basolateral sides of EpiVaginal tissues. All data
were normally distributed and exhibited equal variance. *, P ≤ 0.05; ***, P ≤ 0.001 (n ≥ 3). Error bars represent
standard deviations.

66

G. vaginalis mediates greater damage on the basolateral face of tissue.
Because of the observed differences in growth on opposite sides of the epithelial tissue, we
hypothesized that G. vaginalis would elicit greater cytotoxicity on the apical side of the tissues.
Cytotoxicity was quantified as lactate dehydrogenase (LDH) release, trypan blue uptake, and
formazan production. For LDH quantification, values from treated tissues were compared to those
from untreated and Triton X-100-treated tissues to quantify percent LDH release. The addition
of G. vaginalis to EpiVaginal tissues did elicit LDH release (Fig. 2A), increased trypan blue uptake
(Fig. 2C), and reduced formazan production (Fig. 2E). However, LDH release and trypan blue
uptake were greatest when G. vaginalis was added to the basolateral face (60.4% LDH release and
80.8% of basolateral cells stained) of the tissue relative to apical exposure (8.3% LDH release and
29.0% of apical cells stained) (Fig. 2B). Apically added G. vaginalis elicited some trypan blue
uptake from apical cells, which was significantly different than the trypan blue uptake observed
for untreated tissue (8.1% of apical cells stained; P = 0.04). We confirmed vly expression by G.
vaginalis via reverse transcription-PCR (RT-PCR) (Fig. 3) but observed no significant difference
in vly expression in relation to the side of inoculation. Thus, even though G. vaginalis growth is
greatest on the apical face of the epithelium, epithelial cytotoxicity was greatest at the basolateral
face.
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Figure 2. G. vaginalis tissue cytotoxicity is greatest at the basolateral face of the vaginal epithelium.
EpiVaginal tissues were treated apically or basolaterally with ∼105 CFU G. vaginalis/mL for 16 h. Spent
medium was used for lactate dehydrogenase (LDH) release assays to quantify cytotoxicity. The tissues were
then rinsed and stained with trypan blue, MTT, or H&E. (A) Cytotoxicity of G. vaginalis toward apically or
basolaterally challenged EpiVaginal tissues. The y axis represents the percent LDH release relative to controls.
These data were not normally distributed but exhibited equal variance. (B) Percentage of trypan blue-stained
cells within the most apical or basolateral cell layer. No Treatment indicates the apical layer of untreated tissue.
These data were normally distributed and exhibited unequal variance. (C) Trypan blue-stained tissues. The red
arrows point to trypan blue-stained cells. (D) H&E-stained tissues. (E) Formazan (MTT)-stained tissues. NT, no
treatment; GV-A, tissue challenged apically with G. vaginalis; GV-B, tissue challenged basolaterally with G.
vaginalis. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (n ≥ 3). Error bars represent standard deviations.
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Figure 3. G. vaginalis expresses vly on either side of EpiVaginal tissues. Approximately 109 G. vaginalis AMD in
PBS was added to tissues or media and incubated anaerobically for 4 hours. RNA was then extracted and quantified
using RT-PCR. The expression of vly is relative to G. vaginalis 16s rRNA. GV Media is sBHI and Tissue Media is
VEC-100, both detailed in the methods. Data exhibited a normal distribution and equal variance. * = P ≤ 0.05, ** ≤
0.01, *** ≤ 0.001. n ≥ 3. Error bars represent standard deviation.
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Statin treatment reduces cytotoxicity, but not Gardnerella growth
Results thus far did not support the hypothesis that VLY activity promotes G. vaginalis
growth within the epithelium. As a final test, we investigated whether statin treatment, which was
previously shown to reduce VLY-mediated cytotoxicity against vaginal epithelial cell monolayers,
could reduce G. vaginalis growth in this model. As G. vaginalis cytotoxicity was observed to be
greatest on the basolateral face, we limited our investigation to this side. Similar to monolayer
data, statin treatment was able to reduce G. vaginalis-mediated cytotoxicity, measured by LDH
release, to basolateral epithelial cells (Fig. 4A). However, no reduction in G. vaginalis growth with
statin treatment was observed (Fig. 4B). Collectively, these data suggest that G. vaginalis growth
is not dependent on VLY in this model.

70

Figure 4. Statin pretreatment does not reduce G. vaginalis growth on EpiVaginal tissues. (A) Cytotoxicity of
VLY toward basolaterally challenged EpiVaginal tissues with or without statin pretreatment. (B) Log growth of G.
vaginalis added to basolateral side of tissue with and without statin pretreatment.
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VLY mediates lactate dehydrogenase release only when exposed to the basolateral face.
We then followed-up on the interesting observation that G. vaginalis cytotoxicity was
greatest at the basolateral face of the epithelium. To test whether this difference was dependent on
VLY interactions with the vaginal epithelium, we added supra-physiological (10 μg/mL) levels of
purified, recombinant VLY to the apical or basolateral face of EpiVaginal tissue in 100 μl
phosphate-buffered saline (PBS). After 16 h of anaerobic incubation, LDH that had been released
into the medium was quantified. VLY elicited considerable LDH release from basolaterally
challenged tissues (25.5% of the positive control) but not from tissues challenged apically (0.85%)
(Fig. 5A). LDH release was significantly different between the two treatments (P = 0.0013).

VLY fails to permeabilize the apical epithelium.
We next sought to determine whether the lack of LDH release following apical VLY
exposure was due to the inability of VLY to permeabilize the apical cells. To investigate this, a
trypan blue exclusion assay was performed on tissues at 16 h post-inoculation. The trypan bluestained tissues were fixed, embedded, and sectioned. The sections were then either hematoxylin
and eosin (H&E) stained for gross morphological comparisons of differentially treated tissues or
deparaffinized and immediately overlaid with mounting medium and a coverslip for visualization
of trypan blue staining. From these analyses, we observed that untreated and VLY-challenged
tissues were morphologically quite similar and did not exhibit the extent of damage induced by
Triton X-100 treatment (Fig. 5D). Furthermore, trypan blue was excluded from untreated or
apically challenged cells but was taken up by both apical and basolateral cells of Triton X-100treated tissues (Fig. 5B). Only the most distal cell layer was stained by trypan blue within
basolaterally challenged tissues, suggesting that VLY did not penetrate the tissue (Fig. 5B). The
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quantification of trypan blue-stained cells from each treatment shows that basolateral challenge
with VLY (54.9%) elicits greater cell permeabilization than apical challenge (5.7%) (P = 0.0002)
(Fig. 5C). The percentage of trypan blue-stained cells of untreated tissue (8.1%) was not
significantly different from that of apical VLY-treated tissues. These data suggest that VLY does
not permeabilize cells when introduced to the apical side of vaginal tissue but permeabilizes cells
when it is introduced to the basolateral side.
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Figure 5. VLY elicits cytotoxic effects on basolateral but not apical vaginal epithelial cells. EpiVaginal tissues
were treated apically or basolaterally with 10 μg VLY/mL for 16 h. Lactate dehydrogenase released into spent media
from tissues was quantified as a measure of cytotoxicity. The tissues were then rinsed and stained with either trypan
blue or H&E. Percent permeability of trypan blue was subsequently calculated as described in Materials and Methods.
(A) Cytotoxicity of VLY toward apically or basolaterally challenged EpiVaginal tissues. The y axis represents the
percent LDH release relative to controls. These data exhibited equal variance. (B) Trypan blue-stained tissues. The
red arrows point to trypan blue-stained cells. (C) Percentage of trypan blue-stained cells within the most apical or
basolateral cell layer. No Treatment indicates the apical layer of untreated tissue. These data exhibited unequal
variance. (D) H&E-stained tissues. NT, no treatment; +, positive cytotoxicity control (1.0% Triton X-100); VLY-A,
tissue challenged apically with VLY; VLY-B, tissue challenged basolaterally with VLY. All data exhibited a normal
distribution. **, P ≤ 0.01; ***, P ≤ 0.001 (n ≥ 2). Error bars represent standard deviations.
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CD59 is more abundant on basolateral cells than on apical cells in the EpiVaginal model of the
vaginal epithelium.
We hypothesized that the increased sensitivity of basolateral cells to VLY-mediated
permeabilization could be due to a greater abundance of surface-associated CD59, the VLY
coreceptor. To test this, we performed immunohistochemistry (IHC) analysis on fixed, paraffinembedded tissues and compared anti-CD59 staining on apical cells to that on basolateral cells (Fig.
6A). Quantification of the intensity of anti-CD59 staining per cell revealed that basolateral cells
exhibited a significantly higher (3.4-fold) intensity of staining than apical cells (Fig. 6B)
(P = 0.0004). This suggests that increased VLY-mediated permeabilization of basolateral cells
could be due to higher concentrations of CD59.
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Figure 6. CD59 exhibits higher intensity on basolateral cells of EpiVaginal tissues. Shown is
immunohistochemical staining of untreated EpiVaginal tissue. (A) DAB- and hematoxylin-stained tissue. (B)
Quantification of average DAB staining intensity per cell. Data exhibited a normal distribution and equal variance.
***, P ≤ 0.001 (n ≥ 3). Error bars represent standard deviations.
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Effects of VLY on the cytokine profile are restricted to basolateral exposure.
Although VLY had no cytotoxic effect on apical epithelial cells, we reasoned that VLY
may have other, non-cytotoxic effects. Reports indicate that VLY can stimulate the expression of
certain cytokines, including IL-8, from epithelial cells. We investigated whether these VLYmediated effects were also influenced by tissue polarity. After 16 h of tissue challenge with VLY
(10 μg/mL), the concentrations of 27 cytokines were quantified in samples of media from the
tissues (Fig. 7A). We found that IL-1β and monocyte chemoattractant protein 1 (MCP-1) levels
were significantly increased in media from VLY-challenged tissues compared to untreated tissues
but only when VLY was exposed to the basolateral side of the epithelium (Fig. 7B). A small
increase in the level of RANTES in response to this treatment also achieved statistical significance;
however, the increase was less than 2-fold. No secreted cytokine level was significantly different
from those of controls when tissues were challenged apically with VLY. In order to confirm that
secretion of cytokines was mediated by VLY and not a contaminating protein or endotoxin in the
protein preparation, we used protein prepared from Escherichia coli containing an empty
expression vector in VK2 epithelial cell monolayers and quantified cytokine production. The
concentration of IL-1β was significantly increased upon exposure to VLY, and a similar increase
was not observed from empty-vector-treated cells (Fig. 8). VLY-treated monolayers also exhibited
significantly increased MCP-1 concentrations relative to both the untreated and empty-vectortreated cells. However, when accounting for the increase observed in the empty-vector-treated
cells, the fold change in the concentration of MCP-1 attributable to VLY, and, therefore, the
biological relevance, is reduced. These data suggest that the major cytokine induced by VLY is
IL-1β and that this effect is mediated only when VLY is introduced to the basolateral side of the
vaginal epithelium.
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Figure 7. VLY-mediated cytokine secretion is restricted to the basolateral face. EpiVaginal tissues were treated
apically or basolaterally with 10 μg VLY/mL for 16 h. Samples of spent media from the tissues were then analyzed
by a multiplex cytokine bead array. (A) Mean cytokine concentrations in picograms per milliliter and standard
deviations (S.D.) for each mean. (B) Cytokines exhibiting significantly different concentrations between different
treatments. The data from all three cytokines were normally distributed. IL-1β exhibited unequal variance, while MCP1 and RANTES exhibited equal variance. *, P ≤ 0.05; ***, P ≤ 0.001 (n ≥ 3). Error bars represent standard deviations.
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Figure 8. VK2 monolayers secrete IL-1β and MCP-1 in response to VLY. Vaginal epithelial cell monolayers were
treated with 1µg VLY or empty vector/mL for 4 hours. Samples of spent media were then analyzed by a multiplex
cytokine bead array. IL-1β data were not normally distributed. MCP-1 data were normally distributed. All data
exhibited equal variance. * = P ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001. n ≥ 3. Error bars represent standard deviation.
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G. vaginalis elicits different cytokine secretion profiles when exposed to the apical versus
basolateral face of the tissue model.
To investigate whether G. vaginalis-mediated effects (both VLY dependent and VLY
independent) were also influenced by the polarity of exposure, we exposed the apical and
basolateral sides of the tissue to live bacteria. Samples of media were collected from either side of
the tissues 16 h after bacterial inoculation, and cytokine concentrations were quantified (Fig.
9A and Fig. 10A). When the apical side of the tissues was challenged with G. vaginalis, one of the
cytokines that was induced upon basolateral VLY exposure, RANTES, was actually suppressed
14.8-fold (Fig. 9B). Additional cytokines that were significantly downregulated include vascular
endothelial growth factor (VEGF) (<2-fold), IL-6 (<2-fold), IL-9 (2.5-fold), macrophage
inflammatory protein 1b (MIP-1b) (3.1-fold), IL-8 (3.3-fold), and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (6.6-fold). IP-10 showed a 53-fold decrease in secretion,
which trended toward significance (P = 0.038; no significant differences with post hoc analysis).
Significantly upregulated cytokines were interferon gamma (IFN-γ) (<2-fold), PGDF-bb (<2fold), MCP-1 (<2-fold), and the anti-inflammatory cytokine interleukin-1 receptor antagonist (IL1ra), which exhibited a 5-fold increase compared to untreated controls. Basolateral challenge
with G. vaginalis, similar to VLY, increased the secretion of IL-1β (3.1-fold) (Fig. 10B).
Additionally, basolateral treatment significantly increased IL-12, eotaxin, and IL-1ra (5.1-fold)
secretion and decreased IP-10 secretion 25-fold. The increases in IL-12 and eotaxin secretion were
less than 2-fold and thus may not be biologically relevant. Thus, cytokine changes that were
mediated by purified VLY were absent when purified protein or live bacteria were added to the
apical side of the tissues. Live G. vaginalis bacteria induced IL-1β when exposed to the basolateral
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face, similar to purified VLY. Live bacteria also induced a number of other cytokines in an
apparently VLY-independent manner.
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Figure 9. Apical G. vaginalis tissue challenge dampens tissue secretion of proinflammatory cytokines.
EpiVaginal tissues were treated apically with ∼105 CFU G. vaginalis/mL for 16 h. Samples of spent media were then
analyzed by a multiplex cytokine bead array. (A) Mean cytokine concentrations in picograms per milliliter and
standard deviations for each mean. (B) Cytokines exhibiting significantly different concentrations between untreated
tissues and tissues treated apically with G. vaginalis. All cytokines except IP-10 exhibited a normal distribution. All
cytokines exhibited equal variance. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (n ≥ 3). Error bars represent standard
deviations.
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Figure 10. Basolateral G. vaginalis tissue challenge elicits a different cytokine secretion profile than with apical
challenge. EpiVaginal tissues were treated basolaterally with ∼105 CFU G. vaginalis/mL for 16 h. (A) Mean cytokine
concentrations in picograms per milliliter and standard deviations for each mean. (B) Cytokines exhibiting
significantly different concentrations between untreated tissues and tissues treated basolaterally with G. vaginalis. All
cytokines exhibited a normal distribution and equal variance. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001 (n ≥ 3). Error
bars represent standard deviations.

83

Discussion
G. vaginalis was first implicated in BV almost 70 years ago164. However, its role in the
etiology and pathogenesis of BV remain poorly described, due in part to the lack of a good animal
model and to the physiologic over-simplicity of tissue culture monolayer models. In this study, we
used an organotypic, stratified, polarized model of the human vaginal epithelium to characterize
the influence of host tissue on bacterial growth and to further characterize G. vaginalis-mediated
cytotoxicity and cytokine response. We found striking differences in the interaction between
bacteria and tissue with respect to apical versus basolateral exposure. We speculated that the
absence of lactate dehydrogenase release following apical VLY challenge could be due to low
levels of LDH in apical cells. Within the human vaginal epithelium, cells originate from the
basolateral side, mature, differentiate, and flatten over time, and as apical epithelial cells slough
off, the deeper layers become progressively closer to the lumenal face. During this process, cells
that were once actively replicating, become anucleated, devoid of organelles, and packed with
glycogen27. With this, we postulated that the more apical layers of cells in the tissues simply lacked
the LDH to be released upon pore formation. Alternatively, it was possible that VLY was unable
to form pores on apically distributed cells. To test this, we performed MTT reduction and trypan
blue exclusion assays on VLY-challenged tissues. The MTT reduction assay is a method to
quantify the proliferative capacity of a cell165. So, cells still capable of proliferating will reduce the
yellow MTT to a purple formazan product that stains the cell, while damaged cells or fully
differentiated, non-proliferative cells will remain unstained. The trypan blue exclusion test
operates under the premise that the dye cannot cross healthy, intact host plasma membranes, but
can enter and stain cells in which the membrane has lost its integrity166. From our MTT stained
tissues, we observed that the more apical layers were indeed reduced in their proliferative capacity,
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while densely stained basolateral layers were actively proliferating. However, results from
histological analysis of the trypan blue stained tissues indicate that a lack of VLY-mediated
permeabilization of the apical cells likely caused the lack of LDH release from apically challenged
tissues. Furthermore, our results suggest that this lack of VLY-mediated permeabilization of apical
cells could be due to decreased levels of surface-expressed CD59 (Fig. 6B). It is unclear, however,
whether CD59 expression in vivo is also greater on more basolateral cell layers. Differences in
membrane cholesterol content could also be a contributing factor, but that was not tested in this
study.

While apical VLY challenge failed to permeabilize cells, apical challenge with G. vaginalis
yielded some permeabilization of cells, although it was much reduced relative to basolateral G.
vaginalis challenge. A possible explanation for this could be related to bacterial adhesion to
epithelial cells. When VLY is added alone, the protein is dependent on abundant CD59 to
potentiate binding and subsequent pore formation. When viable bacterial cells promote adhesion,
however, the toxin is delivered directly at the host cell surface. This may reduce the dependence
on CD59. As long as sufficient cholesterol is present in the cell membrane, local delivery of VLY
promotes pore formation and permeabilization, regardless of CD59 abundance. Alternatively, it
is conceivable that bacterial interaction with epithelial cells may alter epithelial expression of
factors to promote pore formation.

We observed a significant difference in bacterial growth when the bacteria were inoculated
apically vs basolaterally. This is likely due in large part to a gravity-mediated increase in contact
between the bacteria and host cells when the bacteria are added to the apical side. It may also be
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due, in part, to the differential distribution of glycogen within the vaginal epithelium, with greater
concentrations locating to the apical face. Polar distribution of glycogen has been documented in
EpiVaginal tissues163. Gardnerella strains are capable of catabolizing glycogen and proteomic
analysis of cervicovaginal secretions from women with G. vaginalis-dominated bacterial
communities detected G. vaginalis specific glycogen degradation proteins, including an alpha-1,4
glucan phosphorylase47,85. Thus, it’s possible that G. vaginalis uses the glycogen produced by
vaginal epithelial cells as a nutrient source. If this glycogen utilization occurs in vivo, it would
describe yet another mechanism by which G. vaginalis is able to compete with commensal
lactobacilli species. The high conservation of the vly gene suggests that it plays an important role
for the bacteria, but this role remains undefined. Our results, which demonstrate that growth is
greater when the bacteria are on the apical face and that VLY fails to function on the apical face,
as well as the inability of statin-mediated reduction in cytotoxicity to reduce G. vaginalis growth,
suggest that VLY-mediated pore formation is not necessary for bacterial growth in co-culture with
vaginal epithelium. Furthermore, it has been hypothesized that VLY and its dependence on human
CD59 contribute to the species selectivity of the pathogen. If VLY were important for growth on
the vaginal epithelium, then, it would be expected that this would only occur in human or
humanized tissues. However, this is not the case, as both G. vaginalis growth and cytotoxicity are
observed in a porcine model of the vaginal epithelium. It is conceivable that VLY may still
promote nutrient acquisition in the more competitive in vivo environment and that these nutrients
come from a source other than the vaginal epithelium (erythrocytes, for example). Another
possible role is that VLY is required to protect G. vaginalis from host innate immunity by killing
neutrophils or other cellular host immune components. Without further study, we cannot rule out
the possibility that VLY exerts effects on apical cells that are unrelated to cell permeabilization.
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Another major finding of the study was that G. vaginalis elicits differential cytokine
secretion profiles on the apical and basolateral faces of vaginal tissue. Apical administration of G.
vaginalis significantly enhanced the secretion of IFN-g, MCP-1, IL-1ra and PDGF-bb and resulted
in decreased secretion of VEGF, IL-6, IL-8, IL-9, GM-CSF, IP-10, MIP-1b, and RANTES.
Basolateral tissue inoculation with G. vaginalis, on the other hand, increased the secretion of IL1β, IL-12, eotaxin, and IL-1ra but decreased the secretion of only IP-10. This is the first time
many of these cytokines have been detected in response to G. vaginalis. A study of monospecies
co-cultures on epithelial monolayers did detect significant differences in PGDF-bb and IP-10
secretion, but the levels of PGDF-bb were much smaller compared to this study and IP-10
increased rather than decreased167. These discrepancies could be due to a lack of cell polarization
or stratification and a lack of bacterial growth in the monolayer system. The results from a three
dimensional tissue model of G. vaginalis infection are in agreement with this study in that no
significant increase in TNF-a, IL-6, or IL-8 were detected162. These data partly reflect in vivo
cytokines profiles in BV positive women. In a study of 430 sexually active African women, a BV
positive status was associated with increased levels of IL-1a, IL-1β, IL-6, IL-12, and IL-8 and
decreased levels of IP-10 in cervicovaginal lavage samples168. Vaginal lavage samples from
pregnant women colonized with BV-associated bacteria exhibited increased levels of IL-1β and
IL-1ra compared to un-colonized women169. Moreover, several other studies have detected an
increase in IL-1β in BV positive women170–172. IL-1β is the most consistent cytokine marker of
BV. Its secretion has been observed in response to other BV-associated pathogens, including
Atopobium vaginae and Prevotella bivia, where bacterial infection in a 3-D vaginal epithelial cell
aggregate model showed that these bacteria induced a 4-fold increase in IL-1β secretion, similar
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to what was detected from G. vaginalis in this study173. Together, these data suggest that G.
vaginalis could contribute, at least in part, to the immunopathology of BV. Other cytokines
detected in vivo but not in these studies could potentially be attributed to the other species
associated with BV.

Interestingly, apically administered G. vaginalis significantly reduced the secretion of
several pro-inflammatory cytokines (GM-CSF, IP-10, MIP-1b, IL-8, and RANTES) and increased
the secretion of the anti-inflammatory cytokine IL-1ra. The cytokines suppressed by G. vaginalis
normally act to recruit, mature, and activate a variety of immune cell types, including neutrophils,
dendritic cells, macrophages, NK cells, and T-cells174–176. The suppression of these cytokines may
explain why BV positive women do not exhibit neutrophil influx into the vaginal lumen. In
addition, although the T-cell response during BV has not been thoroughly investigated, the high
rate of recurrence suggests that adaptive immunity may be impaired. The suppression of IP-10 and
RANTES indicate that T-cell recruitment could be diminished by G. vaginalis in vivo and the
reduction of GM-CSF may interfere with dendritic cell maturation to promote a tolerogenic rather
than immunogenic response to G. vaginalis177–180. Moreover, despite the increase in IL-1β elicited
by G. vaginalis, which is important for an effective host response to several bacterial pathogens,
the increased secretion of IL-1ra may act to inhibit this otherwise proinflammatory response to
promote bacterial survival and persistence in the host181,182. This is the first study to detect this
immunosuppressive capacity of G. vaginalis on epithelial cells and has implications for the role of
G. vaginalis in BV pathogenesis. Perhaps through its immunosuppressive effects on the vaginal
epithelium, G. vaginalis may support the incorporation of other BV-associated species that may
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otherwise be detected and eliminated by the host immune system. Further experimentation is
needed to directly test this hypothesis.

This is the first study investigating the impact of tissue polarity on VLY cytolytic activity.
Other studies investigating VLY-mediated cytotoxicity or pore formation have utilized monolayer
systems, non-adherent erythrocytes and polymorphonuclear leukocytes, or cholesterol rich
liposomes112,113,116,117,120,121. These studies were useful for establishing the cholesterol dependence
of VLY pore formation and for characterizing the role of CD59 in this process, however, these
systems lack the structural and functional complexity the toxin is likely to encounter in vivo. This
study revealed a greater abundance of CD59 on basolateral cells, which may explain, at least in
part, the greater sensitivity of these cells to VLY. Basolateral and apical epithelial cells could also
differ in abundance and/or distribution of cholesterol on the surface. The selectivity is somewhat
surprising, because VLY would be expected to encounter the apical (lumenal) side of the vaginal
epithelium in vivo. One possibility is that this preference minimizes damage and immune
activation, allowing for a commensal state to develop and that VLY-mediated damage only occurs
when there is a breach of the vaginal epithelium, allowing the toxin to reach the basolateral cells.
Microtrauma induced by sexual intercourse or by other, more invasive bacterial species could
cause a breach in the epithelium, possibly explaining, in part, the association between sexual
intercourse and BV onset183–186. Alternatively, VLY may not actually target epithelial cells, but
rather immune cells, in an effort to thwart immune defenses. Further studies are needed to
determine the basis for the polar selectivity of the toxin and the physiologic implications.
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The use of an organotypic model of the vaginal epithelium in this study has enhanced our
knowledge about host-pathogen interactions that may be relevant to BV pathogenesis in vivo.
However, we note a few limitations. The EpiVaginal tissues used in this study did not contain
immune cells such as dendritic cells. Thus, the immune response was that of epithelial cells alone.
This is both a strength, because we know the cell type from which the cytokines derived, and a
limitation, because the absence of immune cells does not accurately reflect the complexity of the
host. Next, these tissue experiments were performed at a pH of 7.2. While this is higher than the
physiological pH (<4.5) of a healthy vaginal environment, it is also more characteristic of a G.
vaginalis dominated environment. Since pH could potentially alter bacterial growth and VLY
activity11,113,187, future experiments using these tissues to investigate BV pathogenesis should take
this into consideration. Finally, G. vaginalis strains can exhibit significant heterogeneity both in
the virulence factors they express and the degree to which they express them85,101,157. It would have
been more ideal to investigate the host response to multiple strains to see if our findings are broadly
applicable to G. vaginalis. Future studies may be aimed at determining the relevance of G.
vaginalis access to the basolateral face in BV pathogenesis and well as identifying the host and
bacterial factors that drive the differential apical vs basolateral response to G. vaginalis and VLY.
It would also be interesting to investigate biofilm formation and multispecies interactions using
these EpiVaginal tissues as an in vitro model.
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CHAPTER 4
Comparative analysis of vaginolysin from Gardnerella spp.
Introduction
Species of the genus Gardnerella, formerly grouped together as Gardnerella vaginalis, have
been considered important etiologic agents in bacterial vaginosis (BV) since its characterization
in the late 1950s164. However, the specific role(s) of the pathogen and its putative virulence factors
have been difficult to establish due to the genetic intractability of the organism. Vaginolysin
(VLY), produced by Gardnerella spp., is one such virulence factor suspected to play an important
role in Gardnerella

colonization and survival within the vaginal mucosa112,116. Like other

cholesterol dependent cytolysins (CDCs), VLY requires adequate membrane cholesterol levels for
oligomerization and subsequent pore formation116,121. However, it also exhibits a requirement for
the human complement receptor, CD59, in that the amount of toxin needed to elicit the same
amount of cytotoxicity on cells lacking human CD59 is increased by 1000-fold121. Several reports
indicate that VLY is toxic to a variety of cell types, including erythrocytes, epithelial cells, and
neutrophils112,113,116. Interestingly, however, we recently reported that the apical face of a polarized
model of the human vaginal epithelium is resistant to VLY, and our data suggested that this was
due to the reduced expression of CD59 on that side188. This finding contradicts in vivo evidence
that suggests that Gardnerella spp. and VLY are pro-inflammatory and contribute to vaginal tissue
damage during BV94,99,115,158,189. Multiple reports have suggested that both commensal and BVassociated strains of Gardnerella exist and a recent study using high-resolution bioinformatics to
enable taxonomic assignment to the subspecies level found that the previous association between
the Gardnerella genus and preterm birth was attributable to a singular subspecies clade83–85,190,191.
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Therefore, to reconcile the contradiction between in vivo data and our in vitro findings, we
hypothesized that species-specific variations in the VLY amino acid sequence may be one factor
that distinguishes avirulent, commensal strains from more virulent BV-associated strains and
sought to characterize VLY differences among Gardnerella strains.

Previous efforts to characterize putative Gardnerella virulence determinants focused on
identifying factors that may be differentially distributed among the distinct Gardnerella clades or
differentially expressed in BV isolates of Gardnerella relative to isolates from asymptomatic
women190. These studies showed that in vitro expression and secretion of VLY is variable among
strains. Specifically, one report found that BV strains expressed two-fold greater vly compared to
non-BV strains157. Another study found significant differences in the level of VLY secreted from
Gardnerella clinical isolates101. However, no significant difference in VLY production was
observed when comparing pairs of different Gardnerella clades133. Beyond these comparisons,
studies have noted the high VLY amino acid identity shared between small samples of Gardnerella
strains (90-99%), but there has yet to be a more comprehensive analysis of the level of VLY
conservation among the now 84 publicly available Gardnerella genomes82,101. Furthermore, VLY
comparisons between the recently proposed 13 distinct Gardnerella species have yet to be made135.
Thus, while previous studies focused on differences in vaginolysin regulation between clades and
BV vs non-BV isolates, we questioned whether VLY amino acid differences between the newly
proposed species could have functional consequences and possibly distinguish pathogenic vs nonpathogenic species of Gardnerella. To do this, we first sought to bioinformatically analyze VLY
amino acid conservation within the publicly available Gardnerella genome sequences. After
identifying conserved differences that could distinguish distinct VLY types, we tested whether a
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selection of these types differentially interacted with vaginal epithelial cells, focusing on
cytotoxicity and cytokine production. Finally, using metagenomic data from a cohort of women
from the Vaginal Human Microbiome Project, we investigated whether these different VLY types
exhibited any significant associations with patient symptoms or in vivo Gardnerella abundance5.
Our findings suggest that amino acid differences alter VLY interactions with vaginal keratinocytes,
which may potentiate differences in BV immunopathology in vivo. These differences may
determine whether or not a productive immune response is mounted and may explain why some
women with BV experience symptoms while others do not.
Results
Conserved amino acid differences distinguish five vaginolysin types
Whole sequence alignment of 84 publicly available VLY sequences showed that the
percent identity between any two pair of sequences ranged from 90.48-100.0%. The average
percent identity for all strains was 96.97%. With this alignment, we noticed that domain 4,
containing the undecapeptide, CD59, and loop regions conserved in CDCs, was particularly
enriched in conserved amino acid substitutions. When we re-aligned the sequences using only the
undecapeptide and CD59 regions, five distinct vaginolysin types were apparent (Figs. 11 and 12).
These types were first distinguished by the sequences comprising the CD59 region, and then
further sub-grouped based on sequence differences in the undecapeptide region. Type 1 VLY
contained aspartate and serine in positions 4 and 6 of the CD59 region, respectively. Type 1A was
characterized by valine at positions -1 and 6 of the undecapeptide region while type 1B had valine
and alanine and type 1C had glutamine and valine at these positions. The CD59 region of type 2
VLY contained asparagine and threonine at positions 4 and 6. The undecapeptide region of this
type was characterized by glutamate at position -1 and valine at position 6. As there was no
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variability in this region, type 2 was not further sub-classified. Finally, type 3 VLY was
characterized by asparagine and serine within the CD59 region and valine and leucine at positions
within the undecapeptide region. Types 1A and 1B appeared to be the most common types among
the available sequences with 45.2% and 32.1% of analyzed strains classified as these VLY types,
respectively. The other types were more rare; 17 of 84 strains were classified as Type 2 VLY while
types 1C and 3 had only a single representative among all of the available strains. In sum, this
survey of VLY amino acid sequences from Gardnerella spp. isolates reveals heterogeneity within
the regions of the toxin known to interact with host cells. Vaginolysin types were delineated based
on conserved sequence differences.
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Figure 11. Alignment of VLY undecapeptide and CD59 regions reveals distinct VLY types. This alignment was
generated using the undecapeptide and CD59 regions of VLY amino acid sequences extracted from 84 Gardnerella
spp. genome sequences available on NCBI. Amino acids shaded in grey are conserved. Colored amino acids are
divergent.
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Figure 12. Five VLY types are distinguishable among Gardnerella strains. VLY type classification based on
undecapeptide and CD59 region sequences of 84 Gardnerella spp. strains. Percent values are the number of strains
with a given VLY type out of all 84 strains examined. Values do not total to 100% due to rounding.
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Some VLY types are restricted to select Gardnerella species
Next, to determine whether these different versions of the toxin are restricted to specific
Gardnerella species, we phylogenetically mapped each available strain using whole genome
sequences, grouped them into one of the 13 proposed Gardnerella species, and marked the VLY
type that each strain encoded (Fig. 13)135. Type 1 VLY was found in all species except for species
5 (G. leopoldii), 6 (G. swidsinskii), 11 and 12. G. leopoldii and G. swidsinskii exclusively harbored
the type 2 toxin. And, surprisingly, while group 4 had a single representative strain with the type
1 VLY, the toxin was absent from the remaining 9 strains in this group. A few other strains from
groups 1-3 were also missing VLY. Thus, it appears that certain vaginolysin types are indeed
restricted to specific Gardnerella species and some species lack vaginolysin altogether.
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Figure 13. Some VLY types are restricted to select Gardnerella clades and species. Distribution of VLY types
amongst Gardnerella clades and species. This tree was generated by alignment of Gardnerella strain whole genome
sequences and then retrieved from NCBI’s Genome Tree report, Rectangle Cladogram layout. Clade and species
assignments were made based on the schemes reported in Ahmed et. al 2012 and Vaneechoutte et. al 2019,
respectively129,135.
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Cytokine secretion profiles of VK2 cells challenged with type 1A and type 2 VLY are similar
While there appeared to be 5 distinct VLY types based on sequence differences, we
suspected that some differences had greater potential to alter protein function than others. For
example, the amino acids distinguishing type 1A and 1B toxins are of the same amino acid class
(nonpolar aliphatic) and we therefore anticipated that they would be phenotypically similar. Type
2 VLY, on the other hand, is distinguished from type 1 VLY by a change in a polar, uncharged
asparagine residue in the CD59 region to a negatively charged aspartate residue. It also has a
negatively charged glutamate residue upstream of the undecapeptide region that is replaced with a
nonpolar, aliphatic valine in type 1A and type 1B VLY. While type 1C and type 3 toxins exhibited
sequence differences that could potentially impart functional diversity, their rarity amongst
available Gardnerella strains prompted us to limit our in vitro analyses to type 1A and type 2
toxins. We hypothesized that differences in these proteins could result in differential interactions
with vaginal epithelial cells and focused our analyses on the cytokine response and cytotoxicity.
To test our hypothesis, we recombinantly produced and purified VLY from strains harboring type
1A (G. vaginalis ATCC 14018) or type 2 (G. leopoldii AMD) toxins. We verified that endotoxin
levels in preparations were low and then added equal amounts (1 µg/mL) of either toxin to VK2E6E7 cell monolayers, verified by analyzing appropriately diluted toxin preparations by
denaturing PAGE (Fig. 14).

To assess differences in cytokine production amongst differentially challenged cells, spent
media samples were collected after 19 hours of co-incubation and concentrations of a panel of 27
different cytokine were determined. The secretion of several cytokines was similarly altered upon
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VK2 cell exposure to either VLY type (Fig. 15). The cytokines with potentially biologically
relevant increases (≥ 2-fold) in secretion upon VLY exposure include IL-2 (3.1-fold), IL-4 (6.6fold), IL-5(13-fold), IL-13 (2.9-fold), MIP-1a (2.1-fold), and GM-CSF (5.6-fold). VEGF was the
only cytokine with reduced concentrations in spent medium following VLY exposure (6.7-fold).
Conversely, the concentrations of many cytokines were significantly different when VK2 cells
were challenged with either VLY type (Fig. 16). Although, only two cytokines exhibited
biologically relevant differences. VK2 cells challenged with type 1A VLY secreted 2.6-fold
greater IL-1ra but 4.4-fold less IL-8 than cells challenged with type 2 VLY. Thus, both VLY types
elicit similar cytokine secretion profiles from VK2 cell monolayers, but there are some differences
in the levels of cytokines secreted in response to treatment with either VLY type.
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Figure 14. VLY concentrations are the same. SDS-PAGE gel showing that the given dilutions of VLY from G.
leopoldii AMD (type 2) and G. vaginalis ATCC 14018 (type 1A) have equal concentrations of 6x-His tagged VLY.
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Figure 15. VLY types similarly alter the secretion of several cytokines. VK2-E6E7 monolayers were treated with
<1 μg VLY/mL for 19 h. Samples of spent media from the cells were then analyzed by a multiplex cytokine bead
array. Mean cytokine concentrations (in picograms per milliliter) exhibiting significantly different concentrations
between untreated and VLY treated cells are shown. White numbers inside the bars represent the fold change in
cytokine secretion relative to untreated and empty vector controls. Error bars represent standard deviations. * = P ≤
0.05, ** ≤ 0.01, *** ≤ 0.001 (n ≥ 3). Empty vector control was included to account for any endotoxin contamination.
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Figure 16. VLY types stimulate differential secretion of select cytokines. VK2-E6E7 monolayers were treated with
<1 μg VLY/mL for 19 h. Samples of spent media from the cells were then analyzed by a multiplex cytokine bead
array. Mean cytokine concentrations (in picograms per milliliter) exhibiting significantly different concentrations
between type 2 and type 1A VLY are shown. White numbers inside the bars represent the fold increase in cytokine
secretion relative to the other VLY type. Bars without numbers have fold changes of < 2. Error bars represent standard
deviations. * = P ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001 (n ≥ 3). Empty vector control was included to account for any
endotoxin contamination.
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Type 1A VLY exhibits greater cytotoxicity on cells with reduced CD59
Next, to quantify differences in cytotoxicity, we similarly added equal concentrations (1
µg/mL) of either toxin to VK2-E6E7 cell monolayers and stained cells with trypan blue after 30
minutes of VLY exposure. When toxins were added to cells cultured for 4 days post-seeding, there
appeared to be no difference in cytotoxicity between the two VLY types (Fig. 18, top). However,
when the toxins were added to cells cultured for 7-days post-seeding, the difference in cytotoxicity
was readily apparent (Fig. 17). Type 1A VLY-treated cell monolayers exhibited 90.3% trypan blue
staining while type 2 VLY-treated cells only exhibited 53.0% (p < 0.0001). We reasoned that,
similar to senescent cells on the apical side of vaginal epithelial organoids, which were found
previously to express less CD59188, that senescent VK2 cells might also produce less CD59,
suggesting that the two VLY types differed in their interactions with CD59, which consequently
resulted in the observed differences in cytotoxicity. To test this, we treated 4-day cells with antiCD59 antibody for one hour prior to VLY challenge and then assessed cytotoxicity with trypan
blue staining. While anti-CD59 pre-treatment reduced cytotoxicity in both type 1A and type 2
VLY-challenged cells (Fig. 18), the reduction in cytotoxicity was significantly greater (p = 0.0021)
in type 2 VLY-challenged cells. These results suggest that type 1A VLY may have a higher affinity
for CD59 than type 2 VLY, and thus under conditions where CD59 is reduced, type 1A elicits
greater cytotoxicity than type 2 VLY.
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Figure 17. Type 1A VLY elicits greater cytotoxicity VK2-E6E7 monolayers were treated with 1 μg VLY/mL 7 days
post seeding, for 30 minutes. Cells were then rinsed, stained with trypan blue, and imaged. A) Images of trypan blue
stained cells. B) Percent cytotoxicity. Percent cytotoxicity was determined by dividing the number of blue stained
cells by the total number of cells. Error bars represent standard deviations. * = P ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001 (n ≥ 3).
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Figure 18. Anti-CD59 pre-treatment has a greater impact on type 2 VLY cytotoxicity VK2-E6E7 monolayers (4
days post seeding) with and without pretreatment (0.2 µg/mL anti-CD59 antibody for one hour) were challenged with
1 μg VLY/mL, for 30 minutes. Cells were then rinsed, stained with trypan blue, and imaged. A) Images of trypan blue
stained cells. B) Percent reduction in cytotoxicity. Percent cytotoxicity was determined by dividing the number of
blue stained cells by the total number of cells. To calculate the percent reduction in cytotoxicity, percent cytotoxicity
in pretreated cells was subtracted from the percent cytotoxicity in non-pretreated cells. Error bars represent standard
deviations. *, P ≤ 0.05; ***, P ≤ 0.001 (n ≥ 3).
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Cohort 1 study participants are simultaneously colonized by several Gardnerella species
To investigate whether these observed in vitro differences could also potentiate in vivo
differences, we analyzed metagenomic data from a cohort of 62 BV-positive women from the
Vaginal Human Microbiome Project (Cohort 1). Because our in vitro data suggest that differences
in toxin function are potentially attributable to differences in the interaction with CD59, our
analyses of in vivo data included type 3 VLY, which has a CD59 region distinct from both type 1
and 2 VLYs. We also grouped type 1A-C together, as their CD59 regions were the same. Since
each functional vaginolysin type is restricted to select Gardnerella species, we began our analyses
by investigating the distribution of each Gardnerella species within our cohort, using cpn60
universal target sequences to resolve distinct species136. Interestingly, we observed that a majority
of our participants were simultaneously colonized by multiple Gardnerella species (Fig. 19). Most
women (90.2%) had 3 or more species present at the time of sampling. The average number of
species present per participant was 9.
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Figure 19. Cohort 1 participants are simultaneously colonized by multiple Gardnerella spp. cpn60 reads were
used to distinguish each Gardnerella species and its relative abundance within the total Gardnerella population of
each sample. Each species is numbered according to the scheme reported in Vaneechoutte et. al 2019, and, where
possible, labeled with a species designation. Each bar represents one sample.
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Type 1 is the dominant VLY type of Cohort 1 subjects
We next assessed whether the three vaginolysin types were differentially distributed among
our Cohort 1 participants. To do this, we summed the number of reads of each type across all
samples and divided by the total number of all vaginolysin type reads from all samples. Type 1
vaginolysin represented 49.5% of the total vly reads while type 2 represented 39.9% and type 3
only 10.7% (Fig. 20). In comparing Gardnerella species distribution to vaginolysin distribution,
there was generally agreement between the species and the vaginolysin type dominating the
sample. For example, in a sample with 64.8% type 1, 23.5% type 2, and 11.6% type 3 vaginolysinproducing Gardnerella, 56.4% of the vly reads are from type 1 VLY, 28.3% are from type 2, and
15.3% are from type 3 (Fig. 21).
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Figure 20. VLY types exhibit unequal distribution in Cohort 1. Percent of total vly reads for a given VLY type.
Type 1 includes 1A, 1B, and 1C.
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Figure 21. Relative abundance of Gardnerella species and VLY type are concordant in Cohort 1 samples. (Left)
Percent of the Gardnerella population in a sample belonging to a species known to secrete a given VLY type,
determined by cpn60 sequencing. (Right) Percent of total vly reads in the sample for a given VLY type.
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Vaginal symptom frequency is increased in women with a majority of type 1 VLY
Overall, 67% of Cohort 1 subjects reported at least one vaginal symptom (itching, odor, or
discharge) (Fig. 22). Using vly read numbers, we next identified the dominant VLY type of each
sample in Cohort 1 and assessed whether women experiencing symptoms were more frequently
dominated by a specific type. If a similar number of reads were observed for two or more toxin
types in a sample, that sample was classified as being dominated by both types. Of the women
who reported any of the three vaginal symptoms, a greater proportion had type 1 as the dominant
VLY type in all cases (Fig. 23). While 57.1% and 42.9% of women experiencing vaginal itching
had type 1 or 3 VLY as the dominant type, respectively, only 14.3% had type 2 as the dominant
type (p=0.09). Sixty eight percent of women reporting vaginal odor were dominated by type 1
VLY while only 24.0% were dominated by type 2 and 12.0% dominated by type 3 (p < 0.001).
And 68.6% of women with vaginal discharge had type 1 as the dominant VLY, with 25.7%
dominated by type 2 VLY and 14.3% by type 3 (p < 0.001). Thus, there does seem to be an increase
in the frequency of symptoms experienced by women dominated by type 1 VLY in this cohort.
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Figure 22. A majority of Cohort 1 subjects experienced at least 1 vaginal symptom. Percent of subjects reporting
vaginal symptoms. Subjects reporting “No” for each of itching, odor, or discharge were counted as “No symptoms”.
Subjects with “NA” or “NS” were not counted. “Symptoms” represents the percent of subjects reporting 1, 2, or 3
symptoms.
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Figure 23. Cohort 1 subjects with type 1 VLY more frequently experience vaginal symptoms. Proportion of
Cohort 1 women experiencing symptoms in each VLY type group. Significant differences in proportions among the
three types were determined by a Homogeneity test, *** ≤ 0.001.
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Cohort 1 subjects in the type 2 VLY group have a significantly increased median relative
Gardnerella abundance
We then grouped participants by their dominant VLY type and determined whether there
were differences in bacterial abundance between each group in Cohort 1. CLARKs was used to
classify taxa from metagenomic reads and to determine the relative abundance of the taxa
comprising the vaginal community profile in each subject. Participants in the type 1 vaginolysin
group exhibited a median relative Gardnerella abundance of 24.1%, while those in the type 2
vaginolysin group exhibited a significantly increased Gardnerella abundance of 62.0% (p=0.0077)
(Fig. 24). Subjects in the type 3 VLY group exhibited the lowest Gardnerella median relative
abundance at 12.9% (p=0.03). Thus, there does seem to be a relationship between VLY type and
Gardnerella abundance in this cohort.
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Figure 24. Cohort 1 subjects with type 2 VLY exhibit increased Gardnerella relative abundance. Median relative
abundance in each VLY type group in Cohort 1. “x” marks the mean relative abundance. * = P ≤ 0.05, ** ≤ 0.01
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Type 2 is the dominant VLY type of Cohort 1 subjects
Because of the small sample size in the previous data set, we sought to give more power to
the observed associations between VLY type, symptoms, and taxa abundance. To do this, we used
a different, larger data set from the Vaginal Human Microbiome Project that consisted of 733
healthy and BV-positive women (Cohort 2). Although this data set did not include metagenomic
data, we used cpn60 read data to extrapolate the dominant VLY type of each sample. We began
our analyses by determining whether the three vaginolysin types were similarly distributed among
our Cohort 2 participants (Fig. 25). In contrast to Cohort 1, Type 1 vaginolysin represented only
31% of the total reads while type 2 represented 61%, making type 2 the dominant VLY type in
Cohort 2 subjects. Surprisingly, only one sample in this cohort had any type 3 vly reads and no
sample in this cohort was dominated by type 3 VLY. However, 2.8% of women were colonized
only by Gardnerella strains lacking the vly gene and VLY-null Gardnerella made up 8% of the
total Gardnerella reads.
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Figure 25. VLY types exhibit unequal distribution in Cohort 2. Percent of total vly reads for a given VLY type.
as determined by cpn60 reads.
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Vaginal symptom frequency is similar in Cohort 2 women, regardless of VLY type or BV status
The overall symptom frequency in Cohort 2 was 35%, understandably less than Cohort 1
considering that Cohort 2 includes BV-positive and healthy women (Fig. 26). When only looking
at BV-positive samples, symptom frequency increases to 53%, which is still less than the 67%
frequency observed in Cohort 1 (Fig. 26). Analysis of symptom frequency among women
dominated by each VLY type revealed no significant differences (Fig. 27). We next assessed
whether there was any significant association between VLY type abundance (number of reads)
and symptom frequency using logistic regression. No significant association was observed for any
VLY type. We then questioned whether our previous findings may be limited to BV positive
women, as Cohort 1 consisted only of BV positive women. However, even after excluding healthy
women from our analyses, we still did not detect any significant association between VLY type
and symptoms, either by looking at symptom frequency or by logistic regression, suggesting that
the finding in Cohort 1 could have been a false discovery due to the smaller sample size and lower
power associated with that cohort (Fig. 28).
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Figure 26. A majority of BV-positive Cohort 2 subjects experienced at least 1 vaginal symptom. Percent of
subjects reporting vaginal symptoms. Subjects reporting “No” for each of itching, odor, or discharge were counted as
“No symptoms”. Subjects with “NA” or “NS” were not counted. “Symptoms” represents the percent of subjects
reporting 1, 2, or 3 symptoms.
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Figure 27. Symptom frequency is similar in Cohort 2 subjects, irrespective of VLY type. A) Proportion of Cohort
2 women experiencing symptoms in each VLY type group. Significant differences in proportions among the three
types were evaluated by a Chi-Square test.
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Figure 28. Symptom frequency is similar in BV-positive Cohort 2 subjects, irrespective of VLY type. A)
Proportion of BV-positive Cohort 2 women experiencing symptoms in each VLY type group. Significant differences
in proportions among the three types were evaluated by a Chi-Square test.
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BV-positive Cohort 2 subjects in the type 2 VLY group have a significantly increased median
relative Gardnerella abundance
Finally, we used 16S read data alongside the cpn60 read data to determine if the abundance
of any vaginally relevant taxa increased or decreased depending on VLY type. Using the entire
762 sample data set, we identified only one significant difference in taxa abundance by VLY type.
Lactobacillus iners abundance was significant increased in women dominated by type 1 VLY
compared to women dominated by type 2 VLY (p= 0.0060) (Fig. 29A). There was no significant
difference in Gardnerella relative abundance between the two VLY types (Fig. 29B). However,
when we excluded healthy women from the analysis, relative Gardnerella abundance was
increased by roughly two-fold in women dominated by type 2 VLY, similar to what we observed
in Cohort 1 (Fig. 30) (p = 0.0002). In sum, the increased relative Gardnerella abundance observed
in type 2 VLY dominant, BV-positive Cohort 1 subjects was also observed in type 2 VLY
dominant, BV-positive Cohort 2 subjects.
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Figure 29. Cohort 2 subjects with type 1 VLY exhibit increased L. iners relative abundance. Median relative
abundance in each VLY type group in Cohort 2. “x” marks the mean relative abundance. * = P ≤ 0.05
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Figure 30. BV-positive Cohort 2 subjects with type 2 VLY exhibit increased Gardnerella relative abundance.
Median relative abundance in each VLY type group in BV-positive Cohort 2 subjects. “x” marks the mean relative
abundance. *** = P ≤ 0.001
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Discussion
In this study, we compared VLY amino acid sequences across the 84 publicly available
Gardnerella genome sequences. Through comparisons focusing on the conserved undecapeptide
and CD59 regions, we were able to distinguish 5 distinct VLY types that were differentially
distributed among the 13 recognized Gardnerella species. While types 1A-C were found in
Vaneechoutte et. al species groups 1-3, 7-10, and 13, VLY type 2 was only found in species groups
5 and 6. These distributions are consistent with a 2012 study that performed a comparative analysis
of 17 Gardnerella isolates129. The analysis of VLY amino acid sequences of these 17 isolates
provided evidence that VLY from clades 1 (species groups 1 and 2), 2 (species group 3), and 3
(species groups 8-10) engaged in recombination between clades while clade 4 (species groups 5
and 6) retained a unique identity. Our study builds upon this by introducing VLY type 3 as an
additional candidate VLY with a unique identity. It was only identified in a single strain
representing species group 12, which does not fall into one of the four previously described clades.
Inspection of the undecapeptide and CD59 regions indicate characteristics of both type 1 and type
2 VLYs. While only ~1% of the publicly available strains we analyzed make this version of the
toxin, 15% of women from Cohort 1 had at least 25% of Gardnerella reads coming from this
species group. Interestingly, all of these samples exhibited less than 20% relative Gardnerella
abundance. Thus, this VLY type warrants more investigation and should be isolated and
functionally compared to the other two predominant VLY types.

Alignment of Gardnerella strains based on whole genome sequences and subsequent
mapping of species group and VLY type revealed that ~22% of analyzed strains were devoid of
vly. While the existence of Gardnerella strains lacking the vaginolysin gene have been noted
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previously, we noticed that species group 4 was particularly enriched in vly deficient strains and
that species group 11, represented by a single strain, was also vly deficient133,157,192. When we
looked at samples containing a large percentage (at least 25%) of either of these two species groups
among the total Gardnerella population, we observed a wide range (9.5-65%) of relative
Gardnerella abundance within the total bacterial population of each sample. We also noticed that
out of all 62 samples of Cohort 1, only one woman was colonized by a single Gardnerella species
group. All other samples contained more than one species, to suggest that the lack of VLY
production from some species can likely be compensated by another, co-colonizing, VLYproducing species. Therefore, although several vly null strains of Gardnerella exist and are
abundant during BV, this in itself is not suggestive of the inessentiality of the putative virulence
factor. Furthermore, what is interesting to consider, in light of this finding that multiple
Gardnerella species coexist in a single host, is the interdependence that may be at play so that
infection with multiple, distinct species is the norm. Future research should be directed at defining
the contributions that disparate Gardnerella species make to promote community success within
the vaginal mucosa.

To determine whether these observed sequence differences could alter VLY protein
function, we performed in vitro assays using recombinantly produced toxins of the two most
common divergent VLY types, type 1A and type 2. Vaginal epithelial cell monolayers were more
greatly damaged by the type 1A VLY, but only when CD59 levels were reduced. These results
were suggestive of an increased affinity for CD59 in type 1A VLY relative to type 2 VLY. Our
findings contradict a 2012 study that compared the hemolytic activity of five Gardnerella strains
with divergent VLY sequences101. This study found that the diversity of the VLY sequences did
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not affect the hemolytic activity of VLY. However, as our findings suggest, differences in
cytotoxicity would only be expected where surface expression of CD59 is limited. CD59 is
abundant on erythrocyte and leukocyte membranes and may be significantly increased in these
cells relative to vaginal epithelial cells, considering the large difference in the concentration of
VLY toxin necessary for cell lysis193. Our experiments with 4- and 7-day vaginal keratinocyte
monolayers may suggest that CD59 decreases with the age of vaginal epithelial cells, which is in
agreement with the fact that the peripheral cells on vaginal epithelia are senescent. This suggests
that in vivo, superficial epithelial cells that are exposed to VLY may be somewhat resistant to its
effects, and even more so to the type 2 version of the toxin.

The cytokines altered in response to either toxin under the same reduced CD59 conditions
were, for the most part, similar. There were some significant differences in cytokine quantities
between differentially challenged cells, likely due to differences in the amount of cell death
induced by either toxin (i.e. more death from type 1A challenged cells, resulting in reduced
cytokine secretion). We recently reported that in a stratified, polarized model of the human vaginal
epithelium, VLY type 2 cytotoxicity was limited to the basolateral side. Apical (lumenal) cells
were resistant (impermeable) to the toxin188. These apical cells also exhibited reduced surface
expression of CD59 relative to basolateral cells. With this, we hypothesized that the observed
differences in cytotoxicity between type 1A and type 2 toxins could potentiate important
differences in the interaction with the host epithelium in vivo. Specifically, type 1A, with a putative
increased affinity for CD59, would be more damaging to the lumenal (apical) side of the vaginal
mucosa which Gardnerella spp. directly interact with in vivo. Because of the reduced CD59
expression on this side, type 2 VLY would elicit much less damage, if any. As a consequence, type
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1A VLY may induce a pro-inflammatory response manifesting in overall tissue inflammation and
related host symptoms (itching, odor, or discharge) whereas type 2 VLY may effectively promote
immune evasion. Essentially, we would expect women colonized by Gardnerella spp. producing
type 1 toxin to more frequently report symptoms and women colonized by type 2 producing
Gardnerella to exhibit increased Gardnerella abundance.

We first investigated this hypothesis using a cohort of BV-positive women from the
Vaginal Human Microbiome project for which metagenomic data was available (Cohort 1). A
majority of samples were simultaneously colonized by multiple Gardnerella species, and thereby
contained multiple VLY types. However, based on vly read data, we were able to determine the
“dominant” VLY type for each sample. When we looked at women experiencing any of the 3
reported symptoms, these women more frequently had type 1 as the dominant VLY type compared
to types 2 and 3. We then grouped the samples by dominant VLY type and looked at the relative
abundance of various taxa. Relative Gardnerella abundance was greatest in women with type 2
VLY as the dominant VLY type, with a median abundance 2 to 4-fold greater compared to women
with type 1 or 3 as the dominant VLY type. While the data from this cohort of women supported
our hypothesis, we wanted to see if our findings would replicate in a larger data set that included
healthy women in addition to BV-positive women. Because data from the small cohort indicated
that cpn60 and vly read data were in agreement, even though we didn’t have metagenomic data for
the larger data set, we extrapolated vly abundance from cpn60 read data. This was achieved by
using the custom cpn60 database made for this study. Since cpn60 sequences are able to classify
Gardnerella at the strain level, and each strain produces a specific VLY type, each cpn60 read was
assigned to a specific VLY type. When we analyzed the data set as a whole for differences in
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symptom frequency and taxa abundance, our initial findings did not replicate. However, when we
analyzed only BV-positive women, we again saw that women with type 2 VLY as the dominant
toxin type exhibited a relative Gardnerella abundance 2-fold greater than women with type 1 VLY.
There was still no difference in symptom frequency. We considered whether the differences in the
findings between the two data sets could be due to differences in the study populations. While a
more thorough comparison of the cohorts is warranted, one readily apparent difference was that
type 1 was the dominant VLY type in Cohort 1, while type 2 was the dominant type in Cohort 2.
Perhaps not unrelated, Cohort 1 subjects exhibited an increase in the overall frequency of
symptoms relative to BV-positive Cohort 2 subjects (67% vs 53%). In addition, we found that BVpositive Cohort 2 subjects were characterized by a significantly increased L. crispatus relative
abundance (data not shown). This is interesting considering that a recent study observed that L.
crispatus was able to repress vly expression194. Thus, even though type 1 VLY-producing bacteria
are there, there may be reduced vly expression in the larger data set due to increased L. crispatus.
Despite these discrepancies and their causes, however, our findings suggest that the differences in
VLY phenotype may only be relevant during BV.

Results from both our in vitro and in vivo data are reminiscent of the findings from studies
investigating the recently discovered candidalysin (CLY) toxin produced by the mucosal
opportunistic pathogen, Candida albicans. Discovered in 2010, this toxin has been shown to elicit
cell death through pore formation, activate innate epithelial immune responses, and promote the
release of alarmins and antimicrobial peptides from epithelial cells195–197. In multiple mucosal
infection models, it is critical for infection, as mutant strains lacking the toxin were avirulent198.
Specifically within the vaginal mucosa, it was found to drive epithelial cell signaling, the

130

recruitment of neutrophils, and ultimately the immunopathology characteristic of vaginal
candidiasis199.

Of particular interest is the finding that different C. albicans strains elicited differing levels
of LDH release from epithelial tissue, and this difference was accompanied by differing levels of
neutrophil recruitment, tissue inflammation, host symptoms (weight loss), and either persistence
or clearance of the pathogen in a murine oral infection model200. Strains of C. albicans that were
more cytotoxic towards the epithelial tissue elicited greater neutrophil infiltration into the tissue,
an increased pro-inflammatory response, increased weight loss, and reduced fungal burden. Less
cytotoxic strains, on the other hand, elicited low levels of inflammation, little, if any, neutrophil
recruitment, significantly less weight loss, and increased fungal burden. For comparison, while all
strains were inoculated with ~ 106 C. albicans cells, high-cytotoxicity strains were reduced to 102
cells per gram of tissue by day 3 post-infection whereas low-cytotoxicity strains were maintained
at 106 cells per gram of tissues at least up to 7 days and at lower but detectable concentrations up
to 4 weeks post infection. The authors of this study hypothesized that CLY played a role in these
observed strain differences, as it is the only described LDH-inducing toxin produced by C.
albicans. However, while strains did differ in toxin gene expression, they did not correlate with
the degree of LDH release. Strain differences in the toxin sequence (nucleotide or amino acid)
were not investigated.

Although the polymicrobial nature of BV and the simultaneous presence of multiple
Gardnerella strains and VLY types in vivo likely contribute to a more complex dynamic than that
transpiring during a C. albicans infection, it is interesting to consider whether something similar
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may be occurring with the different VLY-type secreting strains of Gardnerella. Regarding our
initial question of whether VLY type could distinguish commensal and pathogenic strains of
Gardnerella, our data suggest that the answer is no. This is because the differences in symptom
frequency and abundance were only observed in BV-positive women. It is possible that VLY type
is irrelevant in healthy women because Gardnerella and therefore VLY is maintained at a low
concentrations by the beneficial lactobacilli. However, under conditions promoting Gardnerella
proliferation (i.e. BV), increased VLY concentrations could lead to damage of host cells,
depending on the VLY type. Thus, we postulate that VLY type may impact BV immunopathology,
which could potentially impact BV persistence or recurrence or influence the likelihood of adverse
sequelae. Type 1 VLY, by inducing damage to the epithelium, could drive an immune response
that ultimately leads to its removal, but also results in tissue damage that increases the likelihood
of adverse sequelae. Type 2 VLY, on the other hand, may promote bacterial persistence in the
absence of damage. These interactions may be influenced by other host and bacterial factors at
play. For example, hosts with greater basolateral epithelial cell exposure, due to increased
superficial cell shedding, may elicit an immune response to type 2 VLY, as these proliferating
cells are sensitive to both type 1 and type 2 VLY. Gardnerella strains producing sialidase may
persist despite the induction of an immune response, as there is evidence to suggest that this
enzyme cleaves host IgA produced in response to Gardnerella. Furthermore, the presence and
abundance of other BV-associated organisms and their virulence factors could influence the
immune response, bacterial persistence, and likelihood of adverse outcomes.

To build upon this work and to continue to test the hypothesis that different VLY types affect
BV immunopathology, there are several remaining questions to address. First, our in vitro data
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suggest that VLY types differ in their interactions with CD59 on epithelial cells. While we think
this is driven by differences in affinities for the surface receptor, affinity was not directly measured.
Surface plasmon resonance should be employed to quantify the affinity of each VLY type for
CD59. Additionally, cholesterol-dependent pore forming toxins are ubiquitously produced by a
wide variety of organisms. These toxins exhibit differences in the cholesterol concentration
required for pore formation and oligomerization as well as different pH optima. For example, a
study comparing inerolysin (INY) produced by L. iners and VLY (type 1A) found that INY can
bind cells with lower membrane cholesterol content and has an acidic pH optimum123. VLY, on
the other hand, requires more than double the cholesterol content and exhibits a neutral pH
optimum. The other VLY types should be similarly studied to see if they exhibit any differences
other than affinity for CD59. Next, EpiVaginal tissues should be used to investigate whether
different VLY types promote the release of various alarmins and cytokines and subsequent
neutrophil recruitment. While in this work we quantified cytokine production from VLY treated
VK2 cell monolayers, these cells are phenotypically more similar to the basolateral cells of
EpiVaginal tissue. Our previous study of type 2 VLY on these tissues revealed that the cytokine
response of apically challenged cells to VLY is distinct from the response of basolateral cells.
Furthermore, type 2 VLY did not elicit any pro-inflammatory cytokine production from the apical
side. We predict that EpiVaginal tissues challenged apically with type 1 VLY would secrete proinflammatory cytokines and alarmins, which would signal to recruit neutrophils inoculated into
the medium underlying the basolateral cell layer into the exudate overlaying the apical cells.
Finally, in vivo studies quantifying protective antibody production, adverse outcomes, and BV
resolution and recurrence in women with different dominant VLY types will be essential for
resolving the role of VLY in BV immunopathology. Previous studies of anti-VLY antibody
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production during BV found that more than half of women make anti-VLY during BV which was
protective against adverse pregnancy outcomes. We anticipate that women with type 1 VLY as the
dominant type will have greater anti-VLY production, but that the protective effects may depend
also on the production of sialidase, which is hypothesized to cleave anti-VLY IgA. As various
stimuli can regulate the expression and secretion of virulence determinants in vivo, it would also
be worthwhile to more directly quantify vly expression and protein concentrations to more
accurately ascertain the dominant VLY type of a sample.
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CHAPTER 5
Characterization of a putative phase-variable opacity phenotype conserved
among Gardnerella spp.
Introduction
Bacteria produce a variety of external appendages that allow them to interact with their
environment, including proteinaceous polymeric structures called pili201. These surface organelles
are assembled via multiprotein complexes localized to bacterial membranes and facilitate adhesion
to surfaces, some forms of motility, and DNA uptake, among other functions202,203. For many
urogenital pathogens, pilus production is associated with virulence, as these pili-dependent
functions promote survival and adaptation in the host. For example, uropathogenic strains of
Escherichia coli (UPEC), the etiological agent in a large percentage of urinary tract infections
(UTI), use pili to adhere to urinary tract epithelial cells and to invade bladder epithelial cells204,205.
In Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection, gonorrhea, pili
appear to have numerous functions. Pilus-producing variants are able to attach to human epithelial
cells and resist phagocytosis by neutrophils206. In addition, mutants deficient in pilus production
are impaired in twitching motility and natural transformation207. Furthermore, pili produced by
Gram-positive Group B streptococcus (GBS) facilitate attachment and invasion of cervical
epithelial cells and reduce internalization and killing by macrophages208,209. Thus, pili are virulence
determinants commonly used by diverse urogenital pathogens and aid in colonization of host
tissue, dissemination, and evasion of the immune response.

Various classes of pili can be distinguished based on the pathway used for assembly. For
example, type IV is a ubiquitous class of pili characterized by the dynamic nature of its assembly,
wherein pilin subunits cyclically polymerize and depolymerize to promote both extension and
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retraction of the pilus210,211. Type IV pili can be further subdivided into type IVa and type IVb,
based on the length and amino acid composition of the pilin subunit. Type IVb pilins are typically
longer and more heterogeneous compared to type IVa pilins212. Tight adhesion (Tad) pili are
representatives of the type IVb class and are found in both Gram-negative and Gram-positive
bacteria as well as Archea213,214. Tad loci encode major (flp) and minor (tadE) pilin subunits,
integral membrane proteins that form the secretion apparatus for the pilin subunits (tadB and tadC),
an ATPase that energizes the transfer of pilin subunits from the cell interior (tadA), a prepilin
peptidase that processes pilin subunits prior to integration into the pilus (tadV), and a factor thought
to direct localization of the Tad machinery to the cell poles (tadZ)213,215–218. In the Tad loci of
Gram-negative bacteria, genes that facilitate outer membrane secretion (rcpA, rcpB, and rcpC) are
also included219,220. Autoaggregation, biofilm formation, surface colonization, and natural
competence are some of the functions ascribed to Tad pili in various organisms213,221–224.

While the ability to perform these pilus-dependent functions certainly benefits
microorganisms, the pilus can be targeted by adaptive immune defenses, which may give nonpiliated bacteria an advantage. Additionally, under certain conditions, it may be advantageous for
bacteria to move from one site to another, and non-piliated bacteria may be better equipped to exit
the community. Consequently, bacteria employ various mechanisms to regulate the production of
their pili.

By one such mechanism, called phase variation, bacteria reversibly switch the

production of a certain factor “ON” or “OFF225.” There are several ways to achieve this, but two
of the most common mechanisms involve slipped strand mispairing and site-specific inversion. In
slip strand mispairing, paired DNA segments are separated during DNA repair or replication, and
upon subsequent re-annealing, mispair with a segment upstream or downstream of the correct
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pairing location. This is facilitated by short repetitive sequences, either homo- or hetero-polymeric
tracts of nucleotides, within or upstream of a gene, ultimately altering the reading frame and
leading to altered transcription or translation of a gene or locus. Alternatively, site-specific
inversion is facilitated by a pair of short, often imperfect, inverted repeats that flank a region of
DNA to be inverted. Inversion typically requires a specific recombinase and, depending on the
orientation, can promote or inhibit transcription by altering the location of promoters or other
important regulatory elements. Phase variation of pili is a common strategy used by both urogenital
and non-urogenital pathogens, including UPEC, Proteus mirabilis, Bordetella pertussis,
Salmonella typhimurium, and Haemophilus influenzae226–230. Variance in colony morphology is
often an indicator of a phase variable phenotype and has been used to distinguish pilus-producing
and pilus-deficient strains in a variety of bacterial species231–233. This ability to “flip” a molecular
switch is thought to help bacteria to both respond rapidly to their changing environment and to
also escape recognition by the host immune response225.

Gardnerella spp. are Gram-positive urogenital tract pathogens234. A wealth of evidence
suggests that Gardnerella play a key role in the establishment of bacterial vaginosis, a disease with
multiple adverse outcomes that ultimately reduces the barrier integrity of the vaginal epithelium
and increases the susceptibility to other urogenital pathogens46,47,128,235,236. Gardnerella spp. have
also been implicated in recurrent urinary tract infections60,237. Multiple reports show evidence of
pilus production in Gardnerella spp., however, evidence of the genetic determinants driving
Gardnerella pilus formation is still lacking109–111. Other studies of Gardnerella virulence show
that they are able to auto-aggregate, adhere to cervical and vaginal epithelial cells, and form a
dense biofilm82,107. Moreover, although competence and DNA uptake in Gardnerella spp. have yet
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to be observed directly, Gardnerella spp. genomes encode competence promoting proteins and
show evidence of substantial horizontal gene transfer85,129. These virulence mechanisms are
thought to contribute to Gardnerella spp. pathogenicity and host adaptation and are hypothesized
to be pilus-driven, as they are in other pathogens. However, it has been difficult to directly test
this given that the genes responsible for pilus production are unknown and methods to perform
directed mutagenesis in Gardnerella spp. have not yet been developed.

In this study we describe an opacity colony phenotype that appears to be conserved among
various Gardnerella species. We investigate the contribution of pilus production mediated by a
Tad locus homologue to this phenotype. Opacity appears to be phase variable, which allowed for
the ability to distinguish and purify opaque and translucent colony variants in the absence of the
ability to genetically manipulate the organism. In vitro assays performed with both variants
demonstrate that Gardnerella opacity contributes to dense auto-aggregation and biofilm
formation. Despite the lack of evidence for pilus production and the involvement of the Tad locus,
these results suggest that phase variable Gardnerella opacity could promote survival and immune
evasion in vivo and thus should be further explored to assess its potential as a target in the
development of improved BV therapies.

Results
Gardnerella spp exhibit opacity colony variants that are potentially phase variable
During routine passage of Gardnerella leopoldii AMD on solid medium supplemented
with FBS, we observed the presence of two distinct colony morphologies (Fig. 31). The first
morphotype, “opaque” (op), consisted of round, raised, white colonies. The “translucent” (t)
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morphotype consisted of similarly shaped colonies that were more gray-colored and transparent.
We tested whether this observation was unique to G. leopoldii or applicable to a variety of
Gardnerella species and strains. All tested strains exhibited the presence of both colony
morphologies (Table 8). Interestingly, we observed that the passage of purified, single colonies of
the translucent variant consistently yielded a small fraction of opaque variant colonies (Table 9).
Similarly, albeit, less frequently (~1-5 in every 3500 colonies), we also observed that opaque
colonies could give rise to translucent colonies. This observation led us to hypothesize that opacity
(putatively attributed to differential pilus production) in Gardnerella was phase variable. However,
under the conditions of standard laboratory passage and in most experimental conditions, there is
a switch bias favoring opacity.
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Figure 31. Gardnerella colony variants. Small images were taken with a phone camera. Larger images were taken
on an inverted EVOS® XL Core imaging system digital microscope at 4X magnification.

140

Strain
AMD

Species

Vaneechoutte
et al. species
number
5

Opaque
variant

Translucent
variant

✔

✔

1

✔

✔

Unknown

✔

✔

ATCC
14018
UM35

Gardnerella
leopoldii
Gardnerella
vaginalis
Unknown

UM224

Unknown

Unknown

✔

✔

101
JCP7275
GV1
GV3

Unnamed
Unnamed
Unknown
Gardnerella piotii

8
2
1 or 2
3

✔
✔
✔
✔

✔
✔
✔
✔

Table 8. Various Gardnerella species exhibit both colony opacity phenotypes. The presence of both phenotypes
was confirmed by streaking strains onto sBHI agar plates supplemented with 10% FBS. Only four of the proposed
thirteen Gardnerella species have been given a species name designation. The remaining nine are only recognized by
their number. The strains with both unknown species and species number have not been sequenced to determine which
species number they belong to. Strain GV1 is a clade 1 classified strain. Clade 1 spans Vaneechoutte species numbers
1 and 2.
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Percent switch
Culture
Method
Original Opaque
variant Translucent

C→S+FBS

C→L

C→L+FBS

0
2

0
7.5

0
0

L→L X1 L→L X3
0
20.1

0
34.1

Table 9. Translucent opacity phenotype can switch during routine passage. Switch frequency of G. vaginalis
ATCC 14018 opacity variants. C = colony; S = solid medium; L = liquid medium; + FBS = medium supplemented
with 10% FBS; X1 = single passage; X3 = 3 passages. These are results from a single experiment. While the same
pattern occurs between experiments, the exact percent of switching varies widely.
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Opacity and pilus production
Because of similar observations of distinct colony morphologies attributable to pili in other
bacterial species, we hypothesized that the observed difference in Gardnerella colony morphology
was the result of differences in the production of pili. To test this, we sought to perform
transmission electron microscopy (TEM) on both variants. Unfortunately, TEM imaging of the
variants was interrupted by the shutdowns resulting from the COVID-19 pandemic so we have a
few images of opaque bacteria but not translucent bacteria. In Figure 32, short appendages that
cover the surface of opaque bacteria are visible, and these could be pili. However, the results from
the TEM are still inconclusive.
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Figure 32. Opaque variant cultures contain cells with surface structures resembling pili and fimbriae. TEM
images of G. leopoldii strain AMD bacterial cells. Arrows point to pili/fimbriae-resembling structures.
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Opacity variants exhibit differential resistance to antibiotics and lactic acid
We next questioned whether these two variants exhibited any other phenotypic differences
beyond opacity. To test this, we challenged cells with various inhibitory compounds they are likely
to encounter in vivo (antibiotics, lactic acid, and hydrogen peroxide), quantified bacterial density
at a range of concentrations, and calculated the minimum inhibitory concentration required to
reduce the density by 50% (MIC50). For strain AMD, the translucent variant exhibited a slightly
increased resistance to both antibiotics tested, with higher MIC50 values compared to the opaque
variant (Strep. p = 0.0050; Met. p = 0.029). For strain 14018, on the other hand, the opaque variant
MIC50 for streptomycin was nearly 2-fold greater than that of the translucent variant (p = 0.0001),
yet the opaque variant MIC50 for metronidazole was nearly 4-fold less than that of the translucent
variant (p = 0.0028)(Table 10). The opaque variant appeared to be more resistant to lactic acid, as
both strains exhibited higher MIC50 values for their opaque variants relative to their translucent
variants (AMD p = 0.052; 14018 p = 0.018) (Table 11). Surprisingly, both strains and variants
were quite resistant to hydrogen peroxide, as even the highest (supra-physiologic) concentration
used (25mM) only reduced density to 95% (Fig. 33). Finally, we observed that translucent variant
growth was typically slower than opaque variant growth, for both Gardnerella strains.
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MIC50 (µg/mL)
Streptomycin

Metronidazole

AMD op

1.49 ± 0.03

64.57 ± 1.9

AMD t

1.71 ± 0.05

79.06 ± 5.2

14018 op

4.45 ± 0.09

3.77 ± 0.05

14018 t

2.30 ± 0.03

14.49 ± 1.0

Table 10. Opacity variants exhibit differential resistance to antibiotics. MIC50 of select antibiotics against opacity
variants. MIC50 = minimum inhibitory concentration at which bacterial density is reduced by 50%.
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MIC50 (%)
AMD op

0.33 ± 0.006

AMD t

0.28 ± 0.033

14018 op

0.42 ± 0.008

14018 t

0.24 ± 0.046

Table 11. Opaque variants are more resistant to lactic acid. MIC50 of lactic acid against opacity variants. MIC =
minimum inhibitory concentration at which bacterial density is reduced by 50%.

147

Figure 33. Gardnerella strains exhibit resistance to supraphysiological levels of hydrogen peroxide. Relative
density of opacity variant cultures exposed to 25mM hydrogen peroxide. Density is relative to wells without any
hydrogen peroxide added.
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Opacity enhances biofilm formation
Gardnerella spp. produce biofilms in vitro and in vivo. Because we suspected that the
opacity phenotype was due to the production of Tad pili, and these pili also mediate biofilm
formation in other organisms, we hypothesized that opacity could contribute to biofilm formation
in Gardnerella. We quantified biofilm formation by inoculating growth medium in 96-well plates
with overnight cultures of opaque or translucent variants. After 24 hours of anaerobic incubation,
we removed the media and stained the attached biofilm with safranin. Because translucent variants
exhibited slower growth kinetics relative to opaque variants, we normalized our biofilm readings
against the amount of bacterial growth. This biofilm value was 2-fold greater for opaque variants
relative to translucent variants (Fig. 34). Because of the observed phenotype switching, we plated
the input inoculum as well as output bacteria residing in the medium (planktonic) and comprising
the biofilm to determine the percent of each variant in each population. While variant phenotype
was stable for strain AMD, both planktonic and biofilm bacteria of the translucent variant of strain
ATCC 14018 exhibited a switch towards opacity (Fig. 34).
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Figure 34. Opaque variants produce more biofilm. The percent of each variant in the input inoculum for biofilm
assays (top). Biofilm production normalized to growth (middle). Growth was calculated by diving the output OD600
by the input OD600. The percent of each variant as planktonic bacteria and within the biofilm of wells (bottom). ***
= P ≤ 0.001
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Opacity promotes non-surface attached bacterial aggregation
In addition to biofilm formation, other bacteria expressing Tad pili are able to form
bacterial aggregates in suspension. We wanted to investigate whether the different variants
aggregated under various conditions, hypothesizing that opaque, potentially pilus-producing
variants would exhibit an enhanced aggregation phenotype relative to translucent variants. While
both variants exhibited small (2-10 cells) clusters under a variety of conditions, the addition of
FBS to nutrient deplete (IMDM) medium stimulated the production of large (> 20 µm), densely
packed aggregates from the opaque variants (Fig. 35, left). These aggregates began to form within
5 minutes post exposure to the aforementioned medium. The translucent variant, on the other hand,
was only able to form loosely associated aggregates (Fig. 35, right). The introduction of
antibiotics alone also stimulated the production of these dense aggregates and the addition of
sodium citrate to nutrient deplete, FBS-supplemented medium further enhanced their size (Figure
36). Physical disturbance (i.e. sonication) was sufficient to break up aggregates, however, it is
worth noting that while 30 seconds at the lowest setting yielded single cells in strain AMD,
aggregates of 5-20 cells persisted in strain 14018. Prolonged sonication (> 30 seconds) abolished
aggregate formation in response to FBS. Similarly, when lactic acid, proteinase K, or DNase were
added under conditions normally promoting aggregate formation, aggregate formation was
prevented or reduced. Surprisingly, heat inactivation of bacteria did not eliminate the ability to
form dense aggregates. In sum, these results suggest that while opacity contributes to Gardnerella
dense aggregate formation, there are also other environmental factors that may regulate their size
or structure. Moreover, there are several differences between the two tested Gardnerella strains
regarding what promotes and inhibits aggregate formation. This suggests that aggregate formation,
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like many other virulence factors, may be quite heterogeneous between different Gardnerella
species.
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Figure 35. Opaque variants form large, dense bacterial aggregates in suspension. Bacterial cultures were washed
in PBS then resuspended in IMDM supplemented with 10% FBS. After 90 minutes of incubation, suspensions were
fixed onto slides and Giemsa stained. Top images were taken on an inverted EVOS® XL Core imaging system digital
microscope at 10X magnification. Bottom images were taken with a phone camera using a light microscope at 100X
magnification under oil immersion.
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Figure 36. Various environmental factors regulate aggregate formation and size. Gardnerella aggregation in
suspension after 90 minutes of exposure to the listed compounds and media. Images were taken on an inverted EVOS®
XL Core imaging system digital microscope at 10X magnification. +-- = a score between + and ++.
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Opacity-driven bacterial aggregation does not enhance bacterial survival of opsonophagocytosis
We reasoned that the size of these non-surface attached bacterial aggregates could
potentially impede phagocytosis and thus enhance bacterial survival of the immune response (Fig.
37). To test this, overnight cultures of opaque or translucent variants were added to differentiated
HL-60 cells and bacterial survival of phagocytosis was quantified by sonicating HL-60s and
plating viable bacteria. In contrast to our hypothesis, we observed increased survival from
translucent variants, despite increased aggregate numbers and size in opaque variant samples (Fig.
38). Curiously, results from experiments with strain ATCC 14018 were highly variable. And
although aggregate formation was observed from this strain under conditions similar to those used
in phagocytosis assays (IMDM with serum), no aggregates were observed when the bacteria were
co-incubated with the differentiated HL-60 cells (Fig. 39).
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Figure 37. Bacterial aggregates are much larger than neutrophils. Methanol fixed, Giemsa stained suspensions of
Gardnerella and differentiated HL-60 cells, co-incubated for 90 minutes in IMDM supplemented with 10% human
serum.
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Figure 38. Translucent variants exhibit greater survival of neutrophil challenge. The percent survival of each
AMD variant after 90 minutes of exposure to differentiated HL-60 cells and human serum (top). Images of bacteria
and HL-60 cell suspensions(bottom). After 45 minutes of incubation, suspensions were fixed onto slides and Giemsa
stained to determine aggregation score. Images were taken on an inverted EVOS® XL Core imaging system digital
microscope at 10X magnification. ** = P ≤ 0.01 (n ≥ 3).
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Figure 39. Variants of strain ATCC 14018 do not aggregate in the presence of neutrophils Images of bacteria
and HL-60 cell suspensions. After 45 minutes of incubation, suspensions were fixed onto slides and Giemsa stained.
Images were taken on an inverted EVOS® XL Core imaging system digital microscope at 100X magnification.
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Opacity and the tight adhesion (Tad) locus
Evidence of pilus production in Gardnerella spp. was published in the 1980s. However,
the genes driving pilus production remain undefined. Because we suspected that opacity was due
to pilus production, we screened the available genomes of strains exhibiting both colony variants
for conserved putative pilus machinery. A fully populated tight adhesion (Tad) locus was present
in all strains (Table 12). The Tad locus was also identified in nearly 100 additional strains,
representing all 13 recognized Gardnerella spp. (data not shown). A detailed diagram of the Tad
locus in G. leopoldii AMD is presented in Figure 40. The organization of the Tad locus in
Gardnerella spp. is consistent with that observed in other Gram-positive organisms; it is
particularly reminiscent of the locus described for Bifidobacterium breve223. The flp gene was
originally annotated as tadG. It was only after plugging in its amino acid sequence to PilFind (v1.0)
that it was identified as a pilin (flp)238. A TadV recognition motif (GXXXXEY/F), important for
pilin processing, was also identified in the TadG-annotated peptides in both AMD and 14018,
further supporting their re-annotation as Flp proteins216,223. This motif is also present in the unannotated peptide upstream of Flp, in both AMD and 14018, suggesting it may be a minor or
pseudo-pilin. The tadV gene is located outside of the Tad locus.

Inspection of the G. leopoldii AMD Tad locus revealed numerous elements associated with
phase variation in other phase-variable bacteria, including direct tandem repeats (DTR), polynucleotide tracts, and inverted repeats. We hypothesized that if Gardnerella opacity were driven
by the Tad locus, opaque and translucent colonies would exhibit sequence differences within the
Tad locus at these sequence elements. We initially suspected that the imperfect, DTRs in the tadZ
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gene of the published AMD sequence were driving phase variation and, consequently, the switch
between opaque and translucent colony variants (Fig. 41A). To test this, we designed primers
against the published AMD sequence to amplify a 465 bp region encompassing the DTR and
hypothesized that this region would be different sizes in opaque and translucent variants. We used
these primers to perform colony PCR on opaque and translucent colonies as well as colonies that
were originally translucent but switched to opaque and colonies that were originally opaque but
switched to translucent. However, a gel of the PCR reactions revealed a band of the same size for
each variant, suggesting that the DTR size was unchanged in opaque and translucent colonies.
Furthermore, when the PCR products for each variant were sequenced, there were no sequence
differences among variants. We next hypothesized that an inverted repeat, rather than the direct
tandem repeats, were driving phase variation of the Tad locus. We identified an 18-nt imperfect,
inverted repeat flanking the noncoding region upstream of tadZ and 120-bp into tadB (Fig. 41B).
We predicted that in the published sequence orientation, where IR1 is upstream of tadZ, the Tad
locus is in the “ON” phase, driving pilus production and giving rise to opaque colonies. Upon
inversion, IR1 would be found within tadB, and the Tad locus would be in the “OFF” phase, giving
rise to translucent colonies. However, PCR amplification with multiple primers, product digest,
and ultimately sequencing revealed no sequence differences between variants in this region. This
lack of success in identifying differences in targeted regions of the Tad locus led us to sequence
the locus in its entirety as well as approximately 1500 base pairs upstream. DNA for PCR and
subsequent sequencing was isolated from both liquid-grown cultures and colonies. Again,
however, no sequence differences were detected between variants.
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Without any differences within the 7kb region that was sequenced, we considered two
scenarios. In the first, the Tad locus was not responsible for opacity. In the second, the locus was
responsible for opacity, but expression was turned “ON” or “OFF” by a phase variable regulator
residing outside the locus. In this second scenario, although there are no sequence differences
between the Tad loci of opaque and translucent variants, expression of the locus should be
increased in opaque variants. To test this, we performed RT-PCR using primers designed against
various points within the locus (tadZ, tadC, tadD, and flp), with RNA isolated from both liquid
cultures and colonies. Relative expression values were normalized against 16s values. We
observed no significant differences in expression between opaque and translucent variants (Fig.
42). Thus, the genetic basis for opacity is still unknown.
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Figure 40. Gardnerella genomes contain all of the essential components of a Gram-positive Tad locus. Schematic
of Tad locus organization in G. leopoldii AMD. The identifier above represents the locus tag in the reference sequence:
NZ_ADAM01000002.1. The supposed function of each gene is detailed below.
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Table 12. Gardnerella strains exhibiting both opacity phenotypes encode a complete Tad locus. Strains were
checked for proteins with significant shared amino acid identity to those in strain AMD. Operon = whether all genes,
excluding tadV, are found sequentially in the same region of DNA.
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Figure 41. Putative phase-variable elements in the G. leopoldii AMD Tad locus. A) Direct tandem repeats. B)
Inverted repeats.
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Figure 42. Tad locus expression is the same in both opacity variants. Relative expression of Tad locus genes
normalized to 16S rRNA expression. cDNA was generated from RNA extracted from colonies.
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Discussion
In this work, we describe an opacity colony phenotype that is conserved among different
Gardnerella species. We sought to characterize this phenotype, hypothesizing that it was a
consequence of pilus production driven by the tight adhesion locus machinery. Our results indicate
that opaque variants exhibit significantly enhanced bacterial aggregation, both in suspension and
when surface attached (biofilm). Curiously, opacity alone was not sufficient to drive dense
aggregate formation in suspension. Both strains tested required suspension in a more nutrientdeficient medium (i.e. Gardnerella cannot grow in this medium) and strain AMD also required the
addition of serum. It is unclear whether these conditions simulate the “host” environment, put
stress on bacterial cells, or both. However, considering that the introduction of antibiotics alone
(AMD), or lactic acid alone (ATCC 14018) increased aggregate formation, we speculate that dense
aggregate formation in suspension is a stress response. Furthermore, because the large aggregates
begin to form within 5 minutes of exposure to stimulatory conditions, and heat inactivation of the
bacteria does not impact the ability to aggregate, we suspect that dense aggregation is mediated by
something that is pre-formed in opaque variants. As proteinase K treatment prevents aggregation,
this suggests that the primary mediator of dense aggregation is proteinaceous in nature.

While our attempts to detect differential pilus production between variants were inconclusive,
our data contradict the hypothesis that an ON/OFF switch within the Tad locus regulates the
variation between opaque and translucent colonies. Both the targeted sequencing of regions with
potentially phase variable elements and the subsequent untargeted sequencing of the entire locus
failed to reveal any significant nucleotide differences between variants that would mediate an

166

“ON” versus “OFF” state of the locus. Furthermore, analysis of Tad locus transcript levels
indicates that locus expression is similar in both variants under the conditions tested. The
conservation of the Tad locus across over 100 Gardnerella isolates suggests it serves an important
function for the organism. In the closely related Bifidobacterium breve, it was shown that a Tad
pilus was an essential and conserved host-colonization factor223. While this was in an intestinal
infection model, gut and vaginal isolates of B. breve are indistinguishable, suggesting that the pilus
is also present in vaginal isolates and may similarly contribute to vaginal colonization239. It is still
possible that the Tad locus contributes to pilus production in Gardnerella. Reports of Gardnerella
pilus production describe the loss of piliation following repeated laboratory passage110. As the
strains tested in this study have been passaged innumerable times, it is possible that the piliation
phenotype has been lost. Thus, to investigate whether or not the Tad locus is responsible for
Gardnerella pilus production, the use fresh isolates may be warranted. Alternatively, it is possible
that the Tad locus in Gardnerella contributes to the secretion of a proteinaceous extracellular
coating, as it does in Vibrio vulnificus221. Such a coating has been described for Gardnerella240. In
sum, although the Tad locus in Gardnerella does not appear to be involved in the opacity
phenotype, the locus and its contribution to Gardnerella host-pathogen interaction deserves further
investigation.

While we have not yet ruled out the possibility of pili contributing to colony opacity in
Gardnerella, it is possible that differential expression of surface proteins or differences in
polysaccharide or capsule production mediate opacity, similar to what is observed in other bacteria
241–244

. It is also possible that this phase variable phenotypic change could be dependent on the

switching ON/OFF of a global regulator that controls the expression of a number of genes. In
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Streptococcus pneumoniae, colony opacity is driven by differential epigenetic gene regulation as
a result of a six-phase genetic rearrangement of a restriction modification system to produce
methylases with alternate specificities and thus clones with distinct methylation patterns243. In any
case, we still suspect that whatever generates or regulates colony opacity is subject to phase
variation. If confirmed, this would be the first report of phase variation in Gardnerella. This
observation may also aid in the identification of the genes responsible for opacity and help
demonstrate causality without the ability to generate isogenic mutants due to the genetic
intractability of Gardnerella spp.

During our characterization of the putative phase variability of opacity, we observed a switch
bias in vitro towards opacity, meaning that the frequency of switching from a translucent variant
to an opaque variant was much higher than the frequency of switching from an opaque variant to
a translucent variant under standard culture conditions. This bias is further enhanced during liquid
growth and increases with passage number. We are unsure of the mechanism underlying opacity
switch bias. However, the increased frequency of opaque variants during liquid growth and with
passage number could be due to the observed differences in liquid growth kinetics, as opaque
variants typically exhibit faster growth kinetics relative to translucent variants. This may also
explain differences in switch frequency between strains. Strain ATCC 14018 exhibits an increased
switch frequency relative to strain AMD; strain ATCC 14018 also exhibits faster growth kinetics
relative to strain AMD.

In our initial characterization of variant differences, we investigated resistance to antibiotics
and compounds likely to be encountered in the vaginal environment, i.e. lactic acid and hydrogen
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peroxide. The increased sensitivity of opaque variants to metronidazole can potentially be
explained by their enhanced growth kinetics. As the bactericidal action of this antibiotic depends
first on its reduction under anaerobic conditions, faster growing cells may reduce a greater amount
of antibiotic. In contrast, the opaque variants were more resistant to lactic acid relative to the
translucent variants. If opacity variants are indeed distinguished by increased surface expression
of a compound, this could protect the cell against lactic acid, similar to how surface
polysaccharides were found to enhance E. coli resistance to organic acids245.

We investigated our hypothesis of dense aggregate protection by quantifying variant survival
of phagocytosis. We first developed a neutrophil-like model of phagocytosis using differentiated
HL-60 cells and normal human serum to promote bacterial opsonization. Opaque variants formed
dense aggregates that were much larger than the phagocytes. However, contrary to our hypothesis,
opaque samples in which large dense aggregates were formed exhibited reduced survival of
neutrophil challenge relative to translucent variants. Findings by multiple groups show that
neutrophils are only able to engulf particles and bacterial aggregates up to 10 µm in diameter,
which is approximately the size of neutrophils themselves246,247. Thus, we do not think this is
difference is due to increased opaque variant uptake relative to translucent variant uptake. Instead,
and due to our hypothesis of dense aggregate formation as a stress response, we suspect that
bacterial cells within these dense aggregates may be in an altered metabolic state, existing as viable
but not culturable (VBNC) or persister cells. As a consequence, because opaque variants form
more and larger aggregates than do translucent variants in phagocytosis assays, less culturable
bacterial cells emerge from opaque samples following co-incubation with neutrophils. Therefore,
to test our hypothesis that dense aggregate formation is protective against host defenses, a more
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sensitive method for distinguishing viable (irrespective of cultivability) and non-viable cells, such
as vital dye staining followed by fluorescence microscopy or flow cytometry, must be employed.
Alternatively, even if aggregates are not engulfed, neutrophil extracellular traps (NETs) could be
effective at breaking up clumps or killing bacterial cells within them. This could be why strain
14018 samples lacked aggregates when neutrophils were added. NET formation may also augment
host tissue damage. A study investigating the relationship between pathogen size and neutrophil
function found that large pathogens, including large bacterial aggregates, promoted the formation
of NETs rather than productive phagocytosis or pathogen avoidance248. While NETs can be
beneficial in some circumstances, there is increasing evidence to suggest that NET formation is
more harmful than helpful in the context of many mucosal bacterial infections, particularly those
involving biofilms249.

Under a majority of conditions tested, translucent variants do not form dense aggregates in
suspension. However, we observed some smaller aggregate formation from AMD translucent
variants in phagocytosis assays as well as ample aggregation upon the addition of serum and
sodium citrate to IMDM. Furthermore, aggregates were seen from ATCC 14018 translucent
variants when in IMDM supplemented with heat inactivated FBS. Because of the observed switch
bias towards opacity, this could be mediated by a subset of opaque variants within the translucent
population. Alternatively, this may suggest that opacity is not simply “ON” or “OFF”. Opacity in
opaque variants may be constitutively “ON,” or require much less of a stimulus relative to
translucent variants. In either case, a genetic distinction between opaque and translucent variants
is still expected.
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In conclusion, our data collectively suggest that the opacity phenotype in Gardnerella, which
contributes to bacterial aggregation, may promote survival and immune evasion in vivo, and this
phenotype, therefore, warrants further investigation. Whole genome sequencing was recently
employed to aid in the identification of genetic factors responsible for opacity and to provide clues
as to the mechanism of putative phase variation. Results from sequencing the whole genomes of
both opaque and translucent variants in two different Gardnerella strains identified several
potential “hits”. Multiple variations in the genes of cell wall-anchored proteins were detected and,
interestingly, many of the noted variations reside within poly-guanine tracks. After verification of
the presence of these identified variants via Sanger sequencing, candidates will be tested for
differences in gene expression or protein production. Beyond identification of the genetic and
downstream factors driving the opacity phenotype, it would be worthwhile to quantify the
predominance of each variant in vivo and to test whether certain environmental factors alter the
observed switch bias. Investigating switch frequency under a variety of conditions would help us
understand if the observed switch bias may be due to intrinsic rather than environmental
conditions. For example, if phase shift always favors opacity, regardless of environment, it could
be due to reduced affinity of a regulatory element for the DNA substrate in one orientation (“ON”)
compared to the other (“OFF”) 250. EpiVaginal tissues would be a good environment more closely
approximating in vivo conditions in which to compare variants with respect to switch frequency,
growth, biofilm and aggregate formation, and survival of stressors (antibiotics, lactic acid, and
neutrophils). However, the phase variability of the opacity phenotype has the potential to introduce
significant variability into experiments, especially if the variant distribution in the input inoculum
cannot be controlled or predicted (i.e. liquid cultures inoculated with translucent colony variants
give rise to a variable percentage of opaque variants). In this instance, it may be better to work
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with bacteria grown on solid medium rather than in liquid cultures. Alternatively, the ability to
phase lock variants would reduce experimental variability. This may be possible once the genetic
determinants for opacity are identified and the efficiency of Gardnerella transformation using the
oligonucleotide recombineering method detailed in the following chapter is significantly
enhanced.

172

CHAPTER 6
Method development for site-specific mutagenesis in Gardnerella spp.
Introduction
Comparing isogenic mutants is the gold standard for characterizing the functions of
virulence factors in pathogenic organisms. Both random and site-specific mutagenesis approaches
are available for generating these mutants. Random mutagenesis is advantageous for reverse
genetic approaches to identify novel virulence attributes. Furthermore, classical random
mutagenesis techniques, including the use of UV or chemical mutagens, are still valuable today as
they are broadly applicable to a wide range of organisms and allow for the manipulation of
organisms that are otherwise genetically intractable. One pitfall of these techniques, however, is
that identifying mutants and ensuring that mutants are truly isogenic is often a cumbersome, timeconsuming task. More sophisticated mechanisms of random mutagenesis, such as transposon
mutagenesis, can be highly efficient and more restrictive in the number of mutations generated per
genome. However, not all organisms are amenable to manipulation with common transposon
systems (N. gonorrhoeae and Tn5, for example) and a significant time-investment to identify the
best transposon system for your organism may also be necessary251.

In site-directed mutagenesis, a specific mutation is introduced at a specific location in the
bacterial chromosome or on extrachromosomal plasmids. This is frequently mediated by some
form of homologous recombination, where homologous DNA segments are exchanged. With the
appropriate design, mutations can be introduced into a specific region by flanking the mutation
with DNA sequences that match the sequence at the location where you want to insert the mutation.
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One major setback of site directed mutagenesis is that getting some bacterial species to take up
and incorporate the exogenous DNA required for mutagenesis is rather difficult. Limited bacterial
competence, restriction-modification systems, and a lack of a host-adapted plasmid all have the
potential to impede site directed mutagenesis in a given organism. Moreover, systems designed
for other, even closely related organisms, aren’t always easily adaptable for use in your organism
of choice.

Oligonucleotide recombineering is a ubiquitous homology-based mechanism for directed
mutagenesis that is independent of RecA activity. It is specific, non-hypermutagenic, and is
capable of generating point mutations, deletions, and small insertions. Studies show that the
efficiency of this mechanism of recombination is significantly limited by single-stranded
exonuclease activity252. Consequently, when this activity is reduced, either by using exonuclease
null mutant strains or by saturating nucleases with excess single stranded DNA substrates,
recombination efficiency is comparable to that achieved with RecA-dependent methods (~3 x 106 252,253

)

This method of directed mutagenesis has been performed in various bacterial species,

including Escherichia coli, Legionella pneumophila, Pseudomonas syringae, Salmonella
typhimurium, Shigella flexneri, Lactobacillus reuteri, Lactococcus lactis, and Mycobacterium
tuberculosis253–257.

In these systems, several factors important for transformation efficiency were identified.
As already mentioned, the ability to subvert single stranded restriction endonucleases is crucial, as
recA mutants, only able to perform RecA-independent recombination, exhibit near complete
recombination deficiency in a wild-type background258. Some groups have impaired the restriction
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system by working in backgrounds lacking one or all known single-stranded nucleases, while other
groups found that simply adding high (5 ug) concentrations of the mutant oligo is sufficient to
overcome the inhibitory effect on recombination255. Electroporation is the typical mechanism used
to deliver the oligo into host cells. When preparing electrocompetent cells, growing bacteria in
rich media and harvesting the cells during the early log phase of growth have been shown to
significantly increase the efficiency of recombination253. Furthermore, the recovery time allowed
to the cells following electroporation should be sufficient to promote at least one replication cycle,
particularly if mutants will be subsequently selected and the wild type (sensitive) allele is dominant
to the mutant (resistant) allele253,255. This is because recombination occurs only on one strand and
cells selected immediately after recombination will be heterologous and unable to survive
selection.

Beyond this, multiple aspects of the oligonucleotide design can significantly impact
efficiency. First, the oligo, apart from the mutagenic region, should match the lagging strand of
the chromosome, as oligos designed to match the leading strand exhibit reduced efficiency up to
10,000-fold257. Furthermore, the mutagenic region of the oligo should be flanked on each side by
at least 10-nucleotides of sequence homologous to the desired site of recombination255. However,
increasing the total oligonucleotide length, and consequently, the number of homologous
nucleotides, can increase efficiency up to 3-log, with maximum efficiency achieved with oligos of
50-70 nucleotides253. Next, oligos must be able to stably anneal to the chromosome. One study
empirically determined that this stable annealing is achieved when oligos are designed to have a
Tm of at least 62°C255. Finally, the oligo must be designed so that the aberrant pairing of mutagenic
nucleotides with the chromosome is minimally recognized by the methyl-directed mismatch repair
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(MMR) system of the cell. Evasion of the MMR system, at least in E. coli, can be achieved by 1)
including a C-C mismatch 6 base pairs away from the desired change on the oligo; 2) generating
at least four adjacent mismatches; 3) placing mismatches at four or more consecutive wobble
positions; 4) generating a deletion rather than a substitution253,255.

If all of these aforementioned techniques are used, the maximum recombination efficiency
that can be achieved in the absence of any exogenous recombinase activity is ~10-1000
transformants per 108 viable cells. Practically speaking, this limits the types of mutations to those
with selectable phenotypes or phenotypes that can be enriched under certain growth conditions.
However, this efficiency can be further enhanced by the addition of single strand DNA
recombinases, such as the phage λ Beta or RecT, typically introduced to the bacterial cell via
transduction or via a plasmid259–261. In L. reuteri and L. lactis, the use of RecT allowed for the
generation of recombinants at frequencies ranging between 0.4 and 19.0%256. These frequencies
allow for the identification of mutants without any selection and increase the feasibility of using
oligonucleotide recombineering to generate isogenic mutants that will aid in the characterization
of putative virulence factors.

The lack of methods for genetic manipulation in Gardnerella has significantly hindered
the characterization of putative virulence factors and limited our ability to define a role for the
putative pathogen in BV pathogenesis. In this work, we sought to develop a method for directed
mutagenesis in Gardnerella spp. We elected to design an approach using oligonucleotide
recombineering due to both its ability to direct chromosomal mutations in the absence of any
exogenous functions and the previous success in using this system in both Gram-positive and
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anaerobic organisms. To do this, we designed a mutagenic oligonucleotide that would introduce a
two-nucleotide substitution in the rpsL gene, effectively mutating K43 to R to impart streptomycin
resistance and the ability to select for recombinants. We then altered a variety of parameters to
determine which were important for optimizing transformation efficiency. Using these optimized
methods, we were able to transform 3 strains of Gardnerella representing 3 different species. This
is the first report of directed mutagenesis in Gardnerella and represents a significant advance in
the field. However, continued optimization is necessary to further improve transformation
efficiency in order to increase the practicality of using this tool to generate non-selectable
transformants.
Results
Method development strategy and baseline efficiency
As a starting point, we wanted to establish the electroporation parameters that would produce
a sufficient balance between cell death and survival. We reasoned that the conditions promoting
ample pore formation for DNA delivery would also yield increased bacterial death. However, with
too much cell death, DNA uptake would be irrelevant. Using the pre-programmed settings for
bacteria (Table 13), we measured G. vaginalis ATCC 14018 survival after exposure to each
setting. The “Agr” setting had the greatest impact on survival (Table 14).

Active growth is a requirement for successful transformation in other bacteria using
oligonucleotide recombineering. We generated a growth curve for Gardnerella strains to
determine the OD600 of early log phase growth and thus the OD600 at which we should harvest cells
for electrocompetence. An OD600 value below 0.5 was determined to be within the “early log”
phase of growth (Fig. 43). Cells harvested at a value ~0.35 show a majority of the cell population
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to be dividing (Fig. 44A). After cell harvesting, we prepared the cells for electrocompetence using
a standard protocol developed for Staphylococcus aureus involving multiple washes of the cells in
ice cold 10% glycerol. The original culture is concentrated 100-fold and dispensed in 100ul
aliquots yielding approximately 2x108 cells per aliquot.

Due to the genome of G. vaginalis ATCC 14018 being unclosed, we were unable to distinguish
which of the DNA strands were “leading” and “lagging.” So, when designing mutagenic
oligonucleotides (oligos), we designed them against both strands of a 44-nucleotide region within
the rpsL gene and arbitrarily labeled them “lead” and “lag”. In principle, these oligos, if
incorporated, should change codon 43 from “AAG” to “CGG,” which would result in the
production of arginine instead of lysine. This amino acid change should impart streptomycin
resistance and the ability to select for transformants.

To aliquots of electrocompetent cells, 10ug of either oligo was added. After a 10-minute
incubation on ice, cells were either immediately plated to determine spontaneous background
streptomycin resistance or electroporated using the “Agr” protocol. Immediately following
electroporation, recovery medium (sBHI) was added and the cells were incubated anaerobically
for sufficient time to allow at least one replication cycle to occur (~16 hours). Cells were then
plated on medium with and without streptomycin to determine the transformation efficiency (# of
streptomycin resistant colonies/ all colonies). This initial protocol yielded several streptomycin
resistant colonies following electroporation with either oligo, with the lag oligo producing slightly
more (Table 15). There were no colonies on streptomycin plates to which un-electroporated
bacteria had been added, suggesting that all streptomycin resistant colonies were indeed
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transformants and that background resistance to streptomycin was negligible. Sequencing
confirmed that resistant colonies possessed the intended mutations in the rpsL gene. Based on these
results, the approximate baseline transformation efficiency in G. vaginalis ATCC 14018 using
oligonucleotide recombineering is 252 recombinants per 108 viable cells.
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Protocol
name

Voltage
(kV)

# of pulses

Time
constant
(msec)

EC1

1.8

1

-

EC2

2.5

1

-

EC3

3.0

1

-

StA

1.8

1

2.5

Agr

2.2

1

-

Table 13. Pre-programmed settings of Bio-Rad MicroPulserTM. Adapted from MicroPulserTM Electroporation
Apparatus Operating Instructions and Applications Guide.
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Protocol
name

#
colonies
(50 µl)

#
colonies
(25µl)

CFU/ml

-

-

-

5.7 x 108

EC1

lawn

lawn

-

EC2*

lawn

lawn

-

EC3*

lawn

lawn

-

StA

lawn

lawn

-

Agr

TNTC

2,648

3.97 x 105

Table 14. Viable cell numbers before and after electroporation. “lawn” = no single colonies; “TNTC” =single
colonies, but too numerous to count. OD600 at cell harvest was 0.795. *These electroporation conditions were
conducive to arcing.
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2.5

OD600

2
1.5

AMD

1

0.5

ATCC
14018

0
0 6 20 24 29 35 44 48

Time (hours)
Figure 43. Gardnerella spp. growth curve. Anaerobic growth in sBHI plus 5% human serum at a starting inoculum
of OD600 = 0.01.
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Figure 44. Gram stain of Gardnerella electrocompetent cell preparations. A) G. vaginalis ATCC 14018 opaque
variant. Arrows point to septa of dividing cells. B) G. leopoldii AMD opaque variant.
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Oligo

Strepr colonies per 108
cells

None

0

Lead

92

Lag

252

Table 15. Baseline transformation efficiency in G. vaginalis ATCC 14018 using oligonucleotide recombineering.
The number of streptomycin recombinants per 108 viable cells produced by transformation with a 44 nt oligo, carrying
the rpsLK43R, designed to match one strand of the genome or the other and arbitrarily labeled “lead” or “lag.” These
data are representative of a typical experiment.
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Parameters impacting efficiency
With a successful proof of principle experiment and a baseline transformation efficiency, we
next sought to alter a variety of parameters to determine their impact on transformation efficiency
(Table 16). Single changes were made to the baseline protocol and the number of recombinants
were compared. The greatest reduction in transformants was observed when cells were either
electroporated at room temperature rather than at ~4°C or only allowed to recover for 4 hours; no
streptomycin resistant colonies were observed under these conditions. Harvesting bacterial cells at
an OD600 of 0.5 resulted in a 4-fold reduction in the number transformants. Changing the
electroporation program from Agr to StA or EC1 produced half the number of streptomycin
resistant colonies. Using frozen and thawed cells, rather than freshly prepared cells, and the
addition of sucrose to the wash medium reduced efficiency by one third. Increasing the oligo
concentration had no impact on the number of recombinants.

Having recently identified opaque and translucent colony variants in several different
Gardnerella strains, we questioned whether transformation efficiency significantly differed
between different strains, or variants of the same strain (Table 17). Opaque variants of G. piotii
GV3 exhibited the highest efficiency. Strain AMD was the most difficult to transform, requiring
sonication to get any transformants. Sequencing of DNA from streptomycin resistant colonies
showed that all strains only incorporated the “intended” mutations (Fig. 45). As the mutagenic
oligo was designed against the 14018 rpsL sequence, and this sequence is somewhat divergent in
AMD, the oligo contained a few additional nucleotide differences beyond the “AAG” to “CGG”
encoded to alter codon 43. These additional differences were not incorporated.
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The maximum efficiency we were able to achieve in the absence of exogenous enzymes was
866 transformants per 108 cells. We next attempted to increase this efficiency via the addition of
the single stranded DNA recombinase, Beta from bacteriophage λ. Since a system for recombinant
expression in Gardnerella is unavailable, we elected to load recombinantly produced beta into
Gardnerella cells via electroporation. Purified beta was added 1:1 to the rpsL mutagenic oligo and
increasing quantities of this mixture were added to aliquots of electrocompetent cells subsequently
electroporated with the “Agr” protocol. The addition of Beta did not substantially increase
efficiency, and higher concentrations of protein appeared to negatively impact bacterial viability.
(Table 18). The addition of MgCl2, previously shown to be essential for λ beta binding of DNA,
did not significantly increase the number of recombinants262.
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Parameter

Strepr
colonies per
108 cells

Baseline

636

50 µg oligo

638

EC1

346

StA

348

RT cuvette

0

Freeze/thaw

417

+ Sucrose

418

0.5 OD600

154

4 hr recover

0

Table 16. Impact of altering transformation parameters on recombination frequency. Baseline conditions
included: G. vaginalis ATCC 14018; 10µg rpsLmutlag oligo; OD600 at harvest ~0.35; Agr electroporation protocol;
electrocompetent cell preparation on ice; ice-cold cuvette; freshly prepared electrocompetent cells (no freeze/thaw);
10% glycerol in H2O electroporation medium (no sucrose); 16-hour recovery. “RT” = room temperature. “+ sucrose”
= 0.5M sucrose was added to the 10% glycerol for cell washing.
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Species,
strain

Opacity
variant

Strepr colonies
per 108 cells

G. vaginalis,
ATCC 14018

Opaque

383

G. vaginalis,
ATCC 14018

Translucent

180

G. leopoldii,
AMD*

Opaque

20

G. leopoldii,
AMD

Translucent

0

G. piotii, GV3

Opaque

866

Table 17. Difference in recombination efficiency among Gardnerella species and opacity variants.
Baseline conditions included: 10µg rpsLmutlag oligo; OD600 at harvest ~0.35; Agr electroporation protocol;
electrocompetent cell preparation on ice; ice-cold cuvette; frozen/thawed cells; 10% glycerol in H2O electroporation
medium (no sucrose); 16-hour recovery. * indicates that electrocompetent cells were sonicated after the addition of
the mutagenic oligo.
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Figure 45. Region of Gardnerella rpsL to be mutated. Lowercase, bolded letters represent “intentional” mismatches
to impart streptomycin resistance in both AMD and ATCC 14018. Red bolded letters represent sequence differences
in AMD relative to the ATCC 14018. Lowercase blue letters represent “unintentional” mismatches between the
mutagenic oligo and AMD.
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λ beta
(µl)

Strepr colonies
per 108 cells

None

383

2

130

5

609

10

10

5+

561

Table 18. Impact of λ beta on recombination efficiency. Baseline conditions included: 10µg rpsLmutlag oligo;
OD600 at harvest ~0.35; Agr electroporation protocol; electrocompetent cell preparation on ice; ice-cold cuvette;
frozen/thawed cells; 10% glycerol in H2O electroporation medium (no sucrose); 16-hour recovery. The volume in the
λ beta column is the amount of 1:1 rpsLmutlag oligo (10 µg/ µl): λ beta (0.94 mg/mL) added to 100 µl of
electrocompetent cells. “+” indicates that MgCl2 (1mM) was added during the 1:1 rpsLmutlag oligo: λ beta incubation
step.
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Discussion
In this work we successfully developed a protocol for DNA uptake and subsequent
oligonucleotide-guided recombination for use in Gardnerella spp. This is the first report of any
type of site-directed mutagenesis in Gardnerella. Oligonucleotide recombineering has been
utilized for directed mutagenesis in other prokaryotes, including Gram-positive organisms. Our
maximum efficiency of transformation using this system, 866 recombinants / 108 cells, is
approximately 50 times higher than that reported for E. coli, but similar to that of S. flexneri and
S. typhimurium255. Regarding oligo concentration, 10 ug was sufficient for recombination in
Gardnerella, although lower concentrations were not tested. Reports of recombineering in Gramnegative organisms indicate that 0.1-5 ug oligo is sufficient, while 100ug is required for Grampositive Lactobacillus and Lactococcus species253–256. This requirement for a higher oligo
concentration may be due to a thicker layer of peptidoglycan. While Gram-negative bacteria only
have a cell wall 2-7nm thick (5-10% peptidoglycan by weight), Gram-positive organisms contain
a cell wall 20-80 nm in thickness, made up predominantly of peptidoglycan (50-90% by weight).
Gardnerella is paradoxically enclosed by a thin, 8-12 nm cell wall comprised of only 20%
peptidoglycan263,264. This may explain why the oligo concentration requirements of Gardnerella
are more similar to Gram-negative bacteria, despite being definitively Gram-positive.

Similar to other studies, important parameters for high efficiency transformation included
growth phase (as measured by optical density) and recovery time. In addition, we found that
increasing cuvette temperature significantly reduced efficiency. We also investigated whether
Gardnerella strains and opacity variants exhibited differences in their transformation efficiencies.
The greatest transformation efficiency was observed in G. piotii strain GV3. Interestingly, the
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opaque variant in G. vaginalis ATCC 14018 exhibited a two-fold greater efficiency compared to
the translucent variant. This may be attributable to the production of competence-promoting pili,
as pilus production is suspected to distinguish the two variants. G. leopoldii strain AMD had a
markedly reduced efficiency relative to the other two Gardnerella species. This could be for two
reasons. First, electrocompetent cell preparations between the strains are phenotypically different.
While strain ATCC 14018 and GV3 cell preparations consist predominantly of single cells, strain
AMD exhibits substantial cell aggregation (Fig. 46B). These large (hundreds of cells), dense
aggregates may impede delivery of the oligo into cells and may explain why recombinants were
obtained only after sonication. This difference in recombination efficiency could also be due to
differences in oligo annealing thermodynamics between the two strains. The mutagenic oligo was
designed using the rpsL gene sequence of ATCC 14018 and thus the only differences between the
oligo and the homologous region of the genome are the two intentional base pair differences. The
homologous region in strain AMD, on the other hand, has 4 total base pair differences compared
to the oligo: the two intentional differences and two SNPs divergent from the ATCC 14018
sequence. Thus, the Tm for strain AMD may be suboptimal.

We also observed that strain AMD only incorporated the “intentional” mutations into its
genome. The nucleotides divergent from ATCC 14018 remained unchanged, suggesting that these
mismatches were repaired by mismatch repair machinery. The repair of only some mismatches
can potentially be explained by the differing efficiencies with which different base pair mismatches
are repaired. In E. coli, G:T and A:C mismatches are repaired with high efficiency while C:T
mismatches are repaired with low efficiency265. Both of the unintentional sequence differences in
AMD yield mismatches that are repaired with high frequency (G:T and A:C). Of the two
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intentional mismatches, one is repaired with high efficiency (G:T) and the other with low
efficiency (C:T). It is possible that the consecutive nature of the intentional mismatches prevented
repair of the high repair efficiency mismatch, as has been shown in E. coli253. It is also conceivable
that differences in neighboring base composition enhanced repair efficiency of the unintentional
mismatches266. As a recent study indicates, mismatch repair specificity is highly variable among
bacterial species267. Thus, the rules that govern mismatch repair in E. coli could be substantially
different than those in Gardnerella. It would be interesting to use this protocol for oligo-guided
recombination to further characterize the mismatch repair system in Gardnerella and see how it
compares to better characterized model organisms.

Although we acknowledge that the current efficiency of the system precludes the facile
isolation of non-selectable mutants, there are still multiple scenarios in which it may be of use
without the need to increase efficiency. For example, our protocol could be used to generate a
library of Gardnerella spp. with differing antibiotic resistance profiles that could then be competed
on our EpiVaginal model to characterize inter- and intra- species interactions important for growth
and survival. This would be particularly useful considering that reports by our group and others
indicate that multiple Gardnerella species are simultaneously present during BV136. Our protocol
could also be useful for generating mutants whose growth can be enriched relative to non-mutants
under specific conditions or mutants for which a customized method of selection could be
developed. For example, antibiotic-loaded erythrocytes embedded in agar could be used to select
for loss of function vaginolysin mutants268. As a mix of mutant and wild type cells are added to
the agar, wild type cells secreting VLY will release the antibiotic encapsulated in the erythrocytes
and die upon exposure whereas mutant cells not secreting VLY will not be exposed to the antibiotic
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and grow to sufficient numbers to yield visible colonies. This method is in development in our lab
but further optimization is required. Specifically, more work is required to determine whether a
sufficient amount of antibiotic is being loaded into the erythrocytes and the optimum density of
loaded erythrocytes in the agar. Finally, a method to perform high throughput screening of mutants
while maintaining cell viability would allow us to use our method at its current efficiency to
generate mutations in both coding and non-coding regions of the genome and subsequently isolate
cells with a given mutation. Such a method, live fluorescence in situ hybridization followed by
fluorescence-activated cell sorting (live-FISH FACS), was recently developed to sort specific
taxonomic groups of bacteria from natural bacterial communities and subsequently culture
them269. Fluorescent probes could be designed to distinguish wild type and mutant Gardnerella
cells which can then be sorted with FACS and plated to obtain viable mutants. This would, of
course, require substantial optimization.

Increasing recombination frequency to levels typically achieved with the addition of a single
stranded recombinase (up to 50%) would expand the mutagenic potential of Gardnerella and
would substantially accelerate the identification and characterization of important virulence
factors. Our attempts to increase recombination frequency via the electroporation of purified,
recombinant λ beta alongside the mutagenic oligonucleotide have yet to be successful. However,
there are various aspects of the protocol that must be more exhaustively evaluated before we can
definitively say that this method does not work. Specifically, it is currently unknown whether or
not DNA binding and Beta oligomerization are occurring. It is also unknown if the protein is being
delivered efficiently inside of cells. Furthermore, the ratio of oligo to protein and oligo length may
need to be optimized257,260,270. Alternatively, a recombinase from a more closely related organism
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may be required. Datta et. al cloned in recombinase homologues from both Gram-positive and
Gram-negative bacteria into E.coli and measured oligo recombination efficiency271. Recombinases
from Gram-positives had a 2-4 log decrease in transformation efficiency relative to λ beta. This
decreased efficiency wasn’t improved when using a plasmid that should alleviate the codon-bias,
suggesting that, for whatever reason, Gram-positive recombinases don’t work as well in Gramnegative bacteria. Thus, a recombinase from a Gram-positive bacterium may potentially function
better in Gardnerella. Regardless, we know that our protocol is successful at delivering DNA
inside Gardnerella. Knowing this, it may be worthwhile to attempt plasmid delivery, if not to
perform recombination, at least to express a functional recombinase. A plasmid was recently
developed to produce heterologous proteins in Bifidobacterium bifidum272. As Bifidobacterium
species are closely related to Gardnerella, this might serve as a logical starting point. Furthermore,
as an excess of single stranded oligo is used to saturate single stranded restriction enzymes during
our method to increase efficiency, decoy double stranded substrates might similarly be added to
overcome the restriction system during plasmid transformation.
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CHAPTER 7
Conclusions and future perspectives
The overall aim of these collective works was to characterize putative Gardnerella
virulence factors in order to better understand how members of this genus interact with the human
host, with the long-term goal of understanding how these interactions contribute to the
development of bacterial vaginosis (BV). Our studies focused on vaginolysin (VLY), a
cholesterol-dependent pore-forming toxin, and an opacity phenotype suspected to be driven by
pili. We hypothesized that VLY played a role in Gardnerella nutrient acquisition, targeting the
vaginal epithelium as a source of nutrients, and that opacity promoted immune evasion. To test
these hypotheses, we developed novel Gardnerella infection models. In using these models, we
observed several previously uncharacterized features of the two virulence determinants in addition
to previously undescribed features of Gardnerella spp. as a whole.

In order to test our hypothesis that VLY played a role in nutrient acquisition, we reasoned
that we would need a model of the vaginal epithelium on which Gardnerella would grow. Due to
the lack of Gardnerella growth, we ruled out the use of previously developed murine models.
Because of the proposed species specificity of VLY, we also ruled out the use of the previously
characterized porcine explant model, even though Gardnerella growth was observed in this model.
After failure in getting Gardnerella to grow on human VK2-E6E7 monolayers, we moved to a
commercially available, stratified, polarized, three-dimensional model of the human vaginal
epithelium derived from primary tissues. In this model, Gardnerella grew to in vivo densities;
however, multiple measured parameters suggested that VLY did not contribute to Gardnerella
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growth in this model. Despite the lack of support for our nutrient acquisition hypothesis, this
EpiVaginal model unexpectedly identified multiple polarity-dependent interactions between
Gardnerella and the vaginal epithelium.

First, spent medium from the apical side of the tissue supported a 1-log increase in
Gardnerella growth relative to medium from the basolateral side. Gardnerella tissue growth was
also increased on the apical side compared to the basolateral side. These results suggest that the
apical side of the tissue produces a nutritional component that is either more accessible or more
abundant than it is on the basolateral side. We suspect this nutritional component is glycogen.
Degradation of starch and glycogen was recently observed in G. leopoldii in vitro273. If its
utilization by Gardnerella spp. occurs in vivo, it would describe yet another mechanism by which
Gardnerella is able to compete with commensal lactobacilli species. Second, when we added live
bacteria to the apical or basolateral sides of the EpiVaginal tissues, we observed that apical
challenge suppressed the secretion of several pro-inflammatory cytokines. We hypothesize that
this cytokine suppression may explain why some BV positive women do not exhibit neutrophil
influx into the vaginal lumen and could potentially promote the incorporation of other BVassociated species that may otherwise be detected and eliminated by the host immune system.

Lastly, we found that VLY-mediated permeabilization of epithelial cells was restricted to
the basolateral face of the tissue, potentially due to increased surface expression of CD59 on that
side. Several groups have attributed the reduced barrier integrity of the vaginal epithelium
observed during BV to VLY. However, that seemed unlikely given that Gardnerella is
predominantly found at the apical (lumenal) side in vivo; it is not a particularly invasive organism;
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and, as suggested by our results, the apical side is fairly resistant to VLY cytotoxicity. These results
led us to hypothesize that in vivo VLY-mediated damage to the vaginal epithelium may only occur
after Gardnerella is given access to the more basolateral cells via apical damage or exfoliation
induced by other BV-associated species. However, early studies focusing on VLY characterization
suggested that the toxin, in the context of BV, impacted birth outcomes. Specifically, BV-positive
women able to mount an anti-VLY IgA response had reduced adverse birth outcomes relative to
those who did not mount an anti-VLY response. Additionally, more recent in vivo studies have
observed associations between Gardnerella abundance and preterm birth, Gardnerella abundance
and increased vaginal VLY concentrations, increased VLY concentrations and increased IL-1ß,
and increased IL-1ß and preterm birth. Collectively, these in vivo data suggest that G. vaginalis
and VLY are pro-inflammatory within the vaginal epithelium, which seemingly contradicted our
EpiVaginal findings. In considering these contradictions, and in light of reports suggesting that
both commensal and pathogenic strains of Gardnerella exist, we questioned whether different
species of Gardnerella differentially interacted with the epithelium. As a pilot experiment, we
compared EpiVaginal cytotoxicity when G. vaginalis strain ATCC 14018 or G. leopoldii strain
AMD were added. Interestingly, G. vaginalis elicited greater cytotoxicity from the apical side of
the tissue compared to G. leopoldii. We subsequently questioned whether this difference in
cytotoxicity could be due to differences in VLY.

An alignment of VLY from the two species revealed several amino acid differences between
the two versions of the toxin. We then performed an alignment of 84 publicly available VLY
sequences from different Gardnerella species and this showed that mutations within the
undecapeptide and CD59 regions of the protein sequences were well-conserved and could be used
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to classify distinct VLY-types. Type 1 (strain 14018-like) VLY was characterized by DRS amino
acids within the CD59 region whereas Type 2 (strain AMD-like) VLY was characterized by NRT
amino acids. Type 1 VLY was then sub-classified into Type 1A, 1B, 1C, or 1D based on the
differences in the amino acids within the undecapeptide region. A phylogenetic map of all
compared strains marked with their VLY-type indicated that some VLY types were restricted to
certain Gardnerella species. Specifically, Type 2 VLY was only found in G. leopoldii and G.
swidsinskii. We hypothesized that differences in VLY could alter Gardnerella species virulence.

To begin to test this hypothesis, we recombinantly produced representatives from the Type 1A
and Type 2 VLY toxins and compared their interactions with vaginal epithelial cells. When the
same amount of toxin was added to VK2 cell monolayers, Type 1A VLY elicited more
cytotoxicity, as measured by trypan blue staining, than Type 2. However, this difference was only
observed on more mature cells (7 days post seeding). When the toxins were compared on less
mature cells (4 days post seeding), no significant difference was noted. We hypothesized that that
the more mature, 7-day cells had reduced expression of CD59 relative to 4-day cells, as more
senescent apical cells exhibit reduced CD59 on EpiVaginal tissues, suggesting that when CD59 is
limiting, Type 2 VLY cytotoxicity is impaired. This finding was recapitulated when cells were
pre-treated with anti-CD59; Type 2 VLY cytotoxicity was more greatly reduced than that of Type
1A VLY. Collectively, these data suggest that Type1A VLY exhibits an increased affinity for
CD59 compared to Type 2 VLY. This may explain the initial observation of increased cytotoxicity
on the apical side of EpiVaginal tissue challenged with G. vaginalis ATCC 14018. However, an
experiment using surface plasmon resonance would be needed to more directly measure and
compare the affinity of each VLY type for CD59.
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We next questioned whether these amino acid differences in VLY could impact in vivo
Gardnerella abundance or symptoms. We reasoned that if Type 2 VLY had a lower affinity for
CD59, this would reduce its cytotoxicity within the vaginal epithelium, potentially allowing it to
grow to higher densities. Type 1 VLY, on the other hand, with its increased affinity for CD59
would potentially elicit greater damage to the epithelium, which may stimulate an immune
response manifesting in patient symptoms. To investigate this, we analyzed data from two cohorts
of subjects enrolled in the Human Vaginal Microbiome Project. In cohort 1, we used vly read data
of 62 BV-positive subjects to determine the dominant VLY type in each sample and 16S
sequencing data to determine the relative abundance of vaginally relevant species. We then
grouped subjects by their dominant VLY type and then compared the frequencies of symptoms
and Gardnerella abundance in each group. In this cohort, women with Type 1 VLY as the
dominant type experienced increased symptom frequency whereas women with Type 2 VLY
exhibited increased Gardnerella spp. abundance. The second cohort was comprised of 762 BVpositive and healthy subjects. While we did not have vly read data for this cohort, we used cpn60
read data to extrapolate VLY type abundance. In initial comparisons of all 733 subjects, we didn’t
observe any difference in symptoms or Gardnerella abundance between women dominated by
either toxin. However, when we only analyzed BV-positive subjects, our finding of increased
Gardnerella spp. abundance in women dominated by Type 2 VLY replicated. No differences in
symptom frequency between VLY type groups were noted in BV-positive Cohort 2 subjects.
However, it was interesting that cohorts 1 and 2 as a whole were dominated by different VLY
types and experienced symptoms with frequencies fitting with our hypothesis. Specifically, cohort
1 was dominated by Type 1 VLY and 67% of subjects experienced at least 1 symptom, while
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cohort 2 was dominated by Type 2 VLY and only 53% of BV-positive subjects experienced
symptoms.

These findings suggested that differences in VLY may only be relevant during BV. We further
postulated that VLY type may impact BV immunopathology, which could potentially impact BV
persistence or recurrence or influence the likelihood of adverse sequelae. Type 1 VLY, by
inducing damage to the epithelium, could drive an immune response that ultimately leads to its
removal, but also results in tissue damage that increases the likelihood of adverse sequelae. Type
2 VLY, on the other hand, may promote bacterial persistence in the absence of damage. Beyond
damaging the vaginal epithelium, VLY may help overcome nutritional immunity in vivo by
promoting nutrient acquisition from non-epithelial host cells (i.e. erythrocytes) or may serve to
protect against the immune response by lysing host immune cells. However, further studies are
needed to test these hypotheses and thus the role of VLY in Gardnerella virulence is still unknown.

In preliminary experiments aiming to test the hypothesis that VLY protected Gardnerella
against immune cells (data not shown), we first developed an opsonophagocytosis infection model
using differentiated neutrophil-like HL-60 cells and human serum. We co-incubated immune cells
and Gardnerella together for 75 minutes and then quantified bacterial survival by plating to count
CFUs. In this assay, we observed that a VLY positive strain exhibited 100% survival, while a nonisogenic VLY null strain exhibited significantly reduced survival. While this seemingly supported
our hypothesis, a closer look at the cells to confirm that bacteria were actually being engulfed
revealed that the two strains differed in their formation of large, dense bacterial aggregates. The
VLY positive strain formed very large aggregates several times the size of the neutrophil-like cells,
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and the VLY null strain did not. We reasoned that the survival advantage conferred to the VLY
positive strain via aggregate formation likely outweighed the advantage of VLY secretion, and
thus abandoned further testing our immune protection hypothesis to explore the basis of aggregate
formation.

A variety of conditions were tested to define what factors promoted and inhibited aggregate
formation. In all Gardnerella strains tested, we were able to distinguish at least two colony variants
on solid medium supplemented with FBS. Opaque variants consistently produced large bacterial
aggregates, while translucent variants did not. Interestingly, subculture of translucent variants on
either solid or liquid medium frequently gave rise to opaque variants. And less frequently, opaque
variants gave rise to translucent variants. Collectively, the results suggested that Gardnerella
aggregation was mediated by a pilus susceptible to some form of phase or antigenic variation.
While Gardnerella pilus production was noted by several publications in the 1980s, the genetic
basis for pilus biogenesis remained undefined. Due to its conservation among Gardnerella isolates,
we hypothesized that a tight adhesion locus homologue was responsible for pilus production. We
then reasoned that if the tight adhesion locus were responsible for pilus production, its sequence
would differ between opaque and translucent variants of Gardnerella. Upon sequencing and
analysis of Tad locus transcription, however, no differences between opaque and translucent
variants were noted. Attempts to visualize pilus production via TEM were interrupted, so whether
or not differential pilus production is responsible for variation in opacity is still to be determined.
Recent results from whole genome sequencing implicate various cell wall-anchored proteins. The
contribution of these candidate proteins to opacity is currently being explored.
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In the absence of the ability to generate isogenic mutants, we were able to isolate and compete
these variants in a variety of assays to show that opaque variants exhibited increased biofilm
formation and aggregation in suspension. Surprisingly, the formation of large aggregates in
suspension resulted in reduced survival of neutrophil challenge, as determined by plating viable
bacteria on solid medium. This finding led us to hypothesize that aggregate formation in
suspension was a stress response pushing bacterial cells into an altered metabolic state precluding
their growth on typical culture media, such as that of a persister cell or a viable but unculturable
phenotype. A different mechanism for assaying bacterial viability must be employed to determine
whether the bacteria in these aggregates are indeed viable and thus whether protection is conferred.
Regardless, these results collectively led us to hypothesize that opacity in Gardnerella is a novel,
putatively phase variable virulence factor important for immune evasion in vivo and thus should
be explored further.

Finally, we sought to develop a method for directed mutagenesis in Gardnerella, which, prior
to this work, had yet to be accomplished. We focused our efforts on a RecA-independent
oligonucleotide recombineering-based method because of its simplicity (i.e. lack of exogenous
factors needed) and its proven success in other genetically intractable organisms. This method
introduces mutations via single stranded oligonucleotides that exhibit ~10-40 base pairs of
homology to the desired site of mutation. As a proof-of-principle, we designed an oligo that would
introduce a two-nucleotide substitution in the rpsL gene, effectively mutating the lysine at codon
43 to an arginine. This mutation would impart streptomycin resistance and allow us to select for
recombinants. This method proved successful in three different Gardnerella species. Attempts to
further optimize transformation efficiency and to introduce mutations in vly and the Tad locus
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revealed that this system of recombination in Gardnerella is similar to the RecA-independent
recombination systems characterized in other organisms. Namely, the maximum transformation
efficiency achieved with this system does not allow for the facile identification of mutants without
a mechanism for selection. Thus, while the ability to perform directed mutagenesis in Gardnerella
is certainly an advance for the field, further work is needed to either develop mechanisms to enrich
for non-selectable mutants or to introduce exogenous factors that significantly enhance
transformation efficiency, such as a single-stranded recombinase.

Continuing to build upon the information derived from these collected works has the potential
to improve BV prevention and treatment outcomes. For example, if further characterization of the
distinct VLY types and their interactions with the host supports our hypothesis that type 1 VLY
elicits immune activation, this version of the toxin could potentially be developed as a toxoid
vaccine. If the toxoid is not effective at altogether preventing BV, it may at least have the potential
to reduce the frequency of adverse birth outcomes, as women who naturally generate antibodies
against the toxin seem to be protected. If this version of the VLY toxin is also the factor that
potentiates the development of symptoms, the localized administration of statins or soluble CD59
could reduce symptom burden. As Gardnerella spp. appear to have developed multiple
mechanisms to evade the host immune response, and bacteria are continually evolving to better
adapt to their environment, it is likely that simply targeting VLY is not the be-all and end-all
solution for BV treatment. Further characterization of other virulence determinants is warranted.
Additional optimization of the system we developed for oligonucleotide recombination will allow
for the generation of isogenic mutants that can be used to better characterize previously identified,
putative virulence determinants as well as important factors that have yet to be discovered. The
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opacity phenotype characterized here is an example of one such factor. The diversity in opacity
within the Gardnerella population, introduced by phase variation, may ensure that a subset of
bacteria persists after a given treatment. With more detailed characterization using isogenic
mutants, a method of treatment effective against both variants, or a dual treatment method, could
be developed to potentially reduce the propensity for BV recurrence.
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